sartorius stedim biotech group reference document 2015 including annual ﬁnancial report order intake sale revenue underlying ebitda margin1 million 5002 5539 6149 7221 9464 996 1170 1356 1605 2313 4773 5440 5884 6835 8843 209 215 230 235 262 1000 240 28 800 180 26 600 120 24 400 60 22 200 0 20 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 q order intake q underlying ebitda million q sale revenue underlying ebitda margin key figure figure given million according ifrs 2015 2014 2013 2012 2011 unless otherwise specified order intake sale revenue earnings order intake 9464 7221 6149 5539 5002 sale revenue 8843 6835 5884 5440 4773 underlying ebitda 12 2313 1605 1356 1170 996 underlying ebitda12 sale revenue 262 235 230 215 209 net profit noncontrolling interest 1180 724 663 568 431 underlying net profit 1 noncontrolling interest2 1393 872 752 646 534 research development cost 415 3413 360 318 286 financial data per share earnings per share 768 472 432 370 281 earnings per share14 906 568 490 421 349 dividend per share 2005 130 120 110 100 balance sheet balance sheet total 10661 9073 8734 7939 7208 equity 6472 5391 4818 4350 3956 equity ratio 607 594 552 548 549 financials capital expenditure 545 442 342 500 386 capital expenditure sale revenue 62 65 58 92 81 depreciation amortization 399 356 306 259 245 net cash flow operating activity 1428 1113 901 489 606 net debt 6 864 874 1300 1137 1001 ratio net debt6 underlying ebitda12 04 05 10 10 10 total number employee december 31 4202 3697 32897 2986 2858 1 adjusted extraordinary item 2 information ebitda net profit underlying presentation please refer chapter group business development glossary 3 restated information please refer consolidated financial statement note 4 noncontrolling interest adjusted extraordinary item noncash amortization fair value adjustment hedging instrument well corresponding tax effect item 5 amount suggested board director conseil dadministration subject approval annual general shareholder meeting 6 net debt excludes liability remaining purchase price acquisition 2015 475 million 2014 428 million 2013 348 million 2012 342 million 7 excluding tap biosystems mission sartorius stedim biotech leading provider cuttingedge equipment service devel opment quality assurance production process biopharmaceutical industry integrated solution covering fermentation filtration purifi cation fluid management lab technology supporting biopharmaceutical industry around world develop produce drug safely timely economically nextgeneration process sartorius stedim biotech focus singleuse technology addedvalue service meet rapidly changing technology requirement industry serf strongly rooted scientific community closely allied customer technology partner company dedicated philosophy turning science solution reference document 2015 present original french document de référence section document included translated reference document filed interest investor covered autorité de marchés financier another part reference document 25 february 2016 accordance article 212 13 règlement général may used copy present reference document connection offering security obtained following supplemented prospectus note dopération autorité de marchés financier issued sartorius stedim biotech sa endorsement reference document zi le paluds avenue de jouques made issuer engages responsibility c 91051 13781 aubagne cedex signatory group website wwwsartoriusstedimcom autorité de marchés financier website reference document incorporates reference wwwamffranceorg preceding reference document d15 0090 filed 27 february 2015 d14 0094 filed 27 february 2014 following information included reference present reference document year 2014 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2014 management report appearing page 103 148 18 56 respectively reference document filed autorité de marchés financier 27 february 2015 number d15 0090 year 2013 consolidated financial statement sartorius stedim biotech prepared using international accounting standard report statutory auditor relating statement group 2013 management report appearing page 98 142 18 60 respectively reference document filed autorité de marchés financier 27 february 2014 number d14 0094 01 shareholder 8 chairman message 10 executive committee 12 sartorius stedim biotech share 02 management report 18 structure management group 20 strategy goal 24 group business development 28 net worth financial position 34 sustainability report 48 table concordance 49 statutory auditor report sustainability report 52 opportunity risk report 61 forecast report 63 financial statement parent company sartorius stedim biotech sa december 31 2015 reference document contains statement concerning future performance sartorius stedim biotech sa statement based assumption estimate although convinced forwardlooking statement realistic cannot guarantee actually apply assumption harbor risk uncertainty could lead actual result diverging substantially expected one planned update forwardlooking statement translation original frenchlanguage reference document document de référence 2015 sartorius shall assume liability correctness translation original french reference document legally binding version furthermore sartorius stedim biotech sa reserve right responsible topicality correctness completeness quality information provided liability claim regarding damage caused use information provided including kind information incomplete incorrect therefore rejected throughout reference document difference may apparent result rounding addition content 03 corporate governance 05 annual financial statement sartorius stedim biotech sa note 76 board director committee 85 chairman report pursuant article 158 annual financial statement l 22537 french commercial code 169 statutory auditor report 97 remuneration executive financial statement nonexecutive member board 107 statutory auditor report prepared 108 accordance article l 225235 independent auditor fee 06 supplementary information 172 information legal nature 179 information asset financial position 04 consolidated financial result group statement note 182 special report statutory auditor related party agreement commitment 112 statement proﬁt loss 183 resolution submitted annual combined comprehensive income shareholder meeting april 5 2016 113 statement financial position 205 information reference document annual financial report 114 statement cash flow 208 code afep medef 115 statement change equity 224 glossary 116 note financial statement 226 address 130 note statement proﬁt loss 133 note individual balance sheet item 154 disclosure 156 statutory auditor report consolidated financial statement shareholder chairman message dear shareholder ssb 2015 exceptionally dynamic year profitable growth translated significant marked strong profitable growth though increase underlying earnings per share company recording doubledigit growth soared 595 reaching 906 based strong past four year company increase result board director submit proposal revenue nearly one fifth constant currency annual general shareholder meeting raise clearly exceeded expectation dividend yet 538 200 per share reporting year price share steadily increased past year outperformed french stock one hand benefited healthy market gaining 119 2015 biopharma market environment new medical drug approved high rate saw indication fiscal 2015 characterized financial expand various existing biologics initial success however also operational sign accelerating biosimilars market began achievement expansion appear addition trend towards singleuse portfolio key element total solution bioprocessing system continued unabated provider strategy acquired two smaller company customer drug manufacturing facility offer product service development phase bioprocesses biooutsource specializes moreover succeeded gaining market contract testing service required share especially north america region particularly development biosimilars cellca underrepresented past provides service designing robust efficient reporting year generated 36 production process besides offering great growth sale region starting 25 five year ago prospect acquisition view product line double offer promising synergy potential existing digit including recent acquisition product portfolio expansion broadbased also successfully progressed multiyear key feature consumablesdriven business investment program expanding membrane casting model topline growth result expansion capacity goettingen site germany upgrading profitability driven economy scale bag production tunisia puerto rico additional tailwind favorable currency opening new application lab u keep environment 2015 underlying ebitda high growth rate decided 44 margin surged 262 even accelerate progress multiyear investment program started prepare expansion various production site worldwide 2016 set ambitious target 2016 beyond continue specifically aiming increase sale challenge come right revenue around 12 16 increase product service process pioneer operational profit margin one percentage point singleuse technology aim remain figure given constant currency forefront making customer biopharmaceutical investment global infrastructure capacity production process even reliable efficient expected result capex ratio range 6 future 8 success achieved 2015 show capability furthermore reviewing updating potential company employee target 2020 set year ago therefore would like thank worldwide team view successful achievement far dedication passion accomplishment strongerthanexpected organic growth also appreciate continued trust customer expect 2020 sale revenue reach partner shareholder cordially invite 15 16 billion constant currency continue u road success anticipate underlying ebitda margin attain 29 30 constant currency assuming company acquire future reach similar profitability level existing sincerely business done effort primary focus remain biopharma market various submarkets biotech continue outperform growing global pharma market remaining innovation engine industry providing customer cost effective bioprocessing technology become even joachim kreuzburg essential market matures chairman board ceo biosimilars market emerges executive committee volker niebel executive vice president operation responsible production supply chain management business pro cess management information technology hold university degree business administration economics volker niebel also belongs sartorius group executive committee joachim kreuzburg oscarwerner reif reinhard vogt chairman board executive vice president executive vice president chief executive ofﬁcer research development marketing sale service head finance human resource manages group global charge marketing sale compliance legal affair research development unit service hold vocational corporate communication hold doctorate chemical diploma industrial business hold doctorate economics engineering studied administration reinhard vogt university degree mechanical chemistry molecular biology also member executive engineering joachim kreuzburg germany usa board sartorius ag also ceo ssbs parent oscarwerner reif also member member sartorius group corporation sartorius ag sartorius group executive executive committee chairman sartorius group committee executive committee 12 shareholder sartorius stedim biotech share sartorius stedim biotech share fact share 1 isin fr0000053266 liquidity provider gilbert dupont stock exchange euronext paris market segment local security compartment large cap index sbf 120 sbf 250 cac share cac mid small 190 cac small cac health care number share 15367238 thereof sartorius ag 743 thereof free float 257 voting right 26994624 thereof sartorius ag 846 thereof free float 154 1 december 31 2015 share market volatile whole dynamic share price development reporting year development 2015 sartorius stedim biotech share price global stock market volatile whole showed dynamic development performed better supported beginning year primarily french stock market whole close ecbs expansive fiscal policy remainder 16130 end 2014 share price surged year characterized uncertainty 1191 reaching 35340 yearend 2015 china economic development extent speed recovery u economy share hit lowest closing price year consequence sbf 120 example reached 16135 january 5 2015 peaked decem time high 4143 point april 27 2015 leveled ber 2 2015 35800 3664 point yearend represented overall gain 90 previous year industryspecific index nasdaq biotechnology reached high 4166 point july 20 ended year 3540 equates gain 114 shareholder sartorius stedim biotech share 13 sartorius stedim biotech share january 1 2011 december 31 2015 360 300 240 180 120 60 0 sartorius stedim biotech share 2011 2012 2013 2014 2015 sartorius stedim biotech share sartorius stedim biotech share comparison sbf 120 cac mid small nasdaq biotechnology index indexed january 1 2011 december 31 2015 1050 900 750 600 450 300 150 0 sbf cac sartorius nasdaq 120 midstedim biotechnology small index biotech share 2011 2012 2013 2014 2015 sartorius stedim biotech share sbf 120 cac mid small nasdaq biotechnology index 14 shareholder sartorius stedim biotech share investor relation activity analyst sartorius stedim biotech investor relation activity recommendation financial analyst serve focus maintaining ongoing open dialogue important foundation decision private shareholder potential investor financial analyst institutional investor investing share currently five institution regularly prepare report besides providing firsthalf annual report well update sartorius stedim biotech share holding quarterly telephone conference also regularly published press release presenting research coverage significant company business development institute date recommendation material event reporting year 2015 société générale february 4 2016 buy moreover management team available equita february 2 2016 hold capital market participant site goettingen gilbert dupont february 1 2016 add aubagne well conference road show oneonone meeting international oddo midcap february 1 2016 buy financial market center london paris portzamparc february 1 2016 add frankfurt main new york year review communication focused particular explaining current operating development well portfolio expansion wake acquisition information publication relating company share may found website wwwsartoriusstedimcom key figure sartorius stedim biotech share 2015 2014 2013 2012 2011 1 share price reporting date 35340 16130 12185 7340 4900 high 35800 17165 12400 7603 5489 low 16135 11700 7535 4673 3735 dividends2 200 130 120 110 100 total dividend paid2 million 307 200 184 169 153 3 payout ratio 221 229 245 261 287 dividend yield4 06 08 10 15 20 market capitalization million 54308 24774 18696 11261 7510 average daily trading number share 7353 7014 9011 7464 7435 trading volume share million 4852 2438 2378 1061 852 cac mid small closing price year 11054 9354 8629 6812 5652 sbf 120 closing price year 3664 3360 3337 2793 2397 1 daily closing price 2 2015 amount suggested board director subject approval annual general shareholder meeting 3 based underlying net result 4 dividend relation corresponding closing price year source euronext bloomberg shareholder sartorius stedim biotech share 15 dividend shareholder structure sartorius stedim biotech strives enable share sartorius stedim biotech sa issued capital amounted holder participate adequately company 154 million december 31 2015 success continuously increased dividend divided 15367238 share calculated recent year line objective basically par value 100 share convey follow policy paying relatively stable double voting right total 26994624 share relevant net profit see definition page voting right reporting date 224 shareholder december 31 2015 sartorius ag hold 743 board director submit proposal share capital 846 outstanding voting annual general shareholder meeting april 5 2016 right remaining 257 share free pay dividend fiscal 2015 200 per share float corresponding 154 outstanding net profit 1393 million would voting right represent gain 538 previous year figure 130 therefore total profit distributed shareholding structure would increase 200 million year ago share capital 307 million corresponding dividend payout ratio would 221 compared 229 previous sartorius ag 743 year relation share closing price 35340 december 31 2015 dividend yield would free float 257 06 previous year 08 dividend 100 100 110 110 120 120 130 130 200 200 200 150 100 050 000 2011 2012 2013 2014 20151 1 amount suggested board director subject approval annual general shareholder meeting 16 management report sartorius stedim biotech share management report 18 management report structure management group structure management group group legal structure organization management group change group portfolio sartorius stedim biotech globally operating company 4000 employee worldwide sartorius stedim biotech group consistently subsidiary 20 country parent organized function worldwide company company sartorius stedim biotech group therefore managed along core operating function sartorius stedim biotech sa holding company control group direct indirect global functional organization creates affiliate list affiliate shown page 127 effective platform central strategic control fast efficient collaboration within group approximately 74 share capital around also enables company realize total solution 85 voting right sartorius stedim provider strategy position effectively biotech sa held directly indirectly respect global customer sartorius ag board director sartorius stedim biotech sa consolidated financial statement include composed ten member four non parent company sartorius stedim biotech sa executive director member group audit major affiliate sartorius stedim biotech sa remuneration committee operating level controlling interest pursuant ifrs 10 group managed four executive member implementing group various strategy project local level responsibility national affiliate management body local company manage organization accordance applicable statutory provision article association rule procedure keeping principle corporate governance apply throughout sartorius stedim biotech group worldwide please see detail board director section corporate governance management report structure management group 19 change group portfolio financial controlling key performance indicator year 2015 sartorius stedim biotech acquired company biooutsource ltd cellca sartorius stedim biotech group managed using gmbh april 2015 july 2015 respectively number key performance indicator also decisive determination variable headquartered glasgow uk biooutsource ltd remuneration component executive committee specializes contract testing service bioanalytics manager biosafety generated annual sale approximately 9 million cellca gmbh based key management parameter sartorius stedim laupheim germany offer biopharmaceutical biotech us measure development company service product development annual volume currencyadjusted growth sale revenue sale revenue amounted around 6 million acquisition provide complementary product key profitability measure ebitda adjusted service portfolio sartorius stedim biotech extraordinary item ie underlying ebitda initially consolidated corresponding margin definition term transaction date information presentation see glossary page 224 important indicator include ratio net debt underlying ebitda well capex ratio following financial nonfinancial indicator also reported regular basis order intake underlying net profit earnings per share net profit earnings per share equity ratio net working capital net cash flow operating activity number employee rule annual financial forecast published management beginning fiscal year group refers development sale revenue underlying ebitda expected capex ratio well directional forecast ratio net debt underlying ebitda also indicated group sale revenue order intake mostly similar level sartorius stedim biotech due structure generally show considerable timing difference subject similar growth assumption reason order intake usually budgeted separately component financial forecast 20 management report strategy goal strategy goal sartorius stedim biotech leading international conventional reusable stainless steel system supplier product technology manu provide considerable cost time saving reduce facture medication vaccine biological basis risk contamination sartorius stedim biotech socalled biopharmaceuticals extensive portfolio singleuse technology industry part strategy total solution provider offer biopharmaceutical industry product product company address attractive portfolio cover virtually step market aboveaverage growth rate sale production process increasingly process distribution activity carried globally development encompass cell culture medium field force customer manufacturing seed fermentation cultivation various bioreactor process validated respective authority size cell propagation well range product quality assurance supply essential technology equipment filter aseptic bag cell harvesting purification see leading market position sartorius concentration way final filling stedim biotech process filtration fluid management fermentation membrane chromatography good sartorius stedim biotech focus particular stepping stone sustained dynamic profitable singleuse product represent around three growth future besides realizing organic quarter sale revenue customer growth potential also plan continue expanding singleuse product innovative alternative complementary acquisition alliance integrated product service along customer process chain process development production service evaluation optimization engineering design implementation technical service management report strategy goal 21 sartorius stedim biotech 2020 strategy second regional focus asia especially china south korea india market 2011 group developed strategy long tremendous potential international term target 2020 achieve profitable growth comparison growing higherthanaverage rate assessment sartorius performance nearly participate momentum best possible midpoint trajectory positive company way invested substantially asian sale updated financial plan first time infrastructure well beginning 2016 raising sale revenue profitability forecast 2020 expansion product portfolio view sale revenue sartorius stedim biotech slightly increased target 2020 around concerning development portfolio 15 billion 15 16 billion based current 2020 strategy also provides making acquisition exchange rate regarding company continued besides conducting rd activity entering strong organic growth relatively small alliance acquisition primarily acquisition increase sale contributed focused adding complementary technology organic growth expected higher today product make company portfolio even stance projected 2011 share attractive customer perspective revenue generated acquisition anticipated strengthened portfolio five small medium slightly lower sized acquisition since 2011 lonza tap biosystems allpure technology cellca biooutsource sartorius stedim biotech substantially increased profitability since implementation 2020 strategy improving underlying ebitda margin infrastructure 262 reporting year reason betterthanexpected development higher efficient business process powerful infra economy scale positive currency effect structure sufficient production capacity company underlying ebitda margin expected constitute backbone projected growth reach 29 30 constant currency sartorius stedim biotech increasingly using 2020 instead avout 28 formerly projected standardized business process considerably assuming profitability future extending production capacity various location acquisition would level comparable existing business sartorius stedim biotech 2020 strategic plan implemented various growth initiative following area focus regional growth initiative regionally north america selected country asia focus sartorius growth strategy north america world largest market manufacture biopharmaceuticals market home main competitor group historically lower market share region europe asia accordingly sartorius stedim biotech striving gain market share primarily strengthening sale service capacity reorganizing sale distribution process 22 management report strategy goal sector condition growth regional pharma market sartorius stedim biotech serf customer mainly 34 34 6464 15 15 85 85 biopharmaceutical industry make 41 41 118 118 14 14 91 91 business particularly sensitive development 12 industry 9 significant growth pharmaceutical market 6 important growth driver global 3 pharmaceutical industry remained unchanged reporting year world steadily growing population demographic change improved access 0 health care emerging market particular europe usa japan asiaafrica 20151 australia availability new medication positive factor 2014 countered austerity measure healthcare 1 midpoint forecast range system expiration patent source ims health according market research institute ims health growth global pharmaceutical market 2015 6 slightly longterm average 54 2009 14 previous year strongest aboveaverage growth growth dynamic evident region asia biotechnology market latin america condition favorable owing expansion statefunded healthcare provision market pharmaceutical manufactured using higher outofthe pocket spending usa biotech method grown overproportionately world largest pharmaceutical market growth within world pharmaceutical market many normalized comparison extraordinarily year enjoyed particularly dynamic strong dynamic previous year driven development reporting year large number new product approval primarily attributable launch many new biopharmaceutical drug well additional market penetration existing medicine part expanded indication instance high rd productivity biotechnology sector led almost twice many new approval usa 2014 previous year overall proportion sale revenue world pharmaceutical market accounted medication manufactured using biotech method grew around 20 2012 approximately 24 reporting year biosimilars biological copycat medication played minor role growth biotechnology market 2015 compared market biosimilars europe asia important u market still underdeveloped however industry recorded significant progress reporting year five biosimilars meanwhile submitted u health authority fda approval first market authorization granted basis abbreviated approval procedure management report strategy goal 23 trend towards singleuse system competition biopharmaceutical production continues primary mean company biotech production method much complex biotechnology market differentiate costintensive traditional method competitor innovative prowess quality consequently manufacturer supplier performance product biotechnology continuously looking develop efficient sector constantly discovering new area production technology singleuse product play application expects supplier equally fast decisive role effort require moving creative developing new equipment significantly less capital expenditure reduce cost manufacture biotech product new supplier cleaning validation minimize downtime particular seek exploit opportunity also offer greater flexibility help accelerate time inherent environment gain foothold market thanks particular costefficiency market carefully targeted niche product singleuse technology already become well established supplier meanwhile expanding established large number process step product range continuously manufacture medicine generate round 90 sale revenue validated process replacing product continued soft demand production cycle expensive receive public research sector high proportion followup repeat business particular strength sartorius stedim biotech lie demand laboratory product integrated process solution investigation come publicsector research according development substance lab market observer frost sullivan publicsector production end product offer broadest spending reporting year lay slightly range industry strategic focus singleuse last year level thus corresponding product give u another edge competition moderate growth world economy overall sartorius stedim biotech occupies strong position market worldwide field bioprocess filtration fermentation fluid management membrane chromatography competitor multinationals based usa merck millipore danaher pall general electric healthcare among main rival process area thermo fisher merck millipore key player laboratory field also face competition smaller company applikon individual segment source ims ims health market prognosis may 2015 evaluate pharma world preview 2015 outlook 2020 june 2015 frost sullivan 2015 annual report forecast analysis global market laboratory product november 2015 wwwfdagov citi research biosimilars real dangerous coming soon february 2015 bernstein biosimilars november 2015 24 management report group business development group business development sale revenue sale revenue growth1 region2 million unless otherwise specified reporting year sartorius stedim biotech emea 3972 212 group achieved doubledigit growth rate yet significantly higher projected beginning year development driven stronger expected growth biopharma market market share gain america 3235 247 thus sale revenue rose 194 constant currency 8443 million surpassing guidance issued outset year 4 7 constant currency including effect currency asia pacific 1637 73 sartorius stedim biotech sale revenue surged 294 1 constant currency 2 acc customer location sale revenue 2011 2015 million 5440 5884 4773 5440 4773 6835 8843 5884 6835 8843 1000 following regional change constant currency unless otherwise specified 750 2015 region reported strong gain sale revenue america emea region grew 500 dynamically gained market share according estimate 250 emea generated highest share accounting 0 around 45 sale revenue reported sharp 2011 2012 2013 2014 2015 increase sale revenue 212 3972 million reported 233 compared 3221 million america region represented around 37 sale revenue order intake sale revenue saw strong upsurge 247 3235 million reported 473 compared million 2015 2014 reported const fx 2196 million asia pacific region accounted around 18 total sale sartorius sale revenue 8843 6835 294 194 stedim biotech recorded doubledigit gain order order intake 9464 7221 311 211 volume sale revenue region rose 73 1637 million compared strong basis 2014 reported 155 compared 1418 million product segment contributed expansion especially singleuse technology filter bag biooutsource ltd cellca gmbh acquired reporting year also developed positively contributed around 15 percentage point constant currency sale revenue growth management report group business development 25 development cost earnings 149 million financial result remained broadly prior year level 153 million reporting sartorius stedim biotech adopted slight change period lower yearoveryear interest expense reporting structure result fiscal 2015 compensated higher fair value effect hedging depreciation related capitalized development cost instrument foreign currency loan shown within cost sale ensure compa rability business figure 2014 restated income tax totaled 502 million 2014 314 million see consolidated financial statement note company tax rate 296 299 year reporting year cost sale 4325 million equates underproportionate reporting year net profit attributable increase 249 compared sale revenue growth shareholder sartorius stedim biotech sa 294 cost sale ratio 489 relative 1180 million relative 724 million year earlier 507 year ago statement profit loss functional cost sartorius stedim biotech million 2015 20141 group developed fiscal 2015 follows selling sale revenue 8843 6835 294 distribution cost rose slower sale 158 cost sale 4325 3463 249 1672 million ratio selling distribution cost sale revenue 189 compared gross profit sale 4518 3372 340 211 previous year selling distribution cost 1672 1444 158 research expense research development rose development cost 415 341 217 reporting year 217 415 million equates general administrative 47 sale revenue compared 50 expense 489 387 265 prior year operating income expense 96 02 nm earnings interest concerning general administrative expense tax ebit 1845 1203 534 reported 265 increase 489 million financial income 29 24 184 increase inter alia attributable expansion financial expense 177 177 00 certain function connection financial result 149 153 27 2020strategy relation sale revenue general profit tax 1697 1051 615 administrative expense 55 relative 57 income tax 502 314 599 previous year net result 1195 737 622 attributable fiscal 2015 balance operating income equity holder ssb expense 96 million relative 02 million sa 1180 724 629 year earlier change related amongst others noncontrolling interest 15 12 214 higher extraordinary item well currencyrelated hedging effect 1 restated information please refer consolidated financial statement note overall group operating expense rose 243 year page 110 year accordingly ebit increased proportionately respect sale revenue 534 1845 million group ebit margin 209 2014 176 26 management report group business development earnings underlying ebitda margin1 sartorius stedim biotech group earnings 996 996 1356 1605 1170 1356 1170 2313 1605 2313 interest tax depreciation amortization 209 209 230 235 215 230 215 262 235 262 ebitda used key profitability measure 240 28 provide complete transparent presentation group profitability report earnings adjusted 180 26 extraordinary item underlying ebitda information definition please refer 120 24 glossary page 224 underlying presentation reconciled ebitda key indicator see glossary 60 22 follows reconciliation 0 20 ebit underlying ebitda 2011 2012 2013 2014 2015 million 2015 2014 underlying ebitda million underlying ebitda margin ebit 1845 1203 extraordinary item 74 49 1 adjusted extraordinary item amortization 394 353 underlying ebitda 2313 1605 extraordinary item amounted 74 million previous year 49 million essentially related reporting year earnings sartorius stedim various corporate project integration biotech advanced significantly based strong biooutsource cellca including extraordinary growth sale revenue due economy scale item depreciation amortization group underlying ebitda increased overproportionally ebit see glossary rose 1203 million 442 2313 million respective margin rose 1845 million respective margin increased 235 262 exceeding initial guidance 176 209 240 245 currency effect added around 05 percentage point margin improvement underlying net profit noncontrolling interest group surged 872 million year ago 1393 million fiscal 2015 profit figure calculated adjusting extraordinary item eliminating noncash amortization 129 million previous year 108 million based normalized financial result well corresponding tax effect item underlying earnings per share surged 595 568 year earlier 906 management report group business development 27 underlying earnings per share1 appropriation profit 349 349 421 421 490 490 568 568 906 906 sartorius stedim biotech strives enable shareholder participate adequately company 1000 success continuously increased dividend recent year line objective basically 750 follow policy paying relatively stable share underlying net profit non 500 controlling interest see definition page 139 shareholder 250 board director submit proposal 000 annual general shareholder meeting april 5 2016 2011 2012 2013 2014 2015 payment dividend 200 per share fiscal 1 excluding extraordinary item 2015 130 previous year total profit distributed would accordingly increase 539 200 million year earlier 307 million corresponding dividend payout ratio would 221 million 2015 2014 compared 229 previous year relation ebit operating result 1845 1203 closing price share 35340 december extraordinary effect 74 49 31 2015 would result dividend yield 06 amortization ifrs 3 129 108 previous year 08 normalized financial result1 66 115 normalized income tax 2015 29 2014 292 575 361 underlying net result 1408 885 noncontrolling interest 15 12 underlying net result noncontrolling interest 1393 872 underlying earnings per share 906 568 1 financial result excluding fair value adjustment hedging instrument well currency effect foreign currency loan 2 underlying income tax based underlying profit tax noncash amortization see glossary definition total listed 28 management report net worth financial position net worth financial position cash flow net cash flow financing activity 272 million essentially reflects payment net cash flow operating activity dividend sartorius stedim biotech group increased substantially 1113 million 1428 million reporting cash flow statement summary period gain essentially driven higher earnings net working capital expanded slightly million 2015 2014 lower pace sale revenue fiscal 2015 net cash flow operating activity 1428 1113 net cash flow investing net cash flow operating activity activity acquisition 1063 468 million net cash flow financing activity 272 842 606 606 489 489 901 901 1113 1428 1113 1428 cash cash equivalent 318 185 160 gross debt owed bank 1183 1060 net debt owed bank 864 874 120 80 consolidated balance sheet 40 balance sheet total sartorius stedim biotech group increased 1588 million 0 10661 million yearend 2014 2011 2012 2013 2014 2015 reporting date december 31 2015 noncurrent asset rose 6312 million 2014 524 million net cash flow investing 7153 million 2015 primarily due activity higher last year figure acquisition made reporting year 425 million planned increase mainly reflects investment production capacity higher investment expansion production capacity current asset grew 2762 million 3508 million increase mainly driven cash outflow 539 million related acquisition aforementioned buildup working capital higher reporting period attributable cash cash equivalent compared december 31 purchase biooutsource ltd cellca gmbh 2014 net cash outflow investing activity acquisition thus amounted 1063 million compared 468 million 2014 accordingly group financed entire investment acquisition operating cash flow management report net worth financial position 29 key working capital figure balance sheet structure day asset equity liability 2015 2014 594 594 607 607 696 696 671 671 153 153 137 137 rate turnover 304 304 329 329 253 253 256 256 inventory 100 inventory x 360 60 58 sale revenue rate turnover receivables 50 trade receivables x 360 58 66 sale revenue rate turnover net 0 working capital 2014 2015 2014 2015 net working capital1 x 360 77 81 noncurrent asset equity sale revenue current asset noncurrent liability 1 sum inventory trade receivables current liability less trade payable driven strong earnings equity sartorius net debt underlying ebitda stedim biotech group grew 5391 million 2014 6472 million 2015 equity ratio rose regarding debt financing potential markedly 607 december 31 2014 594 sartorius stedim biotech group ratio net debt underlying ebitda represents key management current noncurrent liability indicator ratio improved 05 04 507 million reach 4189 million mainly year ended december 31 2015 despite two reflects salesled expansion working capital acquisition executed increase gross debt ratio net debt underlying ebitda overall gross debt 1183 million decem ber 31 2015 compared 1060 million year ended december 31 2014 net debt 10 10 10 10 10 10 05 05 04 04 reporting date almost unchanged 20 864 million relative 874 million year ago figure excludes liability remaining purchase 15 price acquisition amounting 475 million 2015 10 05 00 2011 2012 2013 2014 2015 1 net debt excludes liability remaining purchase price acquisition 2015 475 million 2014 428 million 2013 348 million 2012 342 million 30 management report net worth financial position financing treasury research development sartorius stedim biotech group financed research development activity sartorius longterm welldiversified basis cover stedim biotech encompass inhouse develop shortterm cash requirement longterm ments core technology well strategy integration product alliance partner university industry december 2014 sartorius ag entered syndicated credit line agreement 400 million inhouse research development sartorius maturity term extended reporting stedim biotech focus particular following year six year total since sartorius stedim technology area membrane core biotech using credit line volume component type filter product various base 300 million provided sartorius ag see technology broad spectrum application page 151 information bioprocesses singleuse container sensor control technology instance furthermore group longterm loan fermentation moreover extensive expertise agreement kreditanstalt für wiederaufbau bioprocess application development kfw current volume 16 million relating investment production capacity moreover research development activity goal diverse bilateral credit line approximately helping customer continually optimize 36 million total process steadily increase efficiency thus reporting year one focus rd mentioned financing comprise instrument activity development fermentation fixed variable interest financing system eight smallvolume single use facility variable interest rate partly hedged bioreactors operated simultaneously increase general interest rate level multiparallel operation enable customer significantly increase process development sartorius stedim biotech group conduct business productivity across globe thus affected currency fluctuation group u dollar represents area depth filtration working important foreign currency besides development singleuse solution japanese yen british pound swiss franc preparation culture low cell density global manufacturing network production solution characterized particular ease use facility outside germany france north flexible scalability america uk switzerland india enables u compensate majority currency regional perspective largest rd site fluctuation natural hedging located goettingen key rd activity taking place aubagne guxhagen bangalore generally hedge remaining net currency royston overall research development exposure twothirds period 15 activity becoming increasingly international year ahead suitable currency transaction sartorius stedim biotech group stepped research development activity reporting year increasing spending area 217 415 million previous year 341 million respective ratio rd cost sale revenue 47 compared 50 year earlier management report net worth financial position 31 research development cost number application intellectual property million right filed 2015 amounted 95 compared 125 286 286 318 318 360 360 341 341 415 415 previous year result application 60 submitted past year issued 183 patent trademark previous year 134 balance sheet date total 1959 patent 45 trademark portfolio previous year 1811 30 2015 2014 15 number patent trademark application 95 125 registered patent trademark 183 134 0 2011 2012 2013 20141 2015 1 adjusted information please refer consolidated product sale financial statement note page 110 product portfolio sartorius stedim biotech cover virtually step biopharmaceutical production process medium cell cultivation research development ratio bioreactors various size cell propagation sale revenue filter purifying cell material system 60 60 58 58 61 61 50 50 47 47 storage transport intermediate finished product also offer extensive range service 10 support customer complying stringent regulatory process requirement including installation 8 maintenance repair well validation consulting activity contract testing 5 3 acquisition expand process development product range 0 2011 2012 2013 20141 2015 far product portfolio sartorius stedim biotech primarily focussed largescale 1 adjusted information please refer consolidated biopharmaceutical production process however financial statement note page 110 reporting year expanded offering area process development ifrs require certain development cost acquisition two company biooutsource capitalized balance sheet amortized cellca subsequent year reporting year development investment amounted 82 million acquisition biooutsource enables sartorius slightly 84 million year stedim biotech offer broad spectrum analytic amount share 164 2014 198 service test used development group total rd expense depreciation related drug candidate instance characterization capitalized development cost amounted comparison reference generic 52 million reporting period 2014 product well later production process 64 million expense disclosed cost release batch medication sale biooutsources service offer aimed especially strongly growing biosimilar industry protect knowhow pursue targeted intellectual industrial property right policy systematically monitor compliance right review cost benefit viewpoint whether necessary continue maintain individual right 32 management report net worth financial position also strengthened portfolio acquiring cellca expand offer process analytical tool pat company platform technology biopharma concluded development cooperation ceutical company pursue inhouse process reporting year emtec company specializes development partially offer noninvasive flow measurement disposable comprises optimization expression system sensor used variety biopharmaceutical well cell line medium process development process step determine flow mass cell material enable critical parameter measured together singleuse product cell culture real time without direct contact medium medium smallvolume bioreactors allow customer automate optimize built attractive portfolio process process even strongly development optimization especially younger biopharma biosimilar company sale activity expanded portfolio extended sartorius stedim biotech market bioprocess product portfolio directly field sale addition extending product portfolio representative sale activity key account reporting year acquisition sartorius coordinated supported global key account stedim biotech launched new generation existing management moreover sale distribution product line well new singleuse technology activity north america stepped reporting year connection implementation 2014 introduced singleuse fermentation bag 2020 strategy established new made newly developed polyethylene film application center bohemia 2015 following extended application spectrum film bag opening new center shanghai year storage process year review center allow presentation key result customer obtain validation product complete solution well single film material thus significantly demonstration variety different application reduce validation time cost addition customer also opportunity simulate new singleuse bag preconfigured specific experiment take part training also formed process step therefore used directly upon sale cooperation membrane chromatography delivery ge healthcare market leader chromatography see cooperation ge good opportunity reporting year sartorius stedim biotech establish singleuse solution broader base also introduced new singleusebased technology market attractive alternative clarification offer alternative traditional reusable chromatography system traditional preparation culture using centrifuge used separate process step 2014 company began introduce new global carried single step advantage crm system make process even efficient singleuse system saving time money reporting year system implemented europe management report net worth financial position 33 production supply chain management sartorius stedim biotech operates welldeveloped global production network plant europe north america asia largest production site located germany france puerto rico sartorius stedim biotech also manufacturing operation switzerland uk tunisia india production site fundamentally serf center competence particular technology group biggest plant goettingen example concentrate chiefly production membrane filter whereas aubagne mohamdia site primarily manufacture singleuse bag plant yauco supply membrane filter singleuse bag principally u market guxhagen site specializes bioreactors system bioprocess application collaborates closely bangalore site mainly produce stainless steel unit system response doubledigit growth sartorius stedim biotech making ongoing investment expansion production capacity well optimization production process instance additional casting machine production filter membrane commissioned goettingen site yauco preparation undertaken expansion production addition production turnaround time shortened three main bag production plant yauco aubagne mohamdia individual process step decoupled result year review able improve delivery time singleuse bag despite strong demand 34 management report sustainability report sustainability report sustainability one core value firmly methodological note embedded sartorius stedim biotech corporate culture ever since company established indicated otherwise indicator reported sustainable development company hr health safety refer major objective entire group excluding latest acquisition biooutsource cellca together 132 primary business responsibility offer employee headcount acquisition attractive product solution customer included indicator total headcount innovation well strategic operational subindicators headcount region excellence key meeting objective u headcount function group figure thus sustainability mean pursuing business represent 97 total headcount objective use longterm broadly based approach environmental indicator cover production encompassing social ecological interest take site aubagne bangalore goettingen guxhagen responsibility toward various stakeholder lourdes mohamdia new oxford royston stonehouse seriously foster longterm relation deliver tagelswangen yauco representing 84 benefit party involved therefore active group total workforce management social ecological task societal commitment one success factor data collected using sap social information emc environmental data case line approach consider essential local site transmit data via software system comply legal ethical standard general rule required data reported monthlyit manufacture ecological responsibility keep controlled consolidated hr ehs unit environmental impact mind developing largest group site goettingen sartorius product innovation likewise hr policy aimed stedim biotech set process continuous preserving right interest employee improvement groupwide recording reporting actively using developing potential controlling environmental social data global workforce company site around world employer contractor take active part developing regional environment economic f eo success u loyee co indicator social health safety e v l p mp l e ntia glo acti l environmental raw material data te ian ba po ce defined cover impact group able corpo activity since 2012 sartorius stedim biotech tain ra u anagement e reporting social environmental societal e u c tio n l ctiv p r ti n information metric compliance r ese rc h n y ble ctio n c n r cie french grenelle ii environmental law recom l ai g c b ili produ u st mended table concordance shown page 48 ibu ti na l statutory auditor report starting ty n g ec f u page 49 internally figure provide basis oci defining reviewing controlling environmental r oje p n pr al c t f ica l io hr target f e n r log va ar ra st f h e e c inn r r u c uct ius tu sit e r e prod management report sustainability report 35 sustainable corporate management following code conduct sartorius stedim biotech support respect principle defined activity based corporate value united nation universal declaration human sustainability openness enjoyment value right convention international labor govern treat customer business partner organization ilo united nation global investor well work together within compact furthermore reject form company addition value guide u compulsory andor child labor respect special future development company need protect young employee sartorius stedim biotech employee committed taskoriented sartorius stedim biotech conduct business open friendly fair approach interacting accordance globally accepted ethical standard colleague employee third party helping compliance national legal norm create atmosphere respectful cooperation action line good corporate governance tolerate employee discriminated control focusing sustainable value added disadvantaged harassed excluded based principle include protection stakeholder gender ethnic origin race religion age disability interest transparent communication appropriate appearance sexual preference identity origin risk management proper accounting auditing political position expect supplier apply sartorius stedim biotech follows rule standard respect freedom recommendation afepmedef corporate association right individual fairly governance code information provided represented labor organization choosing chairman report page 85 96 reference pursuant local law document sartorius stedim biotech remuneration policy global compliance system ensure aim attract retain motivate employee member executive body manager ensures internal external competitiveness employee comply legal regulation code conducting regular review local market act accordance internal regulation two global incentive program many systematically providing information prevent employee eligible participate linked misconduct avoid financial loss damage success company achievement company image key principle system target defined annual performance review code conduct anticorruption code generally company applies industry standard binding employee complies union agreement germany instance compensation paid according pay code conduct anticorruption code rate set trade union even based serve specific guide requirement regarding local performancerelated component responsible action part employee code help job day work require supplier associate business legally correct morally appropriate manner partner respect applicable human right law training course employee worldwide attend regulation example signing code employee schooled way deal conduct morally legally questionable situation whistleblower portal telephone hotline enable employee supplier customer partner anonymously report dubious conduct compliance also regular topic corporate audit program conduct regularly international subsidiary 36 management report sustainability report encouraging social dialogue employment fair responsibly acting company sartorius employment number reported following stedim biotech maintains open constructive include staff member except vocational dialogue stakeholder group topic trainee intern employee extended leaf dialogue also include sustainability issue absence participating early retirement relevance stakeholder today future plan number recorded head count dealing customer business partner december 31 2015 sartorius stedim biotech supplier sartorius stedim biotech take advantage group employed total 4202 people 536 close relationship previous year headcount increased maintained year also discus standard 146 figure also include 132 employee apply sustainable corporate management two recent acquisition regional groupwide employee survey 163 america recorded highest increase learn employee like company staff number accounting 156 see need improvement draw workforce mainly due firsttime result identify relevant issue consolidation allpure recruitment puerto implement specific measure local business site rico emea continued region highest number employee accounting 714 investor also conduct dialogue workforce total 3 percentage point 157 environmental social responsibility venue rise workforce attributed two road show investor conference capital acquisition reporting year market day event remaining growth due primarily expansion production france tunisia staff number country company maintain good neighborly asia pacific rose 71 relationship nearby resident government official finding interest employee region expectation business operation 3000 3000 655 655 547 547 2592 2592 563 563 511 511 3200 2400 1600 800 0 emea america asia pacific 2015 2014 management report sustainability report 37 employee function employee gender 2696 2696 926 926 332 332 248 248 1861 1861 2021 2021 2289 2289 2518 2518 2287 2287 891 891 301 301 187 187 1125 1125 1268 1268 1377 1377 1552 1552 2800 2800 2100 2100 1400 1400 700 700 0 0 production marketing research administration1 2012 2013 2014 2015 sale development service male female 2015 2014 employee age 1 excluding administrative function performed sartorius corporate administration gmbh part 2015 2014 sartorius stedim biotech group number number 16 20 year 25 06 18 05 21 30 year 1012 249 844 23 broken function manufacture 31 40 year 1242 305 1129 308 area directly related production accounted 41 50 year 996 245 964 263 approximately twothirds workforce 51 60 year 687 169 628 171 increase 179 attributable primarily fact 61 year 108 27 83 23 sartorius stedim biotech hired new employee production site aubagne und mohamdia response good demand disposable bag proportion woman entire workforce 220 group employee worked marketing increased onehalf percentage point sale gain 39 total 79 staff 381 worked research development 2015 representing increase 103 partly due average employee age slightly decreased 400 two acquisition since majority employee 395 year company work rd function growth 325 administration mainly attributable employee benefit expense totaled 2429 million consolidation two recent acquisition new reporting year 1968 million accounted hire finance hr unit france wage salary detail please refer germany well new staff recruited page 130 supportive function puerto rico reporting year administrative employee 59 share total workforce following analysis include 132 employee biooutsource cellca 38 management report sustainability report new hire attrition rate average seniority developing promoting absenteeism potential employee 2015 2014 professional development promotion opportunity new hire 852 504 well assumption project responsibility play key role employee satisfaction step redundancies1 52 43 enhance individual employability create new attrition rate2 including expired fixedterm contract 113 87 professional opportunity u attrition rate2 excluding expired company motivated welltrained employee key fixedterm contract 70 56 factor success professional development average seniority year 80 84 program sartorius stedim biotech cover broad absenteeism3 rate 40 39 range topic help improve language methodological skill provide employee 1 redundancy companydriven dismissal layoff large number advanced training professional 2 express number people leaving company development opportunity offered several different percentage average headcount 2015 3918 including retirement reason employee leaving language specialist training program targeted company onthejob course teach necessary skill 3 excluding time lost due maternity parental sabbatical knowledge meet evolving need leave unpaid leave extended sick leave six employee company refine program week including weekend modify group level regional site level attrition rate express number people leaving company percentage annual performance review conducted employee average head count 113 2015 however group subsidiary encourage individual expired fixedterm contract excluded rate collective performance appraisal cover slightly increased 56 70 general performance review target identification turnover subject sizable regional difference development opportunity sartorius stedim biotech europe especially germany traditionally conduct worldwide accordance uniform lowest level fluctuation whereas change criterion employer common asia turnover thus usually high sartorius stedim biotech possible sartorius stedim biotech fill turnover group german site lowest management vacancy within rank 26 france attrition rate 78 figure accordingly develops promotes employee excluding expired fixedterm contract yet india management potential international level instance sartorius stedim biotech able special program help junior manager develop reduce turnover significantly recent year refine management skill specific variety measure aimed increasing employee project directly related company business loyalty motivation fluctuation experienced management staff sartorius stedim halved 155 2012 70 2015 biotech provides separate development program excluding expired fixedterm contract line leadership guideline strengthen common managerial culture absenteeism rate defined proportion planned working time worked due structured expert career path program enables general absence generally dependent factor sartorius stedim biotech provide specific influenza wave sartorius stedim biotech development opportunity scientist engineer absenteeism reporting year remained rd function raise profile constant 40 average number day missed expert within outside company per employee due illness slightly increased 69 result expert key sartorius stedim biotech day 2014 75 day 2015 technology even greater incentive stay company management report sustainability report 39 using internal job center employee pursue diversity opportunity professional goal addition management specialist career company continuously international company business offer new challenging task enable employee widest range region market world join crossdepartmental project make horizontal today people 60 country work transfer different position area well together company setting team company benefit employee think act ensure different perspective across department location department background combined productively also actively supported relocating staff filling management vacancy aim achieve mix culture gender age group manager site france tunisia puerto rico india germany france usa india example germany sartorius stedim biotech provided 3728544 represented second management level hour training 2015 corresponds vice president continuing internationalize average 124 hour training per employee management lineup medium term scope training hour currently reported corresponds 772 total headcount number post held woman two tier management immediately executive board 246 december 31 2015 2014 252 identifying training talented individual sartorius stedim biotech aim increase proportion woman managerial position 2015 sartorius stedim biotech interesting defined target proportion woman attractive employer fact reflected management german legal entity relatively low turnover rate average company achieved june 30 2017 proportion woman service eight year see page 38 continuously first tier management executive expand personnelrelated program way board scheduled increase 150 attracting retaining developing qualified reporting date june 30 2015 250 employee taking approach ensure second tier 260 300 company remain successful future even faced today shortage skilled worker 2015 sartorius stedim biotech employed 96 people 2014 96 people registered disabled order enhance professional knowledge number 21 work france 72 germany skill experience sartorius stedim biotech offer young people opportunity work within company many year using freedom flexibility work corresponding european union funding program marie curie scheme young scientist generally set employee demanding task leonardo da vinci scheme international vocational delegate responsibility early stage give education possible give intern also freedom define daily work schedule possibility participate training thanks increasing number site respond wide range alliance kedge business school marseille employee need lifestyle permitting france intern aubagne site example company worker flexibly set work schedule attend master business administration option flextime parttime work course offered teleworking enable employee create good work life balance instance german ssb site international scholarship program meanwhile employee opt various workweek schedule supporting talented student graduate flextime parttime work teleworking scientific technical field financially number parttime employee 234 2014 185 also technically personally mentoring equates 58 total headcount 2014 student within organization since 51 sartorius stedim biotech complies 2015 student majoring sale marketing statutory contractual working time obligation opportunity apply scholarship subsidiary working time varies depending local environment business activity 40 management report sustainability report trusting relationship sartorius stedim biotech high safety standard employer employee reduce jobrelated medical condition risk health potential cause industrial accident one aspect corporate culture draw standard international labor regularly promptly share information organization well national regulation employee financial progress strategic recommendation job safety occupational objective change within company condition continuously improved effort information disseminated internal notice responsive concern employee newsletter company magazine among well aubagne site example way country company also comply operate special program implement specific national regulation governing minimum reporting improvement suggested employee prevent deadline regarding change operation potential health hazard regular employee training occupational health safety well france sartorius stedim biotech staff represented environmental protection ensures employee three employee council also applies recognize risk avoid german site employee council hold regular staff meeting 2015 10 collective agreement statistic accident work signed french site 12 german location 2015 2014 cover profit sharing home office equality 1 number work accident 41 54 men woman employee selfservices es number day lost due work manager selfservices ms indian accidents2 1710 1132 subsidiary one collective agreement signed frequency rate3 60 88 deal manufacturing target vacation time severity rate4 2505 1840 instance regarding environmental health safety issue ehs agreement refers 1 excluding accident occurred employee company safety policy several insurance plan travel home work france three collective agreement health 2 measured calendar day 3 insurance signed reporting year represents number accident per 1000000 theoretical working hour theoretical working hour 2015 6826 10613 4 represents number day lost accident occupational health safety per 1000000 theoretical working hour group corporate health management policy cover physical psychosocial workrelated accident site around element health enhance employee performance world dropped 54 41 absolute number motivation reduce illnessrelated cost day lost due work accident time promote awareness personal health among increased compared previous year employee special action day individual mainly due two reason 41 accident site example 2014 introduced advisory occurred five 125 resulted assistance service especially employee traveling 100 day absence case although latter business foreign country staying abroad involve major accident caused event medical emergency safety risk approximately 889 day absence furthermore employee obtain assistance phone find increase explained higher headcount 60 help onsite time france germany frequency rate dropped well previous employee experiencing professional personal year level 88 sartorius stedim biotech regularly problem consult external support service analyzes accident derives preventive measure charge vice president germany may take also use business site advantage annual medical checkup selected partner clinic management report sustainability report 41 ecological sustainability recommendation harmonizing continuously improving process three area sustainable production ecological product worldwide innovation important longterm financial success planning operation look sartorius stedim biotech supply product beyond immediate use resource directly end consumer rather manu understand entire lifecycle product facturers pharmaceutical food chemical including customer process develop also research development laboratory high product efficient safe also level product quality delivery reliability provide ecological benefit building critical customer strictly regulated renovating factory sartorius stedim biotech assesses industry company employ rigorous quality potential environmental impact defines check advanced manufacturing method mitigation strategy necessary supplier process cleanroom technology ensure also required meet specification product used intended comply green approach growth coupled current good manufacturing practice cgmps proportionate use natural resource goal pose risk health safety sartorius stedim biotech achieves various level method process subject constant review information health safety measure adopted part continuous improvement policy sartorius stedim biotech employee described moreover refined appropriately page 40 requirement evolve high standard quality achieved sartorius stedim biotech product reporting year well environmental risk process documented successful identified require company make completion host annual audit customer specific provision annual financial statement certification according standard quality iso 9001 quality management medical device iso 13485 detailed application high standard quality brochure service team provide guidance environmental protection customer correct use product respond rapidly product defect minimize sartorius stedim biotech increasing number adverse consequence sartorius stedim biotech subsidiary apply certification international established traceability system enables u standard thus continuously widening scope recall entire product batch immediately necessary currently manufacturing site certified according internationally recognized quality standard iso 9001 apart tagelswangen improved emission monitoring switzerland employ around 50 staff member legal entity sartorius stedim india sartorius since 2013 sartorius stedim biotech using stedim biotech goettingen since 2015 greenhouse gas protocol ghg global sartorius stedim fmt aubagne certified standard recording greenhouse gas emission international environmental management standard guide reporting co2 emission thus iso 14001 whole 61 manufacturing consider report co2 equivalent co2eq co2 site meet requirement iso 14001 emission gas causing climate change international standard addition subsidiary present stage account emission categorized lourdes mohamdia yauco preparing scope 1 scope 2 scope 1 record co2eq emission certification iso 14001 two plant caused directly production site scope 2 goettingen one guxhagen determines indirect emission arise power manufacture equipment system generation external energy supplier biopharmaceutical production operate energy greenhouse gas emission created management system complies iso 50001 instance manufacture precursor product equates coverage range 44 distribution scope 3 analyzed management system reviewed year plant singleuse bag aubagne sartorius stedim independent organization supported regular ehs biotech considering option gradually meeting briefing ehs officer extending reporting include scope 3 emission international site ensure company complies difficult track calculate relevant environmental law regulation standard company international environmental health occupational safety steering group give 42 management report sustainability report greenhouse gas emission sartorius stedim biotech amount total carbon emission released developed follows 2015 solvent emission occur mainly filter manufacturing goettingen yauco site energy consumption greenhouse gas 406 metric ton reporting year 2014 2015 2014 516 metric ton proportion figure relevance greenhouse gas emission taken total energy consumption mwh 89237 71231 account calculating co 2eq figure electricity 42746 39323 natural gas 43059 29119 fuels1 2331 2009 efficient use energy energy sources2 1101 780 total greenhouse gas emission sartorius stedim biotech strives adapt co 2eq3 24107 208374 consequence climate change reduce scope 15 9556 69664 greenhouse gas emission linked business scope 2 14551 13871 addition make business sense efficiently use key indicator energy company largest location goettingen co2eq emission per employee 74 694 responsible 76 total energy usage co2eq emission per sale revenue focal point effort serf tmio 273 3054 pacesetter company employing stateof 1 data range cover diesel consumption electricity theart technology two energyefficient generator combined heat power plant compressed air 2 including liquid gas center controlling regulating production 3 emission co2eq calculated university equipment sartorius stedim biotech lower carbon applied science art goettingen using emission factor dioxide emission 6000 ton year listed professional software called gabi 4 adjusted smart control system facilitate energy saving 5 excluding fuel consumption car fleet 1300 mwh year company energy management system facilitates systematic identification additional energy saving potential electricity natural gas main energy source representing 95 total energy international site well sartorius stedim consumption goettingen site produce biotech continuously develops manufacturing electricity heat using two combined heat process enhances building facility power plant purchase electricity conserve resource particularly new building supplier largest amount energy increasing proportion renewable energy consumed outside organization linked source energy mix plant yauco transport product material added cover small part energy requirement site energy used business trip employee solar energy furthermore factory commuting us included scope 3 guxhagen tagelswangen source currently recorded energy need local photovoltaic plant use geothermal energy scope 2 emission generated use electricity sartorius stedim biotech make twothirds sartorius reduces environmentally harmful transport climaterelevant emission onethird distance supplying respective market directly emission primarily result use fossil fuel company production site scope 1 natural gas largest source primary greatest degree possible feasible reasonable energy company mix secondary energy use environmentally conscious mean transport source varies among particular region like ship train sartorius lower amount business available consider specific energy used business trip taking step conversion value supplier case increasing use video conference use countryspecific conversion value management report sustainability report 43 success ecofriendly measure water consumption reflected company overall energy 2015 2014 consumption greenhouse gas emission water consumption cbm 336917 299596 increased much lower rate last water consumption per employee cbm 103 100 year company expansion term sale revenue wastewater biological oxygen demandbod1 243 201 reducing climate change 1 contaminated wastewater without sanitary wastewater sartorius stedim biotech measuring scope 3 water primarily drawn public source sartorius well scope 1 scope 2 emission since 2010 stedim biotech also us surface water amount main production site aubagne single wastewater discharged public sewage system use bag using bilan carbone method developed roughly corresponds total water consumption plus french environment energy management rainwater drainage biochemical oxygen demand agency ademe record emission carbon determined production wastewater classified dioxide greenhouse gas resulting significant figure identifies amount entire process upstream downstream dissolved oxygen needed break organic production operation latest analysis 2014 material present wastewater roughly corresponds value obtained previous year main source emission freight transport account 29 use raw material according environmental footprint aubagne site legal regulation impact incoming raw material represents 22 emission business workrelated travel sartorius stedim biotech test safety raw employee 20 building 10 packaging 9 material used ensure comply following identification quantification environmental protection occupational safety main source greenhouse gas emission local regulation europe include rohs current action plan updated optimize directive restriction use certain hazardous distribution finished product include substance electrical electronic equipment commuting plan encourage carpooling public european reach regulation registration transportation among measure evaluation authorisation chemical respective international standard comparable european regulation customer informed sustainable use water resource safety data sheet product safety information warning alert operating instruction water sartorius stedim biotech us hazardous substance present product rinsing manufacture filter membrane according precipitation bath method advanced sartorius stedim biotech defined three type raw casting machine help maximize water efficiency material particularly important manufacturing site goettingen germany bangalore product chemical solvent membrane india company operates water treatment filter cartridge polymer singleuse material system based low water usage strategy stainless steel reusable bioreactors system implemented green facility yauco sartorius 2013 group gradually implementing stedim biotech reduces consumption drinking quantitative indicator raw material water approximately 85 compared 2015 sartorius stedim biotech purchased 4325 metric conventional plant example using rain water ton chemical solvent 2014 3448 metric ton 1467 metric ton polymer 310 metric ton 2014 amount purchased stainless steel reported first time totaled 25870 metric ton 2015 figure indicates quantity purchased invoiced instead amount used 44 management report sustainability report return recyclable material sartorius stedim biotech complies european directive waste electrical electronic sartorius stedim biotech strives reduce waste equipment weee using waste sorting system contributes toward recycling reusable material lowering site germany 43 total proportion waste stored landfill although waste produced using electronic global ehs policy provides guideline signature hazardous material acid specify target met local site oil since 2010 result document latter requested develop appropriate measure production hazardous waste provide digital according national legal requirement proof proper recovery andor disposal ensuring option well internal policy particular effort waste fully tracked end end made share best practice exemplified goettingen site sartorius stedim biotech primarily disposes waste country waste created exception amount waste principle made justified case 2015 2014 instance mohamdia site sends small part waste aubagne disposed properly total amount waste 3471 2812 waste recycling 1712 1461 waste disposal 1759 1351 environmentally friendly expansion waste per employee 106 093 group infrastructure recycling rate 49 52 invest continuously new plant plant expansion accommodate constant growth regarding plantbased solvent goettingen site process sartorius stedim biotech complies made significant improvement past year local regulation practice land use instance solvent used company reduces impact environment manufacture membrane filter cartridge selecting area premise already recovered recycled solvent reprocessing plant developed industrial zone none production site afterwards fed back production site situated nature reserve intact operation without ever leaving premise ecosystem possible maximize green space way maintain closed material cycle minimize minimize impermeable area facility transport requirement reduce quantity good example site bangalore water used waste water produced goettingen although generally estimate impact facility account solvent usage biodiversity negligible sartorius stedim biotech conducting research development strives meet special protection need also continuously reducing overall amount biodiversity hotspot factory tunisia solvent required membrane manufacture use puerto rico located example site less polyethylene packaging sartorius stedim biotech puerto rico expanded 2012 serve switched delivery polypropylene sack central manufacturing logistics site silo manufacture injectionmolded north american market meet highest u component singleuse product standard green resourcesaving efficient construction became first pharmaceutical supplier pharmaceutical industry industry supplier worldwide achieve platinumlevel sartorius stedim biotech currently prohibited certification u green building council regulatory requirement using recycled plastic leed initiative part expansion ground product safety germany goettingen site seeking gain certification consistently employ special waste disposal company german sustainable building council send plastic waste recycling disposed environmentally responsible way manufacturing plant mostly situated france energyrich composite plastic waste industrial area noise pollution resident resulting bag manufacture reused relevant issue company generate energy incineration special power plant large proportion polymer waste separated collected according type material polyamide polyethylene recycling secondary material management report sustainability report 45 within new building extended although singleuse product clear ecological production facility integrate advanced ecological benefit usage generates waste yet utility technology lowering energy consistent reuse recycling improve consumption preventing waste limiting noise environmental performance well ultrapure pollution employee reducing scrap plastic utilize manufacture various single result manufacturing process use product contain around 80 90 often exceed requirement imposed u local energy pure crude oil thus valuable environmental protection regulation secondary raw material high energy content polymer example mean recycled fuel heat power generation sustainable product innovation integrated solution sartorius stedim effort optimize environmental biotech flexact product range example performance product production method approach beyond ecological benefit begin research development stage generally offered singleuse technology flexact reduce amount packaging increase solution reduce need stationary installation share environmentally friendly raw material equipment thus quantity material land step affect safety functionality required versatile central control unit flexact product packaging sartorius stedim biotech instance used number different also work partner industry biopharmaceutical process scientific community sustainable product solution efficient use raw material technical refinement made rd specialist sartopore platinum membrane filter series slashed consumption ultrapure water wetting highperformance product improve rinsing membrane around 95 filter customer environmental footprint significantly lower adsorption lessens amount highvalue protein solution lost result singleuse product becoming increasingly pharmaceutical manufacturer substantially widespread manufacture innovative effective reduce resource recovering higher yield medication practical economic aspect also provide ecological benefit service unit assist customer adapting study shown singleuse product far solution optimally requirement site superior complex reusable system always analyze customer process whole consumption energy water chemical identify potential financial ecological product lifecycle expert compared approach improvement way contribute increasing based primarily reusable material based efficiency environmental compatibility predominantly singleuse material across various customer process scenario included typical industrial 1 manufacturing process monoclonal antibody sinclair lindsay l et al environmental impact result clearcut manufacturer employing mostly disposable technology biopharm int november 2 2008 wwwbiopharmservicescomdocsenvironmentimpactdisposables singleuse solution use around 87 less water pdf rawlings b pora h environmental impact singleuse 30 less energy addition expert found reusable bioprocess system bioprocess int february deployment singleuse solution reduces 2009 18 25 size production unit manufacturer said require 30 less space thus also saving energy material research confirmed energy needed sterilization cleaning material process based singleuse product around half conventional processes1 46 management report sustainability report contributing society local subsidiary involved alongside representative city council industrial business activity many positive effect social community initiative strengthen progress city community competitiveness respective region sartorius stedim biotech operating many focus area infrastructure logistics year instance often one environmental protection education largest local private employer contractor directly indirectly affected business activity main manufacturing site thus supporting local corporate value sustainability openness employment actively promoting regional enjoyment guide u also relationship development together cooperation partner various local stakeholder remain reliable company help shape economic social partner regional organization part environment providing financial support policy maintain constructive open dialogue project education culture social affair sport community based inform additionally contribute toward making region promptly comprehensively operate attractive current activity development could affect future sartorius stedim biotech employee alike also involve project possible expedient example 2015 sartorius stedim social outreach activity targeting area beyond biotech worked close cooperation city home region concentrate field related goettingen local employment agency core business fostering research education employ nine refugee trainee offering supporting event scientific community remain specific practical prospect integration chief priority german community subsequently provided majority intern opportunity qualification job shaping regional environment example project funded yauco reporting year highlighted relatively large production facility sartorius stedim biotech aubagne yauco goettingen local company puerto rico cooperating among key industrial employer respective ten local school award around region instance headquarters aubagne 20 scholarship per year especially talented student city 45000 inhabitant provide lowincome family visit company attractive longterm job 700 people intended motivate take increase around 22 compared 2014 vocational training start university study member large french employer organization sartorius stedim biotech sponsor various youth sport medef sartorius stedim biotech collaborates closely team local sport activity addition national local institute help improve company support two local organization take job market situation another 250 job care homeless yauco industrial sector provided production site singleuse bag mohamdia tunisia alongside commitment regional community expanded yauco plant provides employment sartorius stedim biotech also contributing around 380 people directly sartorius stedim international charitable organization part biotech around 120 additional people initiative christmas donation instead gift since local service provider supplier 2014 reporting year company donated maintenance machine building plant 50000 globally active medical aid security local workforce nearly 1178 people organization action medeor provide healthcare sartorius stedim biotech among large private people refugee camp northern iraq 2014 employer university city goettingen also afmtéléthon received donation conduct major force local economy rural research rare neuromuscular disease german region surrounding nearby guxhagen develop genetic stemcell therapy promising cure management report sustainability report 47 sartorius stedim biotech politically independent sustainable purchasing policy support politician political party finance make contribution sartorius stedim biotech requires business partner kind particularly supplier conduct business activity compliance prevailing law line corporate social responsibility ethical supporting student graduate responsibility sustainable way exclude existing new supplier detect sartorius stedim biotech ensures gain young substantial risk might engage child labor talent dedicated program alliance forced compulsory labor commit international scholarship program provides financial violation human right negative technical personal support student impact company established graduate scientific technical discipline requirement code conduct supplier program intended attract appropriately qualified send supplier service provider young people particularly global growth major supplier required sign written market company enhance international confirmation acknowledging commitment project activity sartorius stedim biotech comply code conduct supplier moreover compliance topic part annual group headquarters aubagne collaborate supplier performance review additionally several school university included monitored part regular quality audit sartorius école dingénieurs marseille enable recently stedim biotech globally standardized qualified biotechnology engineer gain professional procurement channel contract awarded fair experience application engineer marketing transparent process meet generally partnership french higher national school recognized standard biomolecular engineering école nationale supérieure de technologie de biomolécules help finance according general manufacturing policy scholarship awarded student choice sartorius stedim biotech high inhouse manu also successfully collaborate école facturing rate nearly 100 case nationale supérieure de art métiers whose filter membrane regarding trading good student given opportunity attend company sartorius stedim biotech spent 539 million workshop california usa sartorius stedim reporting year mainly supply sourced biotech participates many year actively company based europe u equates program nonprofit organization biotech rate 61 sale revenue partner helping young people lowincome family gain access scientific technical career sponsoring event scientific community partner pharmaceutical biopharma ceutical industry sartorius stedim biotech regularly contributes symposium convention annual conference cover subject development antibody vaccine singleuse system microbiological analysis support example annual aseptic processing conference usbased international society pharma ceutical engineering ispe annual meeting parenteral drug association pda various regional ispe pda convention 48 management report table concordance table concordance grenelle ii french decree april 24 2012 page sustainable corporate management sustainability policy 34 35 scope reporting 34 methodological note 34 attestation regard exhaustiveness fairness information 50 social information employment total workforce breakdown region function gender age 36 37 new hire redundancy 38 compensation benefit expense 35 37 work organization organization working time 39 40 absenteeism 38 social relation organization social dialogue 36 40 outcome collective agreement 40 health safety health safety condition work 40 agreement signed regarding occupational health safety 40 work accident 40 training people development policy implemented regarding people development 38 39 training hour cost 39 equal treatment gender equality 39 employment people disability 39 policy discrimination 35 promotion compliance provision ilo convention compliance freedom association right collective bargaining 35 40 elimination discrimination respect employment occupation 35 47 elimination forced compulsory labor 35 47 abolition child labor 35 47 environmental information general environmental policy environmentrelated assessment certificate 49 training employee ehs issue 39 provision environmental risk 41 pollution waste management emission air 42 44 waste prevention recycling reduction measure 44 noise pollution 45 sustainable use resource water consumption 43 raw material measure undertaken improve efficiency usage 43 44 45 total energy consumption breakdown electricity natural gas fuel 42 land use 45 climate change greenhouse gas emission 42 biodiversity protection impact biodiversity 44 45 societal information territorial economic social impact company activity impact employment regional development 46 47 impact neighboring community 46 47 relation maintained stakeholder condition dialogue stakeholder 36 40 philanthrophic sponsorship activity 46 47 subcontractor supplier integration social environmental stake company purchasing policy 35 47 importance subcontracting integration csr relationship supplier subcontractor 47 fair operating practice action implemented prevent corruption 35 47 measure implemented promote health safety consumer 40 activity support human right 35 management report statutory auditor report sustainability report 49 statutory auditor report sustainability report report one statutory auditor appointed omission explained pursuant third independent third party party consoli paragraph article r 225105 french dated human resource environmental social commercial code attestation completeness information included management report csr information free english translation statutory express limited assurance conclusion csr auditor report issued french provided information taken whole material solely convenience englishspeaking reader respect fairly presented accordance report read conjunction guideline conclusion fairness csr construed accordance french law information professional standard applicable france work carried team four person year ended december 31st 2015 december 2015 february 2016 lasted around three week assisted work shareholder expert corporate social responsibility capacity statutory auditor sartorius performed work accordance stedim biotech company appointed french professional standard order independent third party party certified dated 13 may 2013 defining condition cofrac number 310481 hereby report independent third party performs consolidated human resource environ engagement isae 30002 concerning mental social information year ended conclusion fairness csr information december 31st 2015 included management report hereinafter named csr information 1 attestation completeness pursuant article l2251021 french csr information commercial code code de commerce nature scope work company responsibility basis interview individual charge board director responsible preparing relevant department obtained company management report including csr understanding company sustainability strategy information required article r2251051 regarding human resource environmental impact french commercial code accordance guide activity social commitment line used company hereinafter guideline applicable action programme arising summarised management report available request company head office compared csr information presented management report list provided article independence quality control r2251051 french commercial code independence defined regulatory text event omission certain consolidated french code ethic code de déontologie formation verified explanation provid profession requirement article l82211 ed accordance third paragraph french commercial code addition article r 225105 french commercial code implemented system quality control including documented policy procedure regarding consolidated information disclosed compliance ethical requirement french verified explanation provided professional standard applicable legal accordance article r225105 paragraph 3 regulatory requirement french commercial code statutory auditorss responsibility verified csr information cover scope consolidation ie company subsidiary basis work responsibility defined article l2331 controlled entity attest required csr information defined article l2333 french commercial code presented management report event within limitation set management report 50 management report statutory auditor report sustainability report conclusion regarding csr information considered important3 based work given limitation mentioned attest required csr information parent entity level referred documentary disclosed management report source conducted interview corroborate qualitative information organisation policy action performed analytical procedure 2 conclusion fairness quantitative information verified using csr information sampling technique calculation consolidation data also verified nature scope work information consistent agreement information management report conducted approximately twenty interview person responsible preparing csr level representative sample entities4 information department charge collecting basis activity contribution information appropriate responsible consolidated indicator location risk internal control risk management procedure analysis conducted interview verify order procedure properly applied performed test detail using sampling technique order assess suitability guideline term verify calculation reconcile data relevance completeness reliability neutrality supporting document selected sample understandability taking account represents average 44 headcount industry best practice appropriate 43 98 quantitative environ mental data verify implementation datacollection compilation processing control process reach remaining consolidated csr information completeness consistency csr assessed consistency based understanding information obtain understanding company internal control risk management procedure used prepare csr information also assessed relevance explanation provided information disclosed determined nature scope test either whole part procedure based nature importance csr information respect characteristic believe sampling method sample company human resource environmental size used based professional challenge activity sustainability strategy judgement sufficient provide basis industry best practice limited assurance conclusion higher level assurance would required u carry extensive procedure due use sampling technique limitation inherent information internal control system risk detecting material misstatement csr information cannot totally eliminated management report statutory auditor report sustainability report 51 conclusion based work nothing come attention cause u believe csr information taken whole presented fairly material respect accordance guideline 1 whose scope available wwwcofracfr 2 isae 3000 assurance engagement audit review historical financial information 3 quantitative total number employee end year new hire redundancy number parttime employee absenteeism rate number workrelated accident including commuting accident number day lost due work accident frequency rate severity rate total number training hour wastewater quantity waste recycling quantity waste disposal recyling rate water consumption m3 purchase chemical solvent purchase polymer energy consumption mwh electricity natural gas fuel total greenhousegas emission scope 1 2 qualitative encouraging social dialogue high standard quality environmental protection information related code conduct return recyclable material supporting regional employment development 4 sartorius stedim system gmbh sartorius stedim bioprocess sarl sartorius automation ltd neuillysurseine february 19 2016 one statutory auditor deloitte associes christophe perrau julien rival partner partner sustainability service 52 management report opportunity risk report opportunity risk report every business activity entail opportunity risk throughout group opportunity short managed skill term nature considered annual budget done go long way determining future planning medium longerterm opportunity development company shareholder value tracked systematically part strategic planning managing risk opportunity sartorius stedim status opportunity management permanent biotech aim identify use business fixture corporate management system mean opportunity systematically well recognize also feature discussion decision evaluate risk early stage take measure making process toplevel management counter possible unrealistic expect risk management eliminate risk rather key area opportunity presented approach intentionally take certain risk describe section specific risk measure risk business activity order represent opportunity event develop successful unlocking opportunity however opposite positive direction reason discus endeavor important keep risk contained opportunity section specific risk within acceptable limit control carefully opportunity end chapter sartorius stedim biotech single organizational unit tasked identifying managing area opportunity opportunity risk instead prefers make function integral component groupwide supplier pharmaceutical laboratory planning control system described industry sartorius stedim biotech operates internal control system compliance department futureoriented highgrowth sector responsible development group risk management system including organization assessment rank company one respective reporting process global market leader many subsegments product area believe high quality product strong brand recognition managing opportunity established customer relationship give u strong opportunity continue extending market opportunity management center analysis leadership target market sector environment well assessment trend give strong strict management process cost provides indication future business opportunity opportunity increase profitability key identification potential development target area respect include continued context one key role relevant enhancement procurement chain ongoing manager initially take place local rather effort optimize production central level marketfacing function strategic marketing product management opportunity discussed context individual division play leading role presentation specific risk opportunity respect central business development unit beginning page 54 additionally support area market monitoring data analysis implementation strategic project part strategy review member group executive committee regularly meet manager operational responsibility business development unit discus short medium longterm opportunity potential various business area subsequent step prioritizing opportunity evaluating business management perspective deriving strategic measure allocating resource proceed accordance standardized decisionmaking process applies management report opportunity risk report 53 risk management urgent reporting procedure place ensure new emerging significant risk opportunity management overall net worth financial position profitability responsibility maintenance effective risk identified estimated involving 25 million management system ensuring comprehensive higher audit committee receives consistent management material risk rest necessary detail without undue delay audit committee coordinating developing system responsibility internal control system compliance department audit risk classification committee monitor effectiveness risk management system furthermore carrying first level risk management relates four statutory audit mandate annual financial main risk category defined sartorius stedim statement consolidated financial statement biotech external risk operating risk financial risk independent auditor examine whether early corporate governance risk warning system place capable prompt identification risk could jeopardize future second level consists additional subcategories company classify within main category supply chain risk sale distribution risk quality risk risk management system risk reporting categorize risk according scale heart risk management system implication also perform specific sartorius group risk management handbook evaluation risk assigned value applies throughout entire group organization maximum impact time risk analysis handbook includes definition word record maximum risk without framework structural organization process risk considering probability occurrence reporting monitoring control effect risk mitigation measure effectiveness risk management system based internationally recognized coso standard purpose report assessed also number source contain probability risk shown stipulation handling risk including adjacent column classify particular significance article association rule procedure entire group group company internal guideline probability occurrence groupwide risk reporting system form corner low 5 stone internal risk communication object medium 5 20 make possible address risk structured high 20 continuous manner document accordance relevant statutory regulatory requirement significance prescribed reporting process risk category impact thousand earnings impact asset subsequently described establishes rule limited significance 1000 5000 ongoing review information risk situation new organizational unit joining significant 1000 5000 consolidated group company successively integrated reporting process involves evaluating specific risk probability occurrence scale potential impact well reporting case central risk management unit whenever defined threshold breached 54 management report opportunity risk report explanation principal risk opportunity system reduces risk enabling u monitor control procurement activity moreover conduct regular supplier review also use early general macroeconomic warning system addition always maintain risk opportunity reserve inventory strategic raw material work alternative supplier possible business cycle risk present see low probability occurrence nature various business area mean risk described risk happen sartorius stedim biotech whole insulated occur likely limited significance certain extent full force wider cyclical sartorius group effect opportunity arise area procurement economic development prove positive growth enables u increase order expected turn additionally stimulate quantity thereby strengthen position stronger growth lab product service supplier increased globalization supplier pool hold prospect purchasing general risk favorable term moreover also possibility expanded purchasing activity ability foresee mitigate direct international market leading u identify supplier indirect effect risk broader sense example special product technical expertise could currency crisis natural disaster associated eventually enhance competitive edge damage commercially significant critical infrastructure limited production risk opportunity risk discussed section consider probability occurrence low medium manufacture large proportion case occurrence significant product belong core area technical sartorius group whole individual expertise involve high level vertical group company integration product reusable fermenters bioreactors manufactured collaboration supplier supply chain risk opportunity production risk transferred external third party manufacture product also supply chain extends way bear associated risk capacity bottle procurement production sale distribution neck overcapacity production downtime excessive problem within workflow consequential reject rate high level tiedup working capital effect including delay delivery global contain reduce risk planning supply chain management system instituted production capacity carefully using versatile throughout production process prevent machine semiautomated individual workstation problem largely minimizes associated risk flextime work schedule continuously analyzing controlling operation monitoring production process moreover global involved strongly international alignment manufacturing network enables u compensate organization open whole series opportunity capacity bottleneck shifting production various risk opportunity encountered regional plant within supply chain explained detail regard probability occurrence concerning risk described low risk happen procurement risk opportunity occur significant individual group company purchase wide range raw material component part service supplier consider opportunity various consequently exposed risk unexpected production facility able concentrate delivery bottleneck price increase well specific manufacturing technology result obligatory minimum purchase quantity may enhance production operation greater result claim compensation reach efficiency international production network also quantity global supply chain management make possible capitalize cost advantage management report opportunity risk report 55 offered individual site furthermore continuous quality risk opportunity improvement production simplifying process increasing level automation customer use sartorius stedim biotech product help drive efficiency even higher wide range critical production process including manufacture pharmaceutical food chemical research development sale distribution risk opportunity laboratory main risk encountered area noncompliance agreed quality criterion use variety channel sell distribute lead loss customer product around world potential risk entailed customer may made liable unexpected change demand structure compensation claim employ rigorous quality growing price pressure noncompliance supply check stateoftheart production method agreement concluded customer employ process cleanroom technology ensure targeted market analysis identify emerging demand product satisfy stringent quality trend individual segment early standard high regulatory requirement time respond appropriately technical manufacturing method process subject innovation focus less pricesensitive sale constant review continuous improvement market product validated production process moreover refined appropriately process biopharmaceutical industry reduce requirement evolve successful completion exposure risk growing price pressure host annual audit customer minimized risk exposure area logistics accreditation iso 9001 iso 13485 together recent year setting using central warehouse document high level quality achieved optimize distribution logistics sartorius stedim biotech product process irrespective measure also maintain area well probability risk significant insurance coverage product liability occurring low medium according estimate risk sartorius stedim biotech established case occurrence traceability system enables u recall entire significant sartorius group whole production batch immediately necessary individual group company minimize adverse consequence event defect discovered product opportunity arise area sale distribution increasing breadth consider probability occurrence product range put u position sell new risk described low case product existing customer business occurrence significant sartorius group relationship established whole individual group company long term global presence provide opportunity moreover ongoing project quality requirement growing strengthen direct sale also promise enhance stringent time least result sale prospect regulatory pressure actually regard first foremost risk opportunity open new market prospect also challenging quality demand represent considerable barrier entry potential new competitor provide stimulus technical innovation actively respond 56 management report opportunity risk report rd risk opportunity competitive risk opportunity devote considerable share resource sartorius stedim biotech leading competitive research development potential risk position market area may arise development result competitor larger u share diverge market need exceeding planned status globally operating company example development deadline unintentional transfer include merckmillipore danaherpall serve knowhow competitor advanced project large number customer highly regulated management intensive rd controlling early sector like pharmaceutical food industry involvement customer development technology barrier market entry process substantially limit rd risk patent substantially high regard probability new continuous tracking technology competitor emerging within short term low competitor relevant u secure technology furthermore global presence significantly position mitigates individual regional risk reason see low probability change competitive environment example present risk described might occur consolidation market pose opportunity case could significant sector find ongoing process sartorius group whole change sartorius stedim biotech actively participating made acquisition hand rd sphere also offer continuously recent year reinforce market number potential opportunity intensive position open new potential synergy collaboration partner rank among global market leader field open opportunity u jointly develop product acquisition risk opportunity especially high level innovation area membrane technology fermentation technology nature acquisition provide many opportunity turn expertise specialist put u sale growth extension product forefront global research development portfolio development new market present u opportunity turn contrast purchase sale company part technical knowledge potential sale even company entail number inherent risk stronger position market incorrect valuation assumption insufficient usage anticipated synergy effect prevent risk take various measure particular customer risk opportunity acquisition process performing standard due diligence review addition involve external sartorius stedim biotech source key customer consultant expert purchase sale pharmaceutical chemical food industry process required especially focus drafting research educational institution transaction contract adequately counter public sector customer usually relatively risk especially clause assuring specific large organization existence characteristic contractual warranty guarantee time strong credit rating provision well agreement mechanism business area highly diversified customer base adjustment purchase price liability group whole dependent clause immediately acquisition taken individual key account significant degree place integration phase initiated potential risk likewise detected early present see low probability possible prevented minimized taking risk associated customer might occur appropriate counteraction case occurrence would likely limited significance sartorius group whole consider probability occurrence individual group company risk described low case occurrence significant sartorius group whole individual group company management report opportunity risk report 57 personnel risk opportunity risk associated group accounting innovative technology group sartorius stedim except general typical risk inherent biotech employ large number highly qualified accounting process specific risk concerning group people counter threat demographic accounting discernible typical accounting error change losing employee especially connection example incorrect key position offering performancerelated discretionary decision measurement asset remuneration model targeted continuing professional liability use various common development option attractive social benefit standardized control mechanism integrated continuous education training junior staff accounting process ensures error member within organization interesting recognized corrected early stage people development opportunity success measure apparent low attrition rate recent year many year seniority exchange rate risk opportunity people accumulate average employment contract certain case contain clause prohibiting move generate around half consolidated sale direct competitor revenue foreign currency twothirds total revenue u dollar currency pegged reason regard probability risk u dollar positively negatively occuring low risk happen occur impacted currency effect especially likely limited importance sartorius converting currency balance sheet item group whole opportunity sartorius stedim profit loss item respectively largely biotech primarily arise qualify compensate general risk resulting staff offering training course retain impact individual foreign currency taken staff long term thus covering company number measure besides hedging currency need qualified personnel particularly well global production network thus enables u offset lion share sale revenue received foreign currency within group cost likewise financial risk opportunity incurred foreign currency example manufacture many product north global nature sartorius stedim biotech american market locally therefore group operation mean business activity disadvantaged way competition u inevitably exposed financial risk rival continuously monitor exchange rate significant aside risk associated net currency exposure ie proportion group accounting exchange rate risk interest foreign currency sale revenue remains rate risk liquidity risk described settled cost likewise foreign necessary addressed detail note currency use derivative financial instrument consolidated financial statement vice versa hedging instrument primarily spot forward financial risk notably exchange rate risk swap transaction basis current interest rate risk balanced opportunity anticipated net currency exposure foreign approximately equal magnitude currency level individual case target redemption forward used optimize exchange rate consider probability occurrence make policy hedge 70 exposure risk described following low risk happen advance following 18 month due occur significant sartorius group historic exchange rate low extended hedge whole individual group company u dollar 36 month reporting year hedging transaction set one group staff monitored another separate group see consolidated financial statement p 148 58 management report opportunity risk report interest rate risk opportunity environmental risk concluded fixed interest agreement sartorius stedim biotech established environ portion outstanding loan eliminate risk mental management system encompasses posed variable interest payment however integrated division cover whole series financial instrument outstanding reporting environmentally relevant regulation minimize date subject interest based market rate environmental risk management system almost twothirds currently covered certified compliance iso 14001 number interest rate swap interest rate risk company relatively large manufacturing site opportunity apply remainder monitor respective company organizational unit ensure interest rate trend interest rate exposure particular site law regulation relating constantly facility arrange additional environmental protection observed hedging transaction consider necessary technical possibility limiting environmental risk economically advisable individual loan identified ongoing basis see consolidated financial statement p 150 assess probability occurrence environmental risk low case liquidity risk opportunity occurrence significant group company affected sartorius stedim biotech group actively manages liquidity centrally order check minimize liquidity risk optimize liquidity management risk opportunity within organization purpose use various long shortterm financial instrument besides risk already described sartorius stedim biotech group exposed potential risk term syndicated loan agreement area result pronounced dependence extended one year end system since errorfree operation 2020 subsidiary continue financed primarily essential smooth functioning company financing contract within group business process reduce security risk continuously enhancing implementing security shortterm liquidity procurement also employ guideline policy rule measure various instrument addition credit line based requirement iso 27001 accessed repaid short notice standard german federal office number bilateral credit line place smaller information security bsi standard furthermore scale individual group company furthermore company existing application system use cash pooling agreement selected group checked potential risk regular external company primary tool manage liquidity internal audit appropriate measure taken within group see consolidated financial minimize risk identified continuous alignment statement p 150 strategy business strategy tracking new technical development use advanced hardware software minimize risk inherent regulatory risk operation system environment new erp system commissioned sartorius stedim biotech role supplier biopharmaceutical goettingen group headquarters 2012 industry health care provider mean successively rolled group site around sartorius stedim biotech also affected world since 2015 erp system successfully underlying development area possibility commissioned 2015 north america conducting regulatory authority fda emea adopting project continued focus restrictive approach approval new controlling risk involved maintaining medication remains principal source risk precautionary backup system implementation context move would reduce number new system brings whole series new pharmaceutical product marketed opportunity especially relation efficiency gain would consequently downgrade future prospect standardization harmonization business sartorius stedim biotech medium term process worldwide management report opportunity risk report 59 believe low probability occurrence risk mentioned case occurrence significant sartorius group whole process risk process risk sartorius stedim biotech arise pending forthcoming legal dispute administrative proceeding judicial extrajudicial dispute attended company legal expert engage external lawyer needed present pending discernible legal dispute proceeding lack cost coverage allowance statement financial position could substantial negative impact group insurance taken insurance policy cover wide range risk possible economically advisable insurance policy include coverage liability property damage business interruption transport material pecuniary damage risk provide comprehensive coverage legal cost independent department working conjunction external insurance broker regularly review nature extent insurance protection make adjustment necessary assessment overall risk situation risk outlook feasible adopted countermeasure arranged balance sheet measure reporting year cover discernible risk within sartorius stedim biotech group potential damage net worth financial situation profitability judge probability occurrence risk presented low case occurrence significant sartorius group whole individual group company 60 management report opportunity risk report risk category probability occurrence significance general macroeconomic risk business cycle risk medium significant general risk low significant supply chain risk procurement risk low limited significance produktion risk low significant sale distribution risk medium significant quality risk low significant rd risk low significant customer risk low limited significance competitive risk low limited significance akquisition risk low significant personnel risk low limited significance financial risk risk associated group accounting low limited significance exchange rate risk medium significant interest rate risk medium significant liquidity risk low significant regulatory risk low limited significance environmental risk low limited significance risk low significant process risk low limited significance purpose report assessed probability occurence risk shown adjacent column classify particular significance entire group thorough analysis entire risk situation according current review discernible risk present could jeopardize continued existence group similarly based current review discernible risk could jeopardize future existence group management report forecast report 61 forecast report solid prospect pharmaceutical industry biotech sector enjoys aboveaverage growth future global pharmaceutical industry expert forecast biopharma segment continues driven large part constantly pharmaceutical market enjoying expanding aging global population increasing particularly strong growth year continue access healthcare emerging developing outperform market proportion sale country development new medicine revenue accounted medication vaccine particularly disease currently difficult manufactured using biotech method expected treat however expiration patent austerity rise currently around 24 approximately 27 measure restrict healthcare spending particular 2020 industrialized country trend slow growth industry market researcher ims health ongoing overproportionate growth driven forecasting overall growth 4 7 largely increasing market penetration global pharmaceutical industry period already approved biopharmaceuticals 2015 2020 expansion range indication however comparatively young segment also great u pharmaceutical market world largest innovative power reflected strong research expected grow rate 5 8 average development pipeline overall around 40 period 2015 2020 expansion medication pipeline based biological driven principally new innovative medication manufacturing process fading influence expiring patent expansion state health insurance great innovative power biotechnology sector particularly recent year also seen growth european pharmaceutical market rising number new product approval likely remain moderate next year number newly approved biological medication continuing austerity measure affect national usa last five year around 50 healthcare system thus average growth higher number approval period 1 4 projected region 2020 2006 2010 expansion emerging economy including china india brazil russia contrast remain whole market observer evaluate pharma average around 7 10 per annum 2015 estimate growth global biotechnology 2020 owing demographic trend rising level market average 8 9 per year state investment healthcare system increased year 2015 2020 private spending biopharma growing market q growing aging population q increasing access healthcare 2015 2020 8 9 q strong rd pipeline 24 27 cagr1 q emerging biosimilars market q conventional unclassified q biotechnology 1 evaluate pharma world preview 2015 outlook 2020 june 2015 cagr 2014 2020 62 management report forecast report since number medication manufactured using future business development biotech method due lose patent protection next year expert forecast outlook fiscal 2016 incorporates risk market biosimilars post strong growth opportunity outlined report supply currently 200 company working biopharmaceutical industry business development around world 700 project generally driven stable longterm trend development biotech copycat medicine therefore economic fluctuation play less role however regulatory patent marketingrelated example decision regulatory agency uncertainty making difficult predict regarding drug approval use medication market launch drug accurately market share biosimilars currently still small based assumption relevant trend expert estimate year 2020 sale sartorius stedim biotech correctly quadruple u 10 billion anticipated expect sale revenue grow considerably 2016 thus forecast sale revenue rise 12 16 publicsector research moderate growth constant currency expected management expects underlying ebitda demand public sector likely rise slightly margin rise 1 percentage point 2016 frost sullivan expects growth around 2 constant currency 2015 262 margin usa world largest market laboratory improvement projected equally driven product europe comparatively moderate economic economy scale well favorable growth likely result demand currency development 2015 development slightly last year level one source support last year currency environment full euwide horizon 2020 research positive effect margin 2016 development program provide total hedging activity 80 billion funding 2014 2020 regard financial position forecast source ims ims health market prognosis may 2015 evaluate end 2016 ratio net debt underlying pharma world preview 2015 outlook 2020 june 2015 frost ebitda edge level 04 reported sullivan 2015 annual report forecast analysis 2015 without taking potential acquisition global market laboratory product november 2015 account wwwfdagov citi research biosimilars real dangerous coming soon february 2015 bernstein biosimilars moreover 2016 plan invest 6 8 november 2015 sale revenue primarily expansion production capacity management report financial statement parent company sartorius stedim biotech sa december 31 2015 63 financial statement parent company sartorius stedim biotech sa december 31 2015 financial statement parent company application 40 allowance retained without modification accordance sartorius stedim biotech sa parent company article 158 3 2 4 french general income group company mixt holding company code company managing investment group real estate french company dividend paid april 15 2016 2015 sale revenue generated sartorius stedim amount distributed january 1 2012 biotech sa 1593 k relative 1465 k 2014 eligible tax rebate follows operating profit 3307 k versus 2817 k 2014 net financing income totalled 33286k versus income eligible noneligible 27194k 2014 tax rebate income fiscal year ended dividend distributed net profit 2015 29312 k compared 24845 k 2014 dec 31 2014 19967009 0 dec 31 2013 18412315 0 dec 31 2012 16876856 0 appropriation net profit asm suggest appropriate net profit sartorius stedim biotech sa share capital 2931174842 reporting year 2015 follows share capital december 31 2015 legal reserve 80000 total capital amount fifteen million three hundred balance resulting deduction legal reserve sixtyseven thousand two hundred thirty 2931094842 eight euro 15367238 divided 15367238 share worth one euro 1 fully subscribed following amount added balance paid heading article 6 bylaw yearearlier profit carried forward 1341553087 would yield distributable profit evolution share capital 4272647929 sartorius stedim biotech sa total amount dividend disbursed beginning 2015 fiscal year share shareholder 3073447600 capital company fifteen million three hundred fiftynine thousand two hundred thirty balance resulting disbursement 1199200329 eight euro 15359238 year share capital company rose fifteen million three remaining amount 1199200329 hundred fiftynine thousand two hundred thirty carried next year eight euro 15359238 fifteen million three hundred sixtyseven thousand two hundred therefore considering company hold thirtyeight euro 15367238 stock treasury share net dividend 200 paid option exercised every share par value 1 reduction share capital annual shareholder meeting acknowledges informed new tax regulation must kept mind extraordinary dividend according 2013 finance law shareholder meeting held 19 april 2010 abolished right choose withholding tax term seventh resolution authorized 21 submitting dividend board director trade share distribution progressive scale tax income share buyback program specified 64 management report financial statement parent company sartorius stedim biotech sa december 31 2015 maximum number share purchased share purchased share buyback company authorisation could exceed program allocated following ten per cent 10 total number share objective comprising share capital maximum purchase price fortyfive euro 45 per share 849969 share representing approximately five per ii share thus purchased allocated cent 5 company share capital ex following objective change payment within scope potential ex ternal project handle secondary market liquidity 848741 share representing approximately five per share company cent 5 company share capital deliver share case exercise right delivered case exercise right attached security giving access company attached security giving access mean share capital immediately future date share capital allocate repurchased share bought company company officer employee company andor company group within scope board director report submitted stock option plan free granting extraordinary shareholder meeting 8 april 2014 share company saving plan etc proposed said meeting reallocate share retain company share purchased share buyback program purchased order return exchange pay objective cancellation part share ment within scope potential external project share capital reduction accordance cancel repurchased share authorisation granted extraordinary share capital reduction company shareholder meeting 19 april 2010 pursue objective subsequently permitted applicable law regulation extraordinary shareholder meeting held 8 april 2014 authorized board director proceed meeting held 19 april 2010 board cancellation one several installment director unanimously decided implement decision alone portion share acquired share buyback program pursuant condition set company context share repurchase forth extraordinary shareholder meeting held programme limit ten per cent 10 19 april 2010 company share capital period twentyfour 24 month provided ten percent 10 limit course 2010 fiscal year company applied company share capital acquired one million six thousand ninetyeight necessary adjusted take account transaction seven hundred ten 1698710 share affecting share capital company occur representing approximately exceeding ten per subsequent shareholder meeting cent 10 share capital pursuant share buyback program authorized extraordinary extraordinary shareholder meeting held shareholder meeting held 19 april 2010 8 april 2014 authorized board director reduce company share capital accordingly share acquired aggregate amount sixtyone million three hundred twentyseven extraordinary shareholder meeting held thousand one hundred ninety euro seven cent 8 april 2014 granted board director 6132719007 corresponding average price authorization period twentysix 26 month thirtysix euro ten cent 3610 per share date extraordinary shareholder meeting held 8 april 2014 meeting 17 july 2014 board director light authorisation granted extraordinary shareholder meeting hold 8 april 2014 reduced share capital nominal amount one million thirtysix thousand two hundred thirteen euro ten cent 103621310 cancelling entirety share acquired share buyback program authorised extraordinary shareholder meeting held 19 april 2010 ie one million six hundred management report financial statement parent company sartorius stedim biotech sa december 31 2015 65 ninetyeight seven hundred ten 1698710 share authorisation granted period five specified amount share 5 year date extraordinary represents less ten per cent 10 share shareholder meeting held 8 april 2014 capital company date operation difference purchase price 17 july 2014 board director using cancelled share 6132719007 nominal delegation power granted value 103621310 difference equal sixty extraordinary shareholder meeting 8 april 2014 million two hundred ninety thousand nine decides carry share capital increase hundred seventysix euro ninetyseven cent capitalization five million nine hundred ninety 6029097697 charged thousand one hundred two euro eightytwo available premium thirtyseven million eight cent 599010282 drawn issue hundred eightyeight thousand nine hundred twenty premium set forth annual account nine euro eighteen cent 3788892918 company financial period closed balance twentytwo million four hundred two 31 december 2013 approved extraordinary thousand fortyseven euro seventynine cent shareholder meeting held 8 april 2014 2240204779 item retained earnings share capital increase carried operation reduction share capital increase thirtynine cent 039 nominal le share capital amounted nine million three amount fifteen million three hundred fiftynine hundred sixtynine thousand one hundred thirtyfive thousand two hundred thirtyeight 15359238 euro eighteen cent 936913518 divided share comprising share capital company fifteen million three hundred fiftynine thousand nominal unit value went sixtyone cent two hundred thirtyeight 15359238 share 061 one euro 1 nominal unit value sixtyone cent 061 sum cost relating share capital increase share capital increase charged one several available reserve deduct amount extraordinary shareholder meeting held sum necessary increase legal reserve 8 april 2014 decided increase share capital maximum nominal amount six million six hundred end definite completion reduction fortysix thousand four hundred ninetynine increase company share capital done euro thirtyfour cent 664649934 calculated 17 july 2014 company share capital basis number share existing amount fifteen million three hundred fifty date aforementioned shareholder meeting nine thousand two hundred thirtyeight euro carried proportional 15359238 divided fifteen million three capitalisation available sum drawn issue hundred fiftynine thousand two hundred thirty premium operation done eight 15359238 share nominal unit value increase nominal unit value seventeen one euro 1 million fortytwo thousand three hundred six 17042306 existing share sixtyone cent 061 one euro 1 said extraordinary shareholder meeting authorized board director implement decision increase share capital consequently determine definitive nominal amount share capital increase based number share existing date decision board director complete share capital increase 66 management report financial statement parent company sartorius stedim biotech sa december 31 2015 number share share capital share par share capital share number new date nature transaction value increase premium share transaction transaction exercise share 1st half 2010 subscription option 061 162669 4869394 26667 16999388 103696270 exercise share 2nd half 2010 subscription option 061 85766 2285999 14060 17013448 103782036 exercise share 1nd half 2011 subscription option 061 61000 1344000 10000 17023448 103843036 exercise share 2ndhalf 2011 subscription option 061 15250 722500 25000 17025948 103858286 exercise share 1st half 2012 subscription option 061 50980 1734460 83580 17034306 103909266 exercise share 2st half 2012 subscription option 061 42700 2023000 70000 17041306 103951966 exercise share year 2013 subscription option 061 6100 86200 10000 17042306 103958066 exercise share year 2014 subscription option 061 95416 1348340 156420 17057948 104053482 reduction capital cancellation treasury year 2014 share 061 10362131 16987100 15359238 93691351 increase capital year 2014 nominal value change 100 59901028 15359238 153592380 exercise share year 2015 subscription option 100 80000 1748800 80000 15367238 153672380 sartorius stedim biotech sa shareholding december 31 2015 situation sartorius stedim biotech sa shareholding shareholder share voting right 50 sartorius ag sartorius ag 10 less 50 none none 5 less 10 none none management report financial statement parent company sartorius stedim biotech sa december 31 2015 67 past three year ownership sartorius stedim biotech share capital distributed follows december 312013 december 31 2014 december 31 2015 number share voting number share voting number share voting shareholder share capital right share capital right share capital right sartorius ag 9770178 573 725 9770178 636 726 9770178 636 724 single voting right double voting right 9770178 573 725 9770178 636 726 9770178 636 724 vl finance 1642095 96 122 1642095 107 122 1642095 107 122 single voting right double voting right 1642095 96 122 1642095 107 122 1642095 107 122 total sartorius group 11412273 670 846 11412273 743 848 11412273 743 846 treasury share 1698710 100 00 personnel shareholder general public 3931323 231 154 3946965 257 152 3954965 257 154 single voting right 3720587 218 138 3736229 243 139 3744229 244 139 double voting right 210736 12 16 183150 12 14 212925 14 16 total share 17042306 1000 1000 15359238 1000 1000 15367238 1000 1000 belonging sartorius ag reverse merger sartorius stedim legal disclosure threshold crossed legal disclosure threshold crossed registered fiscal year study share issued capital voting right voting right vl finance 1642095 1069 3284190 1217 sartorius ag 9770178 6361 19540356 7239 total sartorius ag 11412273 7430 22824546 8456 control company december 31 2015 unpaid capital sartorius ag hold directly indirectly 74 none share capital 85 outstanding voting right treasury share without voting right authorized unissued capital staff shareholding none none security representative share capital treasury share held none sartorius stedim biotech sa none 68 management report financial statement parent company sartorius stedim biotech sa december 31 2015 authority delegated annual shareholder meeting board director still valid delegation granted shareholder meeting 8 april 2014 board director 1 delegation power object duration limit use 2015 able increase share capital company limit equal 664649934 corresponding none capitalizing everything portion issue premium maximum nominal amount increase share increasing nominal value existing share currently capital amounting 061 1 granted period 5 year 08 april 2014 able reduce share capital limit amount 10 adjusted capital account none cancellation share purchased share buyback necessary transaction affecting share capital program performed combined shareholder meeting 08 april 2014 actual completion date capital reduction made board director granted period 26 month 08 april 2014 2 delegation competence object duration limit use 2015 ability issue share andor security giving access limit 2000000 corresponding maximum none share capital company andor security giving nominal amount increase share capital right allotment debt instrument maximal nominal amount debt instrument preferential subscription right shareholder 2000000 maximum overall limit maximum nominal amount debt instrument granted period 26 month 08 april 2014 ability issue share andor security giving access limit deducted overall limit 2000000 none share capital company andor security giving increase share capital overall limit right allotment debt instrument without 2000000 debt instrument preferential subscription right shareholder public offering granted period 26 month 08 april 2014 ability issue share andor security giving access limit deducted overall limit 2000000 none share capital company andor security giving increase share capital overall limit right allotment debt instrument without 2000000 debt instrument preferential subscription right shareholder private placement set forth article l411 2 ii french monetary financial code granted period 26 month 08 april 2014 ability event issuance share andor limit amount 10 share capital period 12 none security giving access share capital company month deducted overall limit 2000000 public offering private placement set forth increase share capital overall limit article l411 2 ii french monetary financial code 2000000 debt instrument without preferential subscription right shareholder set issuance price condition defined shareholder meeting maximum ten per cent 10 share capital per year granted period 26 month 08 april 2014 ability increase number share andor security limit amount 15 initial issue share none giving access share capital company issued deducted overall limit 2000000 increase event share capital increase without share capital overall limit 2000000 debt preferential subscription right shareholder instrument management report financial statement parent company sartorius stedim biotech sa december 31 2015 69 granted period 26 month 08 april 2014 ability issue share andor security giving access limit deducted overall limit 2000000 none share capital company consideration increase share capital overall limit contribution kind consisting company share andor 2000000 debt instrument security giving access share capital maximum ten per cent 10 share capital outside public exchange offer initiated company granted period 26 month 08 april 2014 ability issue share andor security giving access limit deducted overall limit 2000000 none share capital company consideration security increase share capital overall limit tendered public exchange offer initiated 2000000 debt instrument company without preferential subscription right shareholder granted period 26 month 08 april 2014 ability increase share capital capitalization limit 2000000 corresponding maximum none reserve earnings premium sum upon nominal amount increase share capital capitalization would permitted independent limit granted period 26 month 08 april 2014 security giving access share capital none stock option none share subscription plan stock option plan detailed table authority delegated board director setting new plan recently expired board director longer delegated authority set new plan 70 management report financial statement parent company sartorius stedim biotech sa december 31 2015 number share total number subscribed number number date total option senior number option target number agm number granted executive initial sub jan 1 granted performance beneficiary authorized option senior bene bene scription based valid plan board meeting granted executive ficiaries ficiaries price dec 31 15 exercisable option option june 23 2000 aug 2 2000 139105 0 0 5 859 0 0 0 0 sept 28 june 23 2000 2001 142855 0 0 7 1194 0 0 0 0 june 23 2000 oct 14 2002 12100 0 0 1 678 0 0 0 0 sept 10 june 23 2000 2003 22000 0 0 1 79 0 0 0 0 june 23 2000 feb 11 2004 66000 0 0 1 642 0 0 0 0 june 23 2000 july 23 2004 140000 0 0 19 923 0 0 0 0 sept 15 june 10 2005 2005 127500 0 0 15 1887 5000 0 0 0 june 10 2005 nov 10 2005 35000 0 0 2 2951 3000 0 0 0 total 684560 0 0 51 8000 0 0 0 0 agm annual general shareholder meeting change number stock option january 1 2012 december 31 2015 2015 2014 2013 outstanding share january 1 8000 23642 24642 allocated period 0 0 cancelled period 0 0 exercised period 8000 15642 1000 lapsed period 0 0 outstanding december 31 0 8000 23642 share capital dilution share subscription warrant none sartorius stedim biotech sa issued share subscription warrant share subscription option granted senior executive company option pledging share exercised fiscal 2015 sartorius stedim biotech sa share pledged none pledging asset share subscription option granted ten top nonsenior executive beneficiary option none exercised 2015 fiscal year none dividend distribution policy option exercised fiscal year company dividend distribution policy based net profit generated group level reported year 8000 option exercised relevant fiscal year well group ten significant accounted total foreseeable growth profitability option exercised 2015 option exercised stock option plan expired management report financial statement parent company sartorius stedim biotech sa december 31 2015 71 april 7 2015 annual shareholder meeting voted payment net dividend 130 per share dividend available payment april 14 2015 dividend interim dividend unclaimed five year following payment date must paid state ie france article 2277 french civil code 2014 2013 2012 2011 2010 dividend per share fiscal year 130 120 110 100 090 number share 15359238 15343596 15342596 15327238 15314738 dividend corrected per share 1 130 120 110 100 090 1 compared number share december 31 2014 senior executive membership committee director receives lumpsum amount 4000 per information sartorius stedim biotech sa senior full year membership addition executive list position hold attendance fee 1200 insofar hold held past five year included chair instead receive lumpsum corporate governance report amount 8000 per full year hold chairperson addition attendance fee remuneration activity committee director meeting attendance fee due together remuneration term previous subsection hereof director meeting attendance fee calculated annual basis method calculating fee valueadded tax reimbursed remains sameit follows corporation insofar member board entitled invoice corporation separately director receive director meeting attendance valueadded tax exercise right fee whose amount allocation established board director consideration limit resolution applied set asm director got executive top management activity group level context director receives fixed remuneration executive corporate officer receive 25000 per year paid annual remuneration membership financial statement adopted annual shareholder meeting fall due total 283200 paid director meeting payment annual shareholder meeting attendance fee 2015 chairman board receives twice amount furthermore member board receive attendance fee 1200 per meeting reimbursement expense addition annual remuneration 72 management report financial statement parent company sartorius stedim biotech sa december 31 2015 compensation executive management team director meeting base fixed annual long term stock departure attendance salary incentive incentive option indemnity fee k k k k k k k total 2014 41730 16850 10850 13500 530 00 00 00 total 2015 67210 18260 13000 35420 530 00 00 00 joachim kreuzburg1 2014 17330 6750 3730 6670 180 00 00 00 joachim kreuzburg1 2015 38410 7260 4360 26640 150 00 00 00 volker niebel1 2014 6250 3000 2430 710 110 00 00 00 volker niebel1 2015 7190 3300 3000 780 110 00 00 00 1 oscarwerner reif 2014 6220 3000 2430 710 80 00 00 00 oscarwerner reif1 2015 7160 3300 3000 780 80 00 00 00 reinhard vogt1 2014 11930 4100 2260 5410 160 00 00 00 reinhard vogt1 2015 14450 4400 2640 7220 190 00 00 00 1 detail please refer chapter corporate governance page 75 109 independent auditor payment term trade payable independent auditor sartorius stedim december 31 2015 balance trade payable biotech sa totaled 1145428 trade payable comprised following kpmg sa represented john evans alternate auditor salustro reydel 89 invoice paid 30 day regarding invoice issue date deloitte associés represented christophe perrau alternate auditor beas 11 invoice paid 60 day regarding invoice issue date group decided settle recommendation green book european community date cumulative overdue trade approval financial statement payable amounted 1 31 december 2014 annual shareholder meeting 7 april 2015 proposed nomination kpmg december 31 2014 balance trade payable replace ernst young audit totaled 975229 trade payable comprised following current regulated agreement 76 invoice paid 30 day regarding invoice issue date shareholder sartorius stedim biotech group requested approve agreement 23 invoice paid 60 day regarding covered article l225 38 french invoice issue date commercial code duly authorized board director form submitted date cumulative overdue trade payable amounted 1 management report financial statement parent company sartorius stedim biotech sa december 31 2015 73 fiveyear financial result parent company sartorius stedim biotech sa k 2011 2012 2013 2014 2015 share capital end period share capital capital stock 10386 10395 10396 15359 15367 number share outstanding 17025948 17041306 17042306 15359238 15367238 transaction financial performance sale revenue excl vat 71855 81942 1501 1465 1593 profit tax employee profit sharing plan amortization depreciation provision expense reversal 23617 26218 21180 25967 29343 income tax 1069 678 292 468 653 contribution employee profitsharing plan 0 0 0 0 0 net profit 23860 26198 20875 24845 29312 dividend paid proposal dividend 13783 15327 16878 18412 19967 earnings per share eps tax employee profitsharing amortization depreciation provision expense 145 158 126 166 195 eps tax employee profitsharing amortization depreciation provision expense 140 154 122 162 191 dividend per share 090 100 110 120 130 personnel workforce size 336 388 0 0 0 personnel cost 11843 14171 0 0 0 social security cost 6574 7969 0 0 0 74 management report corporate governance 76 corporate governance board director committee board director committee board director joachim kreuzburg board director composed ten member chairman chief executive officer four independent director appointed threeyear period date birth 22 april 1965 nationality german organization work board composition must suited shareholding first appointment 29 june 2007 structure size nature activity mandate renewed 16 april 2013 sartorius stedim biotech sa particular appointed date annual general circumstance face shareholder meeting 2016 approve financial statement fiscal year ending composition board director 31 december 2015 31 december 2015 number sartorius stedim biotech share held 1 historical reason due shareholding structure company composition current directorship position board director comittees reflected within group search reference shareholder long lasting balance director representing chairman executive board vorstand shareholder independant director sartorius ag executive vice chairman supervisory board sartorius stedim biotech gmbh reference shareholder take responsibility managing director sartorius lab holding gmbh towards shareholder direct distinct member board director board director one take particular sartorius stedim north america inc care avoid possible conflict interest member board director transparency information provided sartorius stedim filter inc market fairly take interest account member board director sartorius stedim japan kk board director consider would member board director desirable balance membership sartorius stedim lab ltd committee stablished particular member board director representation woman men nationality sartorius stedim biooutsource ltd diversity skill taking measure appropriate president vl finance sa guarantee shareholder market member board director mission carried necessary denver instrument beijing co ltd independence objectivity make public member board director reference document objective method sartorius north america inc resuts politics subject president member executive committee sartorius stedim fmt sa past directorship held past five year within group vice chairman supervisory board sartorius weighing technology gmbh member board director sartorius stedim sus inc member board director sartorius hong kong ltd member board director sartorius scientific instrument beijing co ltd member board director corporate governance board director committee 77 sartorius japan kk volker niebel member board director sartorius biohit liquid handling oy executive member executive vice president operation current directorship position date birth 14 august 1956 outside group nationality german member advisory board regionalbeirat first appointment 29 june 2007 commerzbank ag germany mandate renewed 16 april 2013 chairman advisory board beirat otto bock appointed date annual general holding gmbh co kg germany shareholder meeting 2016 approve member economic advisory board wirtschafts financial statement fiscal year ending beirat norddeutsche landesbank germany 31 december 2015 member supervisory board aufsichtsrat carl zeiss ag germany number sartorius stedim biotech share held 1 past directorship held past five year current directorship position outside group within group member advisory board beirat hameln member board director group gmbh germany sartorius stedim north america inc member board director educational professional background sartorius north america inc member board sartorius stedim filter inc diplommaschinenbauingenieur dr rer pol member board director university degree mechanical engineering sartorius stedim india pvt ltd doctorate economics member board director sartorius stedim biotech beijing co ltd 19921995 research associate institute member board director solar energy research hamelin sartorius stedim lab ltd germany member board director 19951999 research associate faculty sartorius stedim aseptics sa economics management managing director university hanover germany sartorius stedim bioprocess sarl since sartorius ag goettingen germany member executive committee 1 may 1999 recent position sartorius stedim fmt sa promotion executive board vice president finance past directorship held past five year investor relation within group since member executive board 11 nov 2002 sartorius ag goettingen germany managing director geschäftsführer 1 may 2003 spokesman sprecher sartorius stedim biotech gmbh 10 nov 2005 executive board sartorius ag member board director goettingen germany sartorius weighing india pvt ltd since ceo executive board chairman member board director 11 nov 2005 sartorius ag goettingen biohit biotech suzhou co ltd germany currently responsible managing director sartorius stedim fmt sa operation corporate strategy member board director legal affair compliance sartorius stedim sus inc corporate communication managing director sartorius stedim biotech sarl managing director sartorius stedim integrated service sarl managing director sartorius stedim sus sarl 78 corporate governance board director committee educational professional background diplomchemiker dr rer nat university degree m degree chemistry molecular biology doctorate diplombetriebswirt university degree business chemical engineering administration economics 19911995 research associate institute chemical engineering 19831985 schmidt clemens lindlar university hanover germany germany sale manager petro 19952009 sartorius ag goettingen germany chemical industry usa recent position vice president 19851998 gambro ab lund sweden rd technology 19982001 skanska ab malmö sweden 2007 2009 sartorius stedim biotech gmbh member executive recent position vice president management team poggenpohl rd technology gmbh herford germany 2009 2014 managing director sartorius 20012007 sartorius ag goettingen germany stedim biotech gmbh goettingen recent position germany senior vice president operation since 2010 member group executive biotechnology division committee sartorius group 2007 2014 managing director sartorius stedim biotech gmbh goettingen germany reinhard vogt since 2010 member group executive committee sartorius group executive member executive vice president marketing sale service date birth 4 august 1955 oscarwerner reif nationality german executive member first appointment 29 june 2007 executive vice president research development mandate renewed 16 april 2013 date birth 11 november 1964 appointed date annual general nationality german shareholder meeting 2016 approve financial statement fiscal year ending first appointment 21 april 2009 31 december 2015 mandate renewed 7 april 2015 appointed date annual general number sartorius stedim biotech share held 1 shareholder meeting 2018 approve financial statement fiscal year ending current directorship position within 31 december 2017 group number sartorius stedim biotech share held 1 member executive board sartorius ag member board director current directorship position within sartorius stedim north america inc group member board director sartorius north america inc member board director member management board sartorius stedim switzerland ag allpure technology llc member board director past directorship held past five year sartorius stedim malaysia sdn bhd within group member board director sartorius stedim australia pty ltd managing director geschäftsführer member board director sartorius stedim biotech gmbh sartorius shanghai trading co ltd member board director sartorius stedim shanghai trading co ltd educational professional background member board director tap biosystems group ltd corporate governance board director committee 79 member board director liliane de lassus automation partnership cambridge ltd member board director nonexecutive member sartorius stedim biooutsource ltd independent director member board director date birth 29 december 1943 sartorius stedim switzerland ag nationality french member board director sartorius stedim japan kk first appointment 29 june 2007 member board director mandate renewed 16 april 2013 sartorius korea ltd appointed date annual general shareholder meeting 2016 approve past directorship held past five year financial statement fiscal year ending within group 31 december 2015 member board director number sartorius stedim biotech share held 1 sartorius stedim sus inc member board director current directorship position outside sartorius stedim india pvt ltd group member board director sartorius australia pty ltd managing director l2 l conseil sarl member board director management consulting service human resource denver instrument beijing co ltd management member board director sartorius scientific instrument beijing co ltd educational professional background member board director sartorius stedim biotech beijing co ltd phd organic chemistry 1972 member board director mba 1966 sartorius hong kong ltd master degree sanskrit 1969 member board director sartorius japan kk 19691977 scientific employee charge managing director geschäftsführer research french cnrs sartorius weighing technology gmbh national center scientific managing director geschäftsführer research later university sartorius stedim biotech gmbh california berkeley california usa managing director geschäftsführer 19771981 psa automobile citroën sartorius lab holding gmbh head department charge overall manufacturing planning educational professional background programming 19811985 renault automation robotics industriekaufmann vocational diploma industrial vice president strategic planning business administration 19851989 ceo chairman board hightech startup company 19791983 sarstedt ag nuembrecht germany specializing artificial intelligence general manager sarstedt ab cognitech sweden 19892005 consultant human resource 19832007 sartorius ag goettingen germany management company executive recent position senior vice especially multicultural president sale marketing environment biotechnology division 20052007 ceo stedim biosystems since 2009 member executive board 20072008 executive vice president sartorius ag goettingen germany sartorius stedim biotech currently responsible marketing since managing director l2 l conseil sale service may 2008 sarl management consulting 2007 2014 managing director sartorius service management human stedim biotech gmbh goettingen resource germany 80 corporate governance board director committee bernard lemaître current directorship position within group nonexecutive member date birth 16 december 1938 chairman supervisory board sartorius ag nationality french chairman supervisory board sartorius stedim biotech gmbh first appointment 29 june 2007 mandate renewed 16 april 2013 past directorship held past five year appointed date annual general within group shareholder meeting 2016 approve financial statement fiscal year ending chairman supervisory board 31 december 2015 sartorius weighing technology gmbh number sartorius stedim biotech share held 1 current directorship position outside group current directorship position outside group member supervisory board takkt ag member supervisory board wissenschaftliches president financière de la seigneurie sa institut für infrastruktur und kommunikationsdienste la ciotat gmbh und wikconsult gmbh member board director senova system inc usa educational professional background member board director sycovest asset management paris bankkaufmann diplomkaufmann banker university member supervisory board degree business administration dr rer pol post azulis capital sa paris doctoral lecture qualification venia legendi betriebs member supervisory board wirtschaftslehre authorization teach business solon venture ltd london managerial economics university member supervisory board qualium investment sa paris 19701975 research assistant assistant professor university munich past directorship held past five year 19761984 university professor faculty outside group business administration university hanover germany director member supervisory board intrasense sa institute management organization educational professional background 19801981 visiting scholar stanford university california usa 19792007 founder ceo chairman 19841987 university professor faculty stedim sa business administration technical university munich director institute general industrial arnold picot business administration 19882012 university professor executive nonexecutive member director institute date birth 28 december 1944 information organization nationality german management faculty economics ludwig maximilians university first appointment 29 june 2007 munich mandate renewed 16 april 2013 20042005 konrad adenauer visiting professor appointed date annual general georgetown university washington shareholder meeting 2016 approve dc usa financial statement fiscal year ending since 2013 research position center 31 december 2015 information organization management faculty business number sartorius stedim biotech share held 1 adm ludwig maximilians university munich corporate governance board director committee 81 henri riey current directorship position outside group nonexecutive member independent director member supervisory board valneva se date birth 5 november 1961 member supervisory board nanobiotix sa nationality monegasque managing director smag consulting sarl first appointment 29 june 2007 past directorship held past five year mandate renewed16 april 2013 outside group appointed date annual general shareholder meeting 2016 approve member board director financial statement fiscal year ending themis bioscience gmbh 31 december 2015 member board director portugal sanofi pasteur msd number sartorius stedim biotech share held 50 member board director spain sanofi pasteur msd current directorship position outside member board director group uk sanofi pasteur msd member board director president aidea ireland sanofi pasteur msd president groupe hr sa director princess grace foundation monaco educational professional background educational professional background graduated essec ecole supérieure de science economiques et commerciales diplôme institut supérieur de gestion france degree earned french higher institute 1984 1987 international distiller vinters business management institut supérieur de gestion france product manager 1988 1990 urgo laboratory adhesive 19851988 fund manager paribas bank marketing manager 19881996 fund manager responsible 1991 1995 roc sa johnson johnson head european equity fund management international marketing group team barclays bank france 1998 2000 sanofi pasteur msd france product 19961999 head research barclays asset manager adult vaccine management europe 2001 2005 sanofi pasteur head range 19992004 executive vice president barclays europe adult vaccine marketing asset management charge director fund management business 2006 2008 sanofi pasteur msd executive 2004 2013 cfo hendyplan sa manager business management 2009 2010 sanofi pasteur msd vice president business management annemarie graffin since 2011 managing director smag sàrl advice biotech medtech strategy nonexecutive member management independent director date birth 3 may 1961 nationality french first appointment 7 april 2015 appointed date annual general shareholder meeting 2018 approve financial statement fiscal year ending 31 december 2017 number sartorius stedim biotech share held 1 82 corporate governance board director committee susan dexter implementation single use bioprocessing technology nonexecutive member 2004 2008 xcellerex inc ge healthcare independent director chief business officer cmo service date birth 11 october 1955 using fully integrated singleuse nationality american bioprocessing technology sale single use bioprocessing technology first appointment 7 april 2015 since 2008 latham biopharm group principal appointed date annual general consultant vp business development shareholder meeting 2018 approve multiple cmos offering contract financial statement fiscal year ending manufacturing service 31 december 2017 biotechnology life science industry strategic consulting singleuse number sartorius stedim biotech share held 1 disposable technology implementation project management highlevel current directorship position outside business development marketing group advisor speak bioprocess international biosense technology woburn massachusetts usa clinical diagnostic technology based cellular impedence registered address regard social mandate member past directorship held past five year board director general manage outside group ment domiciled company headquarters kalon biotherapeutics college station texas usa retired cmo independent director educational professional background company controlled majority degree certificationsbs immunology shareholder portion independent marketing double major honor american university administrator board member least washington dc usa third board 31 december 2015 board harvard university negotiation course lawyer director sartorius stedim biotech sa harvard university cambridge massachusetts usa composed 40 independent member finance nonfinancial manager harvard independence criterion defined apefmedef university dow chemical company internal code shareholder meeting 7 april 2015 training program elected two new independent administrator 1975 1980 university massachusetts medical pursuant principle good corporate school research mammalian cell governance independent member may culture animal toxicology study principal shareholder employee former group basic research employee supplier banker group major 1980 1986 collaborative research biotechnology customer may link likely sale emerging market impair judgment bioprocessing supplement raw material biomanufacuting sartorius stedim biotech sa board director 1986 1998 celltech biologics lonza biologics includes four independent director mr susan dexter business developmentbioprocessing mr annemarie graffin mr liliane de lassus manufacturing biotechnology mr henri riey based biotherapeutics 1998 2004 collaborative bioalliance dow chemical company dow biotechnology contract manufacturing service vice president business develoment microbial fermentation service technology corporate governance board director committee 83 criterion needed qualify independent plurality mandate director following accordance apef medef governance code may employee senior executive listed company executive director cant employee director parent company exercise two mandate director one consolidated company may listed company outside group including foreign five previous year company addition collect notice may senior executive company board accepting new director company directly indirectly hold mandate listed company director position employee senior executive company either moreover administrator cant exercise currently less five year four mandate listed company outside hold director position group including foreign company may significant client supplier business recommendation applied nomination banker investment banker company renewal administrator mandate group company group represents significant part business may close family tie one information senior executive may auditor company board director met nine time five past year fiscal 2015 may director company twelve year accordance bylaw sartorius stedim biotech sa company diretor owns personally least one share company balanced representation woman men director fulfill mentioned threshold term men woman representation regard number mandate listed objective board reach maintains company percentage least 20 woman threeyear notice least 40 woman sixyear notice executive director maximum two starting 2010 shareholder meeting mandate company belonging group board composed ten member 7 april non executive director maximum four 2015 shareholder meeting nominated two mandated company belonging group additional woman administrator treshold order reach threshold company knowledge within last five year member board director staggering mandate term convicted fraud last five year subject official public according apef medef governance code listed investigation sanction statutory regulatory company staggering term authority organized order avoid renewing group associated capacity manager mandate promote harmonious renewing bankruptcy receivership liquidation administrator mandate 31 december 2015 past five year afferent rule relating staggering term disqualified court acting respected board director partially capacity member administrative renewed seven membership 2016 management supervisory body issuer three member 2018 mandate renew acting capacity management 2016 detailed reference document executive conducting business issuer supplementary information part section resolution past five year submitted annual combined shareholder meeting 5 april 2016 ordinary resolution 84 corporate governance board director committee company knowledge family relationship audit committee exist among member company board director audit committee currently composed four member furthermore company knowledge conflict interest duty member mr henri riey chairman committee since board director private interest december 5 2007 duty director must inform board soon aware conflict interest mr arnold picot even possibility potential conflict must mr liliane de lassus refrain participation discussion mr bernard lemaître relevant subject matter voting associated resolution chairman audit committee mr de lassus independent company knowledge settlement agreement reached shareholder client chairman board director also supplier others appoint member board ceo group permanent guest director audit committee voting right company knowledge service audit committee met five time fiscal 2015 contract linking board member sartorius stedim biotech group granting benefit remuneration committee knowledge company administrator linked sartorius stedim biotech service remuneration committee currently composed contract conferring advantage four member measure taken ensure control done mr arnold picot chairman committee since abusive way following june 29 2007 mr liliane de lassus four independent member board ten mr henri riey member board director mr bernard lemaître two independent member board four member audit committee two four member remuneration two independent member board four committee independent member remuneration committee remuneration committee met fiscal 2015 information organization function activity committee fiscal 2015 please refer chairman report pursuant article l 225 37 french commercial code included publication following page corporate governance chairman report pursuant article l 225 37 85 chairman report pursuant article l 225 37 pursuant article l 225 37 french commercial code chairman board director us report cover fiscal year ended december 31 2015 present composition board director application principle balanced representation men woman condition preparation organization work board director internal controlling control procedure implemented company within group pursuant last paragraph article l 225 235 french commercial code company independent auditor prepare report concerning report chairman board director internal control risk management procedure relative preparation processing accounting financial information corporate governance code since fiscal 2008 sartorius stedim biotech sa board director therefore decided adopt afepmedef recommendation reference code corporate governance see wwwmedeffr afepmedef corporate governance code code defines set regulation good responsible corporate governance follows comply explain principle implemented country european union listed company comply recommendation code must explain corporate governance report accordance article 251 corporate governance code listed company effect presented date code listed company referring code required precisely identify reference document application recommendation case nonapplication one provision company required provide comprehensible relevant circumstantial explanation according rule apply explain recommended amf recommendation n2014 08 22 september 2014 company indicate specific table recommendation applied related explanation 86 corporate governance chairman report pursuant article l 225 37 specific table recommendation afep medef code governance listed company article provision code removed explanation 32 disclosure option selected board director opted chairman function respect essential shareholder third meeting board committee chief executive party fully informed choice made officer order simplify company operational separation office chairman chief executive management increase effectiveness officer maintenance position single office organization turned factor efficient governance considering organization sartorius stedim biotech group mr joachim kreuzburg chairman board ceo sartorius ag mother company group one hand bound controlling shareholder hand involved business affair group particularly know experienced 104 nonexecutive director meeting board meeting organized presence executive recommended nonexecutive director meet member maintain degree information periodically without executive inhouse director member board strengthen open internal rule operation board director must transparent collective character according code afep provide meeting year time medef planning non executive member meet evaluation chairman chief executive officer annually without presence executive internal deputy chief executive respective performance shall member internal rule board mention carried participant shall reflect future possibility non executive member organize kind company executive management meeting 161 independent director within audit committee measure chosen company proportion independent director audit controlled majority shareholder moreover committee excluding director representing employee remuneration committee composed 50 independent shareholder director representing employee member insures independence required achieve taken account least equal twothirds smooth running committee include executive director moreover chairman committee independent member 1621 examination deadline account practical reason connected particular presence audit committee board within committee majority non resident member appointment extension term office meeting audit committee usually take place audit committee chairman proposed day board director taking appointmentsnominations committee specially consideration obligation order give audit reviewed board committee possibility achieving completely mission internal rule board mention document useful information must communicated board chairman chief executive officer uprfront sufficient delay file like transmitted member audit committee sufficient upstream delay latest three day every meeting committee board allowing sufficient delay examination statement meeting 18 committee charge compensation 181 independent director within compensation committee historical reason related company share option composition specialized committee reflecting research shareholder order reflect balance director representing shareholder independent director composed mainly independent director composed 50 independent director chairman compensation committee sartorius stedim biotech group nonindependent also chairman compensation committee sartorius group ag management coherency reason 20 director ethic 20 attendance fee retained action director shareholder personally hold board director left freedom fairly significant number share received attendance director invest insignificantly company fee default hold share upon assuming executive member perceiving attendance fee function must use acquired attendance fee therefore stock option purchase obligation acquired responsibility board complete formulated otherwise list director basic obligation 22 termination employment contract case appointment executive director 22 termination employment contract case recommendation applied 2 4 appointment executive director director corporate governance chairman report pursuant article l 225 37 87 article provision code removed explanation employee appointed executive director mr volker niebel still employment contract recommended terminate employment contract sartorius stedim biotech gmbh put place company company affiliated group started work sartorius group according german law whether contractual termination resignation23 necessary change employment contract someone becomes managing director company work also considered sartorius stedim biotech group controlled german majority shareholder biggest group company german company therefore respect german rule regulation common whole group observed respective group level 23 compensation executive director 2324 award applicable mr oscar werner reif mr volker niebel award option share executive director must mr joachim kreuzburg mr reinhard vogt representing conditional attainment performance target group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech performance action element detailed document reference within part company governance report internal control cf p96 executive director may awarded stock option share mr joachim kreuzburg received course performance share time departure december 2015 subject performance criterion accordance legal provision stock option nevertheless give back share leaf performance share awarded employee sartorius ag 11 november 2017 half necessary provide another scheme involving share leaf sartorius ag 11 november 2019 corporate performance incentive scheme profitsharing scheme mandatory scheme granting bonus share etc total amount stock option plan performance share must represent small fraction capital right balance must struck according benefit derived shareholder management level dilution must taken account furthermore necessary ensure awarded stock option performance share valued accordance ifrs standard represent disproportionate percentage aggregate compensation option share awarded executive director end board must systematically review award new stock option performance share view compensation item awarded executive director concerned board shall responsible determining percentage compensation accordance market standard exceeded said award award overly concentrated executive director according situation company size industry broad narrow scope award number officer etc board must define maximum percentage option performance share may awarded executive director compared aggregate award approved shareholder resolution authorizing award plan submitted vote meeting shareholder must mention maximum percentage form award subceiling executive director award made calendar period eg disclosure financial statement previous financial year probably year order limit windfall effect windfall effect associated bear market prohibited value awarded option performance share may markedly different company earlier practice unless material change scope business justifies revision scheme accordance term determined board announced upon award performance share awarded executive director conditional upon acquisition defined quantity share awarded share available price discount applied upon award stock option particular stock option awarded 88 corporate governance chairman report pursuant article l 225 37 article provision code removed explanation executive director executive director beneficiary stock option andor performance share must make formal commitment engage hedging transaction respect risk either option share resulting exercise option performance share end period determined board director holding share exercise exercise executive director option acquisition share must related serious demanding performance condition met period several consecutive year condition may internal andor external performance requirement ie related performance company benchmark sector etc possible relevant internal external performance requirement combined necessary determine period preceding disclosure annual interim financial statement exercise stock option possible board director supervisory board must determine period applicable determine procedure implemented executive director prior exercise stock option order ensure hold information likely prevent exercise 2325 termination payment severance payment joachim kreuzburg reinhard vogt acceptable executive director whose company oscarwerner reif capped maximum two failed personally failed may receive year fix remuneration reference made respect termination payment upon departure remuneration agreed service contract lined remuneration report approximately half remuneration fix remuneration half remuneration variable remuneration performance target variable remuneration taken account calculating severance payment effective date termination service contract law give major role shareholder making predefined benefit paid termination office executive director subject procedure related party agreement imposes total transparency make termination payment conditional upon performance requirement performance requirement must assessed least two financial year performance requirement set board must demanding may allow indemnification executive director unless departure imposed regardless form departure linked change control strategy payment termination benefit executive director must excluded said executive director elect leave company order hold another position assigned another position within group able benefit near future pension right termination payment exceed applicable two year compensation fixed variable nocompetition clause additionally applied aggregate two benefit must exceed ceiling see hereafter artificial increase compensation period preceding departure prohibited corporate governance chairman report pursuant article l 225 37 89 group also communicates appendix board director shall deliberate prior applied recommendation order give overall making change management structure idea practice concerning corporate governance company shall informed principal organizational change condition preparation organization board director shall examine corporate work board director consolidated account approve manage ment report section annual report dealing corporate governance setting internal rule regulation company policy respect remuneration stock option procedure governing organization functioning board director defined although modification social internal rule regulation board purpose board director must seize published website sartorius stedim shareholder meeting transaction concern biotech sa publication particular preponderant share asset activity report group internal rule modified board board director shall convene annual share director 18 february 2015 order bring holder meeting propose change article line new provision afrp medef association governance code listed company mission mentioned summarize internal board director deal matter concerning bylaw board director proper operation company take decision subject concern activity report board director fiscal 2015 mission board director met nine time fiscal main mission board director year average attendance 100 follows board reviewed approved corporate board director shall define company consolidated account 2014 strategic goal assess overall perspective least year proposed board director considered debated ceo ensure goal implemented following meeting shall also appoint corporate officer responsible managing company pursuit strategy 1 strategic direction major group project review delegation authority 2 annual halfyear quarterly financial statement board director shall review management 3 budget presented executive management group monitor quality information 4 information financial structure provided shareholder market cash flow item financial statement material event 5 significant offbalance sheet commitment occur especially company shareholding 6 risk indicator group 7 internal organization project board director responsible approving 8 stock market performance strategic investment project transaction 9 selfassessment board member particular acquisition disposal likely 10 element remuneration due attributed materially affect company result structure 11 modification bylaw balance sheet risk profile 12 internal rule modification board director audit committee remuneration board director beforehand decide committee significant transaction outside scope 13 renewal mandate one executive announced strategy vice president 90 corporate governance chairman report pursuant article l 225 37 14 nomination two new independent board information provided director director member 15 change one costatutory auditor board meeting director receive report 16 operation share capital agenda item require prior consideration 17 project acquisition follow due time following notification recent acquisition 18 situation statutory auditor preliminary figure annual interim regard green book statement generally sent director least one week meeting audit committee 2015 board member carried formal always held day day assessment work board director board meeting questionnaire sent board member summary result show positive overall addition board meeting chairman regularly assessment board performance selfassessment informs director event development show director consider well informed may material impact group operation executive management company information previously communicated belief ceo moderating properly board discussion board director member board director receive copy evaluation three objective press release published company director may time request take stock modality performance information chairman board board shall assess relevance request verify important question properly prepared debated measure effective contribution adminis board committee trator board work due competency involvement debate audit committee remuneration committee responsible studying making committee chairman submitted work report preparation board main deliberation board discussion order improve board efficiency independent auditor invited two board circumstance committee relieve meeting board legal power decision allowed cause division within college stay responsible accomplishment mission committee dont replace emanation board director facilitating work committee board may consult performance function main company executive member informed chairman board director subject reporting back board committee board may request external technical study relating matter within competence expense company informed chairman board director board director subject reporting back board corporate governance chairman report pursuant article l 225 37 91 case making use external consultancy service audit committee duty field example remuneration advice order obtain accounting policy internal controlling consist information concerning system level mainly remuneration force main market committee ensure objectivity review annual corporate consolidated concerned service account reviewing halfyearly annual corporation consolidated account including board meeting preceded meeting note financial statement least one two committee depending management report presented board item agenda committee report director annual general shareholder board work observation submit meeting convened approve statement opinion proposal recommendation fiscal 2015 presenting observation recommendation board director procedure committee also defined review account committee consider internal rule regulation important operation conflict interest could occurred member committee board chosen board director appointment renewal ensuring suitability consistent application president audit committee mandate accounting method procedure chosen proposed remuneration committee subject company guaranteeing correct specific review board director application duty audit committee review accounting treatment significant transaction carried company audit committee assist board director company accounting policy reporting review scope consolidated company treasury hedging instrument internal necessary reason certain company external controlling financial communication risk included management audit committee duty area external member audit committee therefore controlling consist either financial accountant expertise submitting recommendation board proportion independent administrator director concerning statutory auditor audit committee lower two third appointment reappointment annual shareholder meeting end committee committee include executive director steer statutory auditor selection procedure submits recommendation board respect audit committee shall consult director proposed shareholder meeting statutory auditor well financial committee proposes board director accounting financial investment director shall selection procedure particularly tender possible interview take place might necessary supervises tender committee requires without presence validates tender specification also approves management company choice consulted firm ensuring highest lowest bidder committee ask external expert needed selected ensuring expertise independence analyzing issuing opinion definition scope timetable assignment fee analyzing independence legal auditor 92 corporate governance chairman report pursuant article l 225 37 end committee informed year audit committee duty area financial statutory auditor communication consists reviewing company proposed financial communication respect declaration independence publication parent company consolidated halfyearly annual corporate account amount fee paid network quarterly result statutory auditor company controlled firm entity hold accrued benefit committee may also perform activity directly linked mission deemed necessary appropriate committee auditor board director information concerning benefit accomplished activity report audit committee fiscal 2015 audit directly linked auditor mission audit committee met five time fiscal committee examines statutory auditor year average attendance 95 risk threating independence protective measure made reduce risk also activity report audit committee ensure amount fee paid board director help board fully informed company group portion facilitating deliberation represents revenue office network likely impair statutory main subject audit committee review auditor independence context following accordance green book policy role audit established european 1 examining corporate consolidated annual commission beenproposed sartorius account reviewing financial statement quar stedim biotech sa shareholder meeting 7 april terly halfyearly annual corporate con 2015 nominate solidated account including implementation specific action related ifrs standard kpmg sa auditory auditor replacing ernst 2 working hedging instrument young audit 3 review internal audit work 4 review quarterly risk management report salustro reydel alternate auditor replacing 5 approval auditor fee auditex 6 30 june 31 december 2015 audit ac count auditor presented essential audit committee duty field risk result audit option decided analysis prevention consist 7 situation statutory auditor regard green book defining internal audit plan group 8 internal rule modification audit commit company obtaining report audit carried tee defining necessary action plan 9 nomination statutory auditor implementing new procedure respective 10 vl finance sa internal organization sartorius company stedim biotech sa 11 share buyback program examining company exposure significant 12 capital increase risk risk mapping committee review risk balance sheet commitment appreciates importance weakness received informs board appropriate verifying appropriate application internal control accounting financial reporting procedure corporate governance chairman report pursuant article l 225 37 93 duty remuneration committee remuneration committee deliberated main following topic purpose remuneration committee help company board director establish 1 target achievement remuneration policy corporate officer 2 reviewing remuneration executive particular incentive mechanism granting member board director share subscription option share purchase option 3 reviewing payment director fee free allotment share company may 4 structure board director introduce 5 update internal rule remuneration committee must put board remuneration mr joachim kreuzburg director best condition determine mr reinhard vogt discussed within overall remuneration benefit executive remuneration committee sartorius stedim biotech director board director responsible determined remuneration committee decision otherwise committee must sartorius ag informed remuneration policy non executive director occasion committee within scope remuneration committee associate executive director consulted board director proposal concerning remuneration committee also re ponsibility give recommendation regard total budget allocated director fee new potential director committee member term allocation thereof taking account circumstantially considered element actual presence director board meeting need taken account deliberation possibly committee meeting desirable balance membership board fixed remuneration corporate officer regard composition evolution term variable remuneration shareholding company balance men general policy granting share sub woman within board identification scription option share purchase option free evaluation potential candidate desirability allotment company share extension term need particular organize policy director nomination renewal procedure order select future independent administrator achieve study potential candidate taking measure limitation power chairman regarding others chief executive officer activity report remuneration committee june 29 2007 board director voted 2015 combine function chairman chief executive officer without limitation power remuneration committee met included internal regulation fiscal year average attendance 100 board director mainly strategic investment project transaction especially activity report board director help acquisition disposal may lead material board fully informed facilitating profit loss impact procedure concern deliberation presentation report operation one million euro corporate made remuneration committee necessary governance structure adopted overwhelming board deliberate remuneration majory french company board executive director without presence director allows simplifying operational management company order increase efficiency taking account presence controlling shareholder company capital well continued application company best principle corporate governance 94 corporate governance chairman report pursuant article l 225 37 remuneration senior executive part remuneration cross charged annually senior nonexecutive board member sartorius stedim biotech group mandataires sociaux remuneration mr oscarwerner reif total remuneration including benefit paid mr volker niebel discussed within remuneration year senior executive chairman committee subsequently voted annual board director chief executive officer shareholder meeting sartorius stedim director including sharebased payment disclosed biotech gmbh mr oscarwerner reif corporate governance report sartorius mr volker niebel employment contract stedim biotech group remuneration consists fixed variable component line respective degree remuneration committee set review responsibility remuneration board director executive member furthermore remuneration committee also responsible checking annual director internal control procedure fee paid director mr joachim kreuzburgs mr reinhard vogts introduction remuneration determined annually sartorius ag supervisory board remuneration objective defined chairman consists fixed variable component internal control system sartorius stedim biotech line respective area responsibility follows variable portion contains short mid longterm component shortterm component paid prevent risk would endanger quality every year mid term component paid every asset sartorius stedim biotech even existence three year based average achieved ensure executive management activity target threeyear term long term transaction completed conduct component comprised phantom stock plan employee comply guideline defined subject risk remuneration component executive management applicable law regula depends development sartorius ag share tions fundamental value standard internal price period least four formerly three rule business ethical code year year payable price exceeds convention healthcare industry least 75 formerly 10 per year relative time ensure accounting financial information phantom stock assigned share price management data provided executive outperformed tecdax comparative index management company accurately reflect amount paid capped maximum operation sartorius stedim biotech 25 time share price time phantom prevent risk arising operation error fraud stock assigned based case actual especially accounting financial area annual tranche concerned use component designed longterm incentive effect entail risk recommendation adopted scope internal control german french corporate governance code date payment made internal control system described cover parent mr joachim kreuzburg ormr reinhard vogt according company affiliate phantom stock plan component internal control environment internal control core business people individual attribute including integrity ethical value expertise environment operate engine drive organization foundation support company corporate governance chairman report pursuant article l 225 37 95 risk assessment process risk mapping audit committee company must aware deal audit committee responsible carrying risk face must set objective integrate necessary review evaluation internal sale production marketing financial controlling procedure including relating activity organization operates financial information also assist concert must also establish mechanism preparation group consolidated financial identify analyze manage related risk statement information audit committee control activity risk management control activity undertaken every level group ensure internal control sartorius stedim biotech group inevitably efficient checking accuracy completeness exposed wide variety risk nature authorization validation recording transaction operation around world accordingly internal ensuring different people discharge different risk management system set help duty reduce risk error fraud identify assess manage risk efficiently within risk management system ad hoc information communication committee comprised representative different department regularly study current issue risk availability accurate reliable complete management enables committee provide information essential achieve business executive management overview risk objective enable proper reporting party company exposed enabling take concerned compliance applicable law appropriate action required regulation internal auditing department monitoring control management internal auditing department charge responsibility authority must defined monitoring effectiveness suitability risk understood level company internal management internal control system control function effectively duty must sartorius stedim biotech group company well assigned way person work always compliance activity process internal checked approved different person external rule standard provides size local unit concerned permit independent auditing consulting service responsibility initiating authorizing recording focus primarily compliance relevant legal processing transaction must always assigned provision improvement business process different individual company ensure independence internal auditor audit committee receives unit management responsible maintaining least year report internal auditing internal check internal control time department work done according audit plan established committee finding regard group affiliate internal controlling role finance controlling department executive management finance controlling department track chairman chief executive officer monitor operation project optimize responsible internal control system group profitability cash flow providing management level also responsible internal external stakeholder reliable development operation monitoring management information internal control controlling system providing necessary assurance step two department define group accounting implemented rule method principle financial process fiveyear business plan budget etc well reporting tool order monitor daytoday business 96 corporate governance chairman report pursuant article l 225 37 procedure preparing group financial executive management review effectiveness statement accounting financial internal controlling financial reporting regularly information particular verifies transaction recorded consistently accordance ifrs account affiliate prepared accordance international accounting standard applied group accounting policy data group set accounting reporting adjusted necessary produce company manual order ensure pertinence trans account comply applicable local legal action asset recognized within time set tax provision integrated consolidation software used management reporting purpose produce group financial statement internal control 2015 since 2013 group decided implement internal control perspective group hard close process 30 november order focused following year anticipate improve annual audit accounting standard training code conduct anticorruption code consolidated financial statement prepared accordance ifrs accounting standard collaborator consult sartorius code currently adopted european union conduct sartorius anticorruption code consolidated financial statement comply initial training process closed transferred accounting rule method detailed note controlled operation consolidated financial statement role group finance controlling midterm prospect department group continue work internal control finance controlling department check issue strengthening approach risk mapping quality reporting package submitted risk management process based affiliate focusing primarily following element element amf internal control reference checking corporate data consolidated adjustment framework entered locally intercompany elimination accounting treatment nonrecurring transaction addition process defining mandatory reporting period verifying principal minimum standard internal control applying movement opening closing balance group company followed publishing sheet prepare cash flow statement group internal control handbook pursued 2016 finance department also verifies result procedure including currency translation intercompany elimination etc aubagne february 18 2016 key point review include preparation validation statement change chairman shareholder equity cash flow statement mr joachim kreuzburg financial information reporting group rule procedure relation financial reporting accounting set accounting reporting manual application compliance principle rule procedure direct responsibility finance director affiliate must ensure information provided via management information system complies fully applicable disclosure requirement corporate governance remuneration executive nonexecutive member board 97 remuneration executive nonexecutive member board information remuneration based remuneration refer financial key figure executive board member sartorius group sartorius stedim biotech group fully consolidated specifically element parameter remuneration sartorius stedim biotech represents approx 70 executive board member differ business asset sartorius group member time member fore development sartorius stedim biotech executive board major shareholder sartorius ag significant influence financial result member mem sartorius group thus variable remuneration bers sartorius ag executive board receive sartorius ag executive board member also fixed variable remuneration sartorius ag executive member board sartorius portion fixed remuneration charged stedim biotech however component sartorius stedim biotech sa reflecting role muneration member described refer director company portion defined parameter financial key figure sartorius scheme director meeting attendance fee group total part bylaw company portion total remuneration charged variable remuneration ssb group management service based proportional work sartorius stedim biotech portion variable remuneration paid please refer also section related party annually linked weighted target achievement financial statement note allocation key following financial key figure sale reve applied component remuneration nue order intake underlying ebitda ratio net debt underlying ebitda component minimum target achievement required maxi 1 remuneration executive member mum payout ratio defined amount paid board member executive depends degree respective financial board major shareholder sartorius ag target achieved financial target mentioned joachim kreuzburg reinhard vogt line budget approved annually supervisory board sartorius ag cap provided general fixed remuneration variable component paid variable perfor mancebased remuneration calculated upon approval total amount remuneration executive company annual financial statement board member sartorius ag reflects scope respective fiscal year settled paid responsibility executive member con following fiscal year cerned executive member personal performance company economic situation sustainable multiyear component longterm incentive progress addition amount benchmarked peer company vertical remu weighted component determined multiyear neration structure within company well assessment depend degree target peer company remuneration comprised achieved supervisory board defines fixed nonperformancebased component setting subordinate target constituted variable performancebased component consolidated net profit assessing viewed annually ensure remains appropriate development company share price multiyear variable performancebased remuneration compo component providing longterm incentive based nents consist paid annually mul threeyear average consolidated net profit tiyear component intended longterm fouryear average share price respectively incentive fixed nonperformancebased remuneration component paid two fiscal year paid year granted 100 net profit earliest three fiscal target achievement variable annual longterm year share price performancebased component generally represent half total remuneration excludes pension commitment defined benefit plan well fringe benefit target set performance 98 corporate governance remuneration executive nonexecutive member board consolidated net profit assigned based case actual annual tranche concerned subordinate target basis assessment consolidated net profit minority interest ex assignment phantom stock payment cluding amortization impairment value intan monetary equivalent depend mean value calculat gible asset due business combination pursuant ed average price class sartorius ag ifrs 3 target achievement component share closing auction xetra trading frank based threeyear average consolidated net furt stock exchange last 20 day trading profit achieved compared average annual previous year last 20 day trading budget three year smooth prior submission payment request serf amount paid partial payment amounting compensate shortterm fluctuation 50 target achievement first fiscal share price year effected overpayment result partial payment offset final payment phantom stock blocked four week calculation target achievement third preceding scheduled publication date quarterly year remuneration component mini preliminary yearend result 20 day trad mum target achievement cap applied ing stock exchange following actual publica component well tion quarterly preliminary yearend result blackout period intended prevent executive board b phantom stock plan member profiting insider knowledge joachim kreuzburg reinhard vogt c pension commitment eligible participate phantom stock plan responsibility sartorius ag level according company remuneration policy executive board member sartorius ag receive issue shadow share called phantom performancerelated benefit commitment stock executive board member treated defined benefit plan reappointed first owner certain number share time addition including basic pension sartorius ag without however entitled commitment provide executive board member ceive dividend development value make contribution variable earn phantom stock linked development ings company match contribution sartorius share increase decrease bonus amount executive board member may share price taken account later phantom choose receive defined benefit form stock valuated based share price time monthly retirement pension old age one equivalent paid provided associ time payment cover member retirement pen ated condition met phantom stock cannot trad sion old age invalidity well form ed entail share subscription right survivor benefit surviving spouse chil dren decedent according sartorius phantom stock plan executive board member credited beginning beyond commitment joachim kreuzburg every year phantom stock unit valued additionally entitled former company pension agreed monetary sum value phantom stock scheme receive performancebased retirement bene paid entire annual tranche fit based salary german federal civil servant payment requested earliest classified grade 10 salary class b ministry offi period four year later eight year cials according federal civil service remunera tion act bundesbesoldungsgesetz benefit executive board member entitled receive paid form retirement pension old age payment phantom stock unit share invalidity well form survivor benefit price time payment request appreciat surviving spouse child decedent ed least 75 per year relative time phan tom stock assigned share price member turned 65 shall considered outperformed tecdax comparative index regular age limit member shall auto phantom stock plan rule subsequent change matically entitled receive benefit parameter used comparative stock valuation amount paid capped maximum 25 time share price time phantom stock corporate governance remuneration executive nonexecutive member board 99 remuneration component 2015 thus considered granted 2015 share transferred subject holding period remuneration system provides supervisory end november 10 2019 joachim board sartorius ag discretion may grant kreuzburg leave company prior november 11 executive board member special compensation based 2017 request shall required transfer member exceptional performance share back company joachim kreuzburg leaf company november 11 2017 severance cap november 11 2019 request joachim kreuzburg shall required transfer half service contract include severance pay cap share granted back company maximum two annual salary cover case amount resulting since december 16 2014 sartorius ag executive board membership share granted spread employee terminated prematurely potential amount benefit expense full vesting period paid sartorius ag recognized profit loss fiscal 2015 amount 542 k accordingly recognized noncompetition clause account sartorius stedim biotech executive board member sartorius ag postcontractual noncompetition obligation 2 remuneration executive member accordance german law obligation last board part sartorius two year executive board member left stedim biotech group oscarwerner reif group time noncompetition volker niebel clause waived terminated executive board member may claim half recent annual general fixed remuneration remuneration received company total amount remuneration executive fringe benefit member reflects role director company scope responsibility executive member executive board sartorius ag member concerned executive member personal entitled use company car reclaim ex performance company economic situation penses incurred business travel covered sustainable progress addition amount accident insurance insurance fringe benchmarked peer company benefit addition receiving remuneration vertical remuneration structure within compa component mentioned insurance provides ny well peer company remuneration application deductible excess comprised fixed variable component amount required law reviewed annually ensure remains appro priate case 100 target achievement sharebased payment variable remuneration component represent approxi mately half total remuneration excluding fringe remuneration policy executive board member benefit portion fixed component allocated sartorius ag provide transfer role director company portion sartorius ag share compensation member defined scheme director meeting attendance exception made december 2014 fee part bylaw company joachim kreuzburg variable remuneration joachim kreuzburgs third appointment member executive board chairman ceo expired variable portion remuneration contains november 10 2015 resolution supervisory component paid annually component board december 16 2014 joachim kreuzburg determined multiyear assessment reappointed member executive board chairman ceo company term annually paid variable remuneration vember 11 2015 november 10 2020 employ ment contract entered force november 11 portion variable remuneration paid 2015 provides granting joachim kreuzburg 25000 annually linked weighted target achievement ordinary share 25000 preference share following financial key figure sale company supplementary compensation component revenue order intake underlying ebitda ratio share transferred december 18 net debt underlying ebitda 100 corporate governance remuneration executive nonexecutive member board component minimum target achievement fringe benefit quired maximum payout ratio defined amount paid depends degree executive member entitled use respective financial target achieved company car reclaim expense incurred business financial target mentioned line travel covered accident insurance budget approved annually insurance fringe benefit addition receiving remuneration component mentioned b longterm incentive longterm component multiyear assessment determines degree target achieved basis assessment consolidated net profit minority interest excluding amortization impair ment value intangible asset due business combination pursuant ifrs 3 target achieve ment component based threeyear average achieved compared threeyear average annual budget smooth amount paid partial payment amounting 50 target achievement first fiscal year ef fected overpayment result partial payment offset final calculation target achievement third year remuneration component fixed variable mini mum target achievement cap applied component well severance cap oscarwerner reif limited service agreement sartorius stedim biotech gmbh place case severance would receive payment amount reflecting remaining duration contract capped two year given contract expire april 30 2016 severance payment would reflect remaining duration potential amount would paid sartorius stedim biotech gmbh volker niebel employed sartorius stedim biotech according german labor contract case termination german labor law would apply potential severance due amounting half monthly salary based total package per year employment minimum noncompetition clause executive director postcontractual non competition obligation accordance german law sartorius stedim biotech sa controlled german company obligation last two year director left group time noncompetition clause waived terminated director may claim half recent annual remuneration received company corporate governance remuneration executive nonexecutive member board 101 table summarizing remuneration oscarwerner reif option share granted executive vice president research development executive board member k year 2015 year 2014 joachim kreuzburg remuneration due 713 622 chairman board chief executive officer valuation option granted reporting period 0 0 k year 2015 year 2014 valuation performance share granted previous year 0 0 remuneration due 3439 1652 total 713 622 valuation option granted reporting period 0 0 valuation performance share granted previous year 402 81 reinhard vogt total 3841 1733 executive vice president marketing sale service k year 2015 year 2014 amount crosscharged company remuneration due 1201 1144 sartorius ag sartorius stedim biotech group valuation option granted concerning joachim kreuzburg 1583 k amount reporting period 0 0 charged sartorius stedim biotech sa submitted valuation performance vote annual shareholder meeting share granted previous year 244 49 accordance afepmedef code amounted total 1445 1193 804 k volker niebel amount crosscharged company executive vice president operation sartorius ag sartorius stedim biotech group concerning reinhard vogt 1158 k amount k year 2015 year 2014 charged sartorius stedim biotech sa submitted vote annual shareholder meeting remuneration due 716 625 accordance afepmedef code amounted valuation option granted reporting period 0 0 568 k valuation performance share granted previous year 0 0 total 716 625 102 corporate governance remuneration executive nonexecutive member board summary remuneration oscarwerner reif1 executive board member executive vice president research development joachim kreuzburg1 year 2015 year 2014 chairman board chief executive officer amount amount amount amount k due paid due paid year 2015 year 2014 fixed remuneration 330 330 300 300 amount amount amount amount k due paid due paid variable remuneration fixed remuneration 726 726 675 675 annually paid 297 256 243 189 variable longterm remuneration incentive 78 54 71 68 annually paid 436 373 373 268 exceptional remuneration longterm incentive 2664 5378 667 479 director attendance exceptional fee remuneration benefit director kind2 8 8 8 8 attendance fee total 713 648 622 5645 benefit kind2 15 15 18 18 1 oscarwerner reif receives salary sartorius total 3841 6492 1733 1440 stedim biotech gmbh duty performed sartorius stedim biotech group 2 1 company car joachim kreuzburg receives salary sartorius ag duty performed entire sartorius group remuneration determined annually supervisory board sartorius ag reinhard vogt1 2 company car executive vice president marketing sale service year 2015 year 2014 volker niebel 1 amount amount amount amount executive vice president operation k due paid due paid fixed year 2015 year 2014 remuneration 440 440 410 410 amount amount amount amount variable k due paid due paid remuneration annually paid 264 226 226 164 fixed remuneration 330 330 300 300 longterm incentive 722 300 541 270 variable remuneration exceptional remuneration annually paid 297 256 243 189 director longterm attendance incentive 78 54 71 68 fee exceptional benefit remuneration kind2 19 19 16 16 director total 1445 985 1193 860 attendance fee 1 benefit reinhard vogt receives salary sartorius ag kind2 11 11 11 11 duty performed entire sartorius total 716 651 625 568 group remuneration determined annually supervisory board sartorius ag 2 1 company car volker niebel receives salary sartorius stedim biotech gmbh duty performed sartorius stedim biotech group 2 company car corporate governance remuneration executive nonexecutive member board 103 information remuneration performance share available nonexecutive board member board member remuneration nonexecutive board member performance share available corporate officer defined board director internal rule number sartorius stedim biotech sa comprises fixed remu performance share share available neration meeting attendance fee reimbursement available date acquisition corporate officer1 plan reporting period condition outofpocket expense member also serving mem ber committee board receive higher fixed joachim kreuzburg applicable remuneration volker niebel applicable oscarwerner reif applicable reinhard vogt applicable table director meeting attendance fee liliane de lassus applicable remuneration received bernard lemaître applicable nonexecutive board member arnold picot applicable henri riey applicable k year 2015 year 2014 total liliane de lassus 1 performance share bonus share allocated director attendance fee 510 498 board member within framework l2251971 remuneration article following commercial law bernard lemaître subjected additional requirement laid director attendance fee 498 498 recommendation afepmedef october 2008 remuneration arnold picot director attendance fee 550 538 remuneration henri riey director attendance fee 550 538 remuneration susan dexter director attendance fee 362 remuneration annemarie graffin director attendance fee 362 remuneration total 2832 2072 104 corporate governance remuneration executive nonexecutive member board performance share granted board member performance share program place board member sartorius stedim biotech sa information provided table refers phantom stock plan sartorius ag plan relates joachim kreuzburg reinhard vogt executive board member sartorius ag valuation share performance share granted according agm reporting period corporate officer number consolidated issuer date share granted account date date performance company group plan year methodology acquisition availability conditions1 joachim kreuzburg 1840 454 jan 1 2015 jan 1 2019 volker niebel oscarwerner reif reinhard vogt 1114 275 jan 1 2015 jan 1 2019 liliane de lassus bernard lemaître arnold picot henri riey total 2954 729 2015 2014 k k total 2731 496 phantom stock 1375 440 sartorius ag share granted 1356 56 dr joachim kreuzburg 2212 330 phantom stock 856 274 sartorius ag share granted 1356 56 reinhard vogt 519 166 phantom stock 519 166 sartorius ag share granted 0 0 corporate governance remuneration executive nonexecutive member board 105 fair value granted jan 1 fair value fair value number yearend yearend phantom subscription particular dec 31 dec 31 change stock unit price year 2014 2015 paid fair value exercisable k k k k 2015 dr joachim kreuzburg tranche phantom paid stock unit 2011 5165 2662 138 344 0 344 0 2015 tranche phantom stock unit 2012 4416 3312 146 365 365 0 0 tranche phantom stock unit 2013 2289 6936 159 224 397 0 173 tranche phantom stock unit 2014 2008 8403 169 193 422 0 229 total tranche previous year 13878 612 1126 1184 344 402 tranche phantom stock unit 2015 1840 9878 182 0 454 0 272 total 15718 794 1126 1638 344 674 reinhard vogt tranche phantom paid stock unit 2011 3193 2662 85 212 0 212 0 2015 tranche phantom stock unit 2012 2699 3312 90 223 223 0 0 tranche phantom stock unit 2013 1397 6936 97 137 242 0 105 tranche phantom stock unit 2014 1220 8403 103 117 256 0 139 total tranche previous year 8509 375 689 721 212 244 tranche phantom stock unit 2015 1114 9878 110 0 275 0 165 total 9623 485 689 996 212 409 stock option granted reporting stock option granted historical information period board member issuer company group applicable applicable stock option granted top ten noncorporate officer exercised stock option exercised reporting period board member applicable applicable 106 corporate governance remuneration executive nonexecutive member board additional information executive board member indemnity compensation due employment additional regard termination noncompetition corporate officer contract pension plan contract position clause indemnity yes yes yes yes joachim kreuzburg ceo chairman 1 3 2700 675 volker niebel 2 none 350 300 oscarwerner reif 2 none 800 300 reinhard vogt 1 3 1640 410 1 joachim kreuzburg reinhard vogt service contract without social security component sartorius ag duty performed member executive board major shareholder sartorius ag standard practice germany 2 oscarwerner reif volker niebel service contract employment contract respectively sartorius stedim biotech gmbh duty performed managing director company standard practice germany 3 general pension plan place sartorius ag level joachim kreuzburg reinhard vogt level entitlement benefit paid company pension plan depends respective tenure corporate governance statutory auditor report prepared accordance article l 225 235 107 statutory auditor report prepared accordance article l 225 235 free translation english report issued provided chairman report respect french provided solely convenience internal control risk management procedure englishspeaking reader report read relating preparation processing conjunction construed accordance accounting financial information french law professional auditing standard procedure consisted mainly applicable france obtaining understanding internal control year ended 31 december 2015 risk management procedure relating preparation processing accounting shareholder financial information information presented chairman report based capacity statutory auditor sartorius existing documentation stedim biotech sa accordance article obtaining understanding work involved l225235 french commercial code code de preparation information existing commerce hereby report report documentation prepared chairman company determining significant weakness accordance article l22537 french internal control procedure relating commercial code year ended 31 december preparation processing accounting 2016 financial information would noted course engagement properly disclosed chairman responsibility prepare chairman report submit board director approval report internal control risk management basis work nothing report procedure implemented company information respect company containing disclosure required article internal control risk management procedure l22537 particularly term corporate relating preparation processing governance measure accounting financial information contained report prepared chairman board responsibility accordance article l22537 french commercial code code de commerce report information contained chairman report respect internal control risk management procedure relating disclosure preparation processing accounting financial information hereby attest chairman report includes attest report contains disclosure required article l22537 disclosure required article l22537 french commercial code code de commerce french commercial code code de commerce specified responsible verifying fairness disclosure marseille february 19 2016 conducted work accordance statutory auditor professional standard applicable france french original signed kpmg audit deloitte associés information internal control risk division kpmg sa management procedure relating preparation processing accounting john evans christophe perrau financial information partner partner standard require perform necessary procedure assess fairness information 108 corporate governance independent auditor fee independent auditor fee principal independent auditor kpmg sa deloitte et associés 480 avenue du prado c 90021 13272 marseille 10 place de la joliette le dock atrium 104 cedex 08 france bp 64529 13567 marseille cedex 02 france represented john evans represented christophe perrau first commissioned combined general first commissioned annual general share shareholder meeting 7 april 2015 holder meeting 19 may 2006 date commission expires 2021 annual general date commission expires 2018 annual general shareholder meeting approve 2020 financial shareholder meeting approve 2017 financial statement statement member ofthe compagnie régionale de versailles member compagnie régionale de versailles independent auditor fee kpmg deloitte k 2015 2014 2015 2014 audit independent audit certification parent company consolidated financial statement parent company 56 98 75 270 87 171 subsidiary 511 898 161 581 398 783 service directly related audit service parent company subsidiary subtotal 567 997 236 850 485 955 service legal tax corporate 2 03 11 38 23 45 information technology 0 00 31 112 0 00 subtotal 2 03 42 150 23 45 total 569 1000 278 1000 508 100 corporate governance independent auditor fee 109 substitute independent auditor salustro reydel beas 3 cours du triangle immeuble le palatin 92939 79 villa houssay 92200 neuilly sur seine france parisla défense cedex france represented jeanclaude reydel represented alain pons first commissioned annual general share commissioned annual general shareholder holder meeting 7 april 2015 meeting 19 may 2006 date commission expires 2021 annual general date commission expires 2018 annual general shareholder meeting approve 2020 financial shareholder meeting approve 2017 financial statement statement member compagnie régionale de versailles member compagnie régionale de versailles ernst young total 2015 2014 2015 2014 2015 2014 13 520 55 458 144 137 142 151 12 480 61 508 132 749 255 817 816 779 714 760 25 1000 116 967 132 749 255 817 960 916 856 911 0 00 4 18 101 57 183 30 29 84 89 0 00 0 00 27 151 0 00 58 55 0 00 0 00 4 33 44 251 57 183 88 84 84 89 25 1000 120 100 176 1000 312 100 1048 1000 940 100 110 corporate governance consolidated financial statement note 112 consolidated financial statement note statement profit loss comprehensive income statement profit loss comprehensive income note 2015 2014 12 month 12 month k k sale revenue 10 884331 683524 cost sale 432546 346315 gross profit sale 451785 337209 selling distribution cost 167191 144356 research development cost 41529 34121 general administrative expense 48912 38653 operating income expense 12 9621 233 earnings interest tax ebit 184532 120312 financial income 13 2854 2411 financial expense 13 17708 17672 financial result 14854 15261 profit tax 169678 105051 income tax 14 50184 31378 net profit period 119494 73673 attributable equity holder sartorius stedim biotech 117999 72442 noncontrolling interest 24 1495 1231 earnings per share 16 768 472 diluted earnings per share 16 768 472 comprehensive income 2015 2014 12 month 12 month note k k net profit period 119494 73673 cash flow hedge 31 1392 3612 effective portion change fair value 9320 3295 reclassified profit loss 7928 317 income tax cash flow hedge 19 418 1084 net investment foreign operation1 6646 6898 income tax net investment foreign operation 19 1992 2069 foreign currency translation difference 21840 20570 item may reclassified subsequently profit loss 16212 13213 remeasurements net defined benefit liability 25 195 6957 income tax remeasurements net defined benefit liability 19 7 1885 item reclassified profit loss 202 5072 comprehensive income tax 16010 8141 total comprehensive income 135504 81814 attributable equity holder sartorius stedim biotech 133697 80047 noncontrolling interest 1807 1767 1 caption refers foreign exchange gain loss connection intragroup loan granted longterm basis consolidated financial statement note statement financial position 113 statement financial position dec 31 2015 dec 31 2014 note k k noncurrent asset goodwill 17 336959 313786 intangible asset 17 143349 113160 property plant equipment 18 222875 192195 financial asset 1330 1214 asset 751 653 deferred tax asset 19 10042 10169 715306 631177 current asset inventory 20 146970 109975 trade receivables 21 142344 124787 financial asset 22 8362 6847 current tax asset 9783 8890 asset 11541 7123 cash cash equivalent 31831 18544 350831 276166 total asset 1066137 907343 equity equity attributable ssb sa shareholder 641441 532445 issued capital 23 15367 15359 capital reserve 235231 235047 retained earnings including net profit 390843 282039 noncontrolling interest 24 5778 6653 647219 539097 noncurrent liability pension provision 25 31737 30583 provision 28 3278 2891 loan borrowing 26 12602 15880 finance lease liability 30 16937 16770 financial liability 27 51488 44724 deferred tax liability 19 30186 27814 146229 138662 current liability provision 28 8014 6224 trade payable 29 100598 81139 loan borrowing 26 87214 71764 finance lease liability 30 1506 1567 financial liability 29 41327 48078 current tax liability 19964 10107 liability 14067 10705 272690 229584 total equity liability 1066137 907343 114 consolidated financial statement note statement cash flow statement cash flow note 2015 2014 12 month 12 month k k profit tax 169678 105051 financial result 13 14854 15261 earnings interest tax ebit 184532 120312 depreciation amortization fixed asset 1718 39856 35620 increase decrease provision 2528 730 1314 income tax paid 14 43570 27793 gross cash flow operating activity 180087 129453 increase decrease receivables asset 2122 11466 15285 increase decrease inventory 20 32428 11053 increase decrease liability 2729 6596 8197 net cash flow operating activity 142789 111312 acquisition intangible tangible asset 1718 52985 47067 proceeds disposal fixed asset 657 592 payment 113 3953 net cash flow investing activity 52441 42522 payment acquisition consolidated subsidiary 9 business operation net cash acquired 53888 4291 net cash flow investing activity acquisition 106329 46813 change capital 23 175 144 interest received 13 129 688 interest paid financial charge 13 2937 4982 dividend paid shareholder sartorius stedim biotech sa 19967 18410 noncontrolling interest 446 401 gross cash flow financing activity 23046 22961 change noncontrolling interest 24 7531 0 proceeds loan borrowing raised 26 35234 0 repayment loan borrowing 26 31891 61247 net cash flow financing activity 27234 84208 net increase decrease cash cash equivalent 9226 19709 cash cash equivalent beginning period 18543 35605 net effect currency translation cash cash equivalent 4062 2648 cash cash equivalent end period 31832 18544 note consolidated financial statement integral part statement consolidated financial statement note statement change equity 115 statement change equity foreign currency non issued capital hedging pension retained translation group controlling total k capital reserve reserve reserve earnings reserve equity interest equity balance jan 1 2014 10396 278791 222 4428 199021 5662 478339 3499 481838 net profit period 0 0 0 0 72442 0 72442 1231 73673 comprehensive income period 0 0 2528 5033 4829 19995 7605 535 8141 total comprehensive income 0 0 2528 5033 67613 19995 80047 1767 81814 stock option 9 135 0 0 0 0 144 0 144 dividend 0 0 0 0 18410 0 18410 401 18811 purchase price liability forward non controlling interest 0 0 0 0 7255 0 7255 0 7255 change non controlling interest 0 0 0 0 0 0 0 1876 1876 change capital 4954 43879 38925 0 0 0 0 change 0 0 0 0 421 0 421 88 509 balance dec 31 2014 jan 1 2015 15359 235047 2306 9461 279473 14333 532444 6653 539097 net profit period 0 0 0 0 117999 0 117999 1495 119494 comprehensive income period 0 0 974 78 4654 21404 15698 313 16010 total comprehensive income 0 0 974 78 113345 21404 133697 1807 135504 stock option 8 184 0 0 0 0 192 0 192 dividend 0 0 0 0 19967 0 19967 446 20413 change non controlling interest 0 0 0 0 5064 0 5064 2235 7299 change 0 0 0 0 139 0 139 0 139 balance december 31 2015 15367 235231 3280 9539 367926 35736 641441 5779 647220 amount 7255k shown retained earnings 2014 refers acquisition allpure technology llc please refer note 9 change capital 2014 include cancellation treasury share capital increase change nominal value share detail please refer note 23 increase noncontrolling interest fiscal 2015 refers acquisition additional share company sartorius korea biotech please refer also note 24 116 consolidated financial statement note note financial statement note financial statement 1 general information 2 change format statement profit loss sartorius stedim biotech leading provider cuttingedge equipment service starting 2015 group recognizes amortization development quality assurance production capitalized development cost within cost sale process biopharmaceutical industry presentation comparative figure 2014 integrated solution covering fermentation filtration adjusted accordingly previously related purification fluid management cell culture medium expense allocated research lab technology supporting biopharmaceutical development expense effect two industry around world develop produce concerned item follows impact ebitda drug safely timely economically next ebit net profit generation process sartorius stedim biotech focus singleuse technology addedvalue service million 2015 2014 meet rapidly changing technology requirement cost sale 40 44 industry serf strongly rooted scientific research development cost 40 44 community closely allied customer 0 0 technology partner company dedicated philosophy turning science solution headquartered aubagne france sartorius stedim 3 effect new financial reporting biotech sa listed euronext paris isin code standard fr 0000053266 following new accounting rule applicable sartorius stedim biotech sa ultimate parent first time present financial statement company sartorius ag headquartered goettingen impact presentation germany listed several german stock company net worth financial position exchange isin code 0007165607 ordinary share profitability earnings per share 0007165631 preference share annual improvement ifrs 20112013 cycle compliance european regulation issued december 2013 includes amnedments 16062002 july 19 2002 requiring listed company ifrs 1 ifrs 3 ifrs 13 ia 40 use international accounting standard consolidated financial statement sartorius ifric 21 levy stedim biotech group year ended december 31 2015 compliant standard following standard amendment yet interpretation ifrs ifric iasb adopted applied consolidated financial statement european union available reporting year yet adopted following site eu application obligatory 2015 httpeceuropaeuinternal_marketaccountingiasind ex_enhtm consolidated financial statement prepared euro unless otherwise specified amount disclosed thousand euro abbreviated k case sum figure given report may precisely equal stated total percentage may exact due rounding consolidated financial statement approved board director february 18 2016 submitted approval shareholder meeting april 5 2016 consolidated financial statement note note financial statement 117 applicable endorsement financial standard title year from1 eu commission amendment ia 19 employee contribution february 1 20151 yes annual improvement ifrss 20102012 cycle issued dec various 2013 february 1 20151 yes amendment ifrs 10 ifrs 12 ia 28 investment entity applying consolidation exception january 1 2016 amendment ifrs 11 accounting acquisition interest joint operation january 1 2016 yes ifrs 14 regulatory deferral account january 1 2016 amendment ia 1 disclosure initiative january 1 2016 yes amendment ia 16 ia 41 agriculture bearer plant january 1 2016 yes amendment ia 16 clarification acceptable method depreciation ia 38 amortization january 1 2016 yes amendment ia 27 equity method separate financial statement january 1 2016 yes annual improvement ifrss 20122014 cycle issued sep various 2014 january 1 2016 yes ifrs 15 revenue contract customer january 1 2018 ifrs 9 financial instrument january 1 2018 ifrs 16 lease january 1 2019 amendment ifrs 10 sale contribution asset investor associate ia 28 joint venture na 1 required applied endorsed eu commission standard may provide earlier mandatory application group anticipate stage analysis group sartorius stedim biotech control entity significant impact consolidated account exposed right variable return change moreover group involvement entity elected early adopt new standard liability affect return power amendment interpretation standard entity mandatory application subsequent december 31 2015 enterprise included consolidated financial statement time sartorius stedim biotech sa subsidiary acquired 4 significant accounting policy control date control cease subsidiary included basis basis preparation annual financial statement reporting period parent company using uniform group consolidated financial statement group recognition measurement method based principle historical cost acquisition construction production intragroup asset liability equity income exception item reflected fair value expense cash flow relating transaction financial asset held trading available sale tween member group eliminated full derivative consolidation consolidation business combination consolidated financial statement sartorius business combination measured according stedim biotech group include annual financial acquisition method identifiable acquired asset statement company controlled assumed liability potential liability recorded directly indirectly sartorius stedim biotech sa fair value date combination term ifrs 10 consolidated financial statement accounting investment subsidiary 118 consolidated financial statement note note financial statement significant acquisition purchase price currency different presentation currency allocation carried assistance translated exchange rate prevailing independent thirdparty valuation specialist balance sheet date income expense cash valuation based information available flow entity translated using acquisition date average rate year extent rate represents approximate value exchange rate group determines goodwill acquisition date used date transaction absence significant fluctuation resulting translation difference recognized comprehensive fair value consideration transferred income amount recognized noncontrolling longterm loan settlement neither interest acquiree planned likely foreseeable future group applies principle net investment foreign business combination carried stage operation exchange difference resulting fair value previously held equity interest loan recognized comprehensive income acquiree less accordance ia 2132 net recognized amount generally fair value exchange rate major currency identifiable asset acquired liability euro considered follows assumed yearend exchange rate average exchange rate difference negative gain 1 2015 2014 2015 2014 purchase gain recognized immediately income usd 108870 121410 110969 132881 gbp 073395 077890 072593 080619 expense directly related business combination jpy 13107000 14523000 13435238 14030709 recorded profit loss incurred inr 7202150 7671900 7122490 8106162 krw 128078000 132480000 125747421 139865446 cny 706080 753580 697587 818674 foreign currency transaction functional currency presentation currency consolidated financial statement sale revenue sartorius stedim biotech group euro financial statement presented thousand euro revenue derived selling product financial statement company transaction rendering service recognized sale revenue denominated foreign currency operational revenue recognized translated functional currency operating income sale recognized subsidiary exchange rate applicable date statement profit loss significant risk transaction monetary asset debt reward ownership good denominated foreign currency transferred customer company retains translated exchange rate balance sheet neither continuing managerial effective control date rate gain loss recognized good sold amount revenue cost profit loss period incurred incurred measured reliably probable economic benefit associated transaction flow translation financial statement prepared company foreign currency subsidiary financial statement prepared foreign currency translated pursuant ia 21 effect change foreign exchange rate accordance concept functional currency foreign subsidiary regarded independent subdivision sartorius stedim biotech group asset including goodwill liability entity functional consolidated financial statement note note financial statement 119 construction contract profit loss item cannot allocated one mentioned functional area recognized construction contract contract specifically income expense includes essentially negotiated construction asset effect translation transaction foreign combination asset closely interrelated currency sale fixed asset allowance trade interdependent term design technology receivables reorganization extraordinary function ultimate purpose use expense income grant related income outcome construction contract recognized income reasonable estimated reliably revenue constructiontype assurance condition attached grant project generally recognized complied grant received percentageofcompletion method based recognized systematically income percentage cost date compared total period related cost recorded estimated contract cost expected loss construction contract recognized expense immediately borrowing cost contract disclosed receivables liability borrowing cost expensed incurred unless percentage completion cumulative work directly attributable acquisition contract cost contract result exceeds construction production qualifying asset advance payment received construction contract therefore part cost asset recognized receivables amount due qualifying asset defined asset take customer balance deduction advance substantial period time six twelve month payment received negative obligation get ready intended use construction contract recognized liability amount due customer income tax functional cost current income tax determined based respective local taxable income period local general operating expense recognized profit tax rule addition current income tax include loss based function within group expense adjustment uncertain tax payment tax refund relating crossfunctional initiative project period yet assessed change deferred tax assigned respective functional cost based asset liability included income tax ex appropriate allocation principle cept change recognized comprehensive income caption cost sale includes cost product sold acquisition cost merchandise deferred tax asset liability determined based sold addition directly attributable expense temporary difference carrying raw material supply employee benefit amount tax basis asset liability expense except special case provided ia 12 including energy expense cost sale also includes loss carry forward tax credit measurement overhead allocated manufacturing based tax rate expected effective area corresponding depreciation period asset realized liability amortization settled selling distribution cost pertain particular purpose tax rate tax rule used cost sale marketing function enacted substantively enacted distribution advertising market research reporting date deferred tax asset recognized deductible temporary difference tax loss research development cost comprise cost unused tax credit extent research product process development unless probable group future taxable recognized asset income charged item general administrative expense mainly includes employee benefit expense cost material general administrative area 120 consolidated financial statement note note financial statement goodwill capitalized development cost essentially cover cost allocated staff involved rd goodwill represents future economic benefit raw material supply outside service arising asset acquired business directly attributable overhead intangible asset combination individually identified generated internally amortized straight line separately recognized basis useful life generally exceed five year according ia 36 goodwill acquired business combination may amortized rather must internally generated intangible asset may tested annually impairment soon recognized development cost included indication asset impairment period incurred cost research activity reported expense period purpose impairment testing goodwill must incurred allocated acquirer cashgenerating unit cgus expected benefit amortization intangible asset based synergy combination cgu smallest following estimated useful life group asset generates cash flow continuing use largely independent cash flow software 2 5 year asset capitalized development cost 4 6 year customer relation technology 5 15 year brand name na intangible asset intangible asset acquired recorded cost less accumulated regular amortization calculated property plant equipment according straightline method impairment loss useful life intangible asset property plant equipment caption period group expects use recorded cost related asset depreciated asset estimated useful life using straight line method cost incurred within scope development new product method capitalized depreciation fixed asset based following internally generated intangible asset following period useful life criterion met building 15 50 year technical feasibility completing intangible machinery 5 15 year asset available use sale factory office equipment 3 13 year intention complete intangible asset use sell tangible asset subject impairment test whenever indicator impairment see note ability use sell intangible asset impairment nonfinancial asset demonstration intangible asset generate probable future economic benefit availability adequate technical financial resource complete development use sell intangible asset ability measure reliably expenditure attributable intangible asset development consolidated financial statement note note financial statement 121 impairment nonfinancial asset operating lease lease rate paid lessee recognized expense lease book value carrying amount property plant rate received lessor recognized income equipment intangible asset subject respectively leased asset continues impairment testing indication recognized lessor balance sheet property impairment least year asset plant equipment indefinite useful life yet service category composed primarily goodwill accordance ia 36 impairment asset asset impaired inventory recoverable amount asset estimated recoverable amount asset cashgenerating raw material supply including merchandise unit higher fair value less cost sell reported inventory average cost asset cgu value use event principle finished good work progress individual asset recoverable amount cannot reported cost conversion cost includes estimated recoverable amount asset cash direct cost allocated material generating unit cgu estimated appropriate portion production material handling overhead general administrative estimated recoverable amount asset expense fixed asset normal depreciation cgu go book value carrying amount amortization rate based normal carrying amount reduced recoverable amount production capacity provided expense allocated priority goodwill caused production cause asset impairment removed inventory must valued lower amount book value asset cgu credited cost net realizable value net realizable newly estimated recoverable amount however value represents estimated selling price book value increase limited value asset ordinary course business less estimated cost cgu would asset impairment loss completion estimated cost necessary recognized previous financial year marketing sale distribution inventory risk exist risk reduced shelf life result storage period limited usability lease inventory marked accordingly lease arrangement whereby lessor conveys lessee return payment series pension obligation payment right use asset agreed period time according ia 17 lease classified pension provision similar obligation either operating finance lease finance recognized consolidated financial statement lease lease transfer substantially risk sartorius stedim biotech group accordance reward incidental ownership asset actuarial principle ia 19 employee benefit lease designated operating lease stipulates projected unit credit method method measurement addition known group lessee finance lease pension life expectancy expected cash amount equal fair value leased property value method take account future salary lower present value minimum lease pension increase payment recognized asset balance sheet simultaneously recognized financial actuarial gain loss recognized liability minimum lease payment essentially comprehensive income pension reserve consist finance charge reduction accordance standard ia 19 outstanding liability measured according effective interest method leased asset depreciated straightline basis period expected useful life shorter lease term 122 consolidated financial statement note note financial statement provision nonderivative financial instrument provision recognized liability third upon initial recognition nonderivative financial party incurred outflow resource instrument recognized fair value plus probable amount obligation transaction cost except financial asset fair reasonably estimated amount recognized value profit loss transaction provision represents best estimate obli cost incurred recognized profit loss gation closing date provision maturity acquisition date group determines outcome expected intervene classification financial asset one 12 month discounted determination category provided ia 39 financial instrument present value expenditure expected settle recognition measurement availableforsale obligation financial asset loan receivables financial liability classification determines asset provision reviewed regularly adjusted liability financial valuation method subsequent information becomes available circum closing amortized cost fair value stance change estimate provision warranty cost based historical experience cash cash equivalent restructuring provision set connection program materially change scope business group considers highly liquid investment performed segment business unit manner less three month maturity date business conducted case acquisition cash equivalent mainly includes restructuring expense include termination benefit check cash hand deposit bank cash compensation payment due termination cash equivalent measured fair value agreement supplier dealer including leasing purpose consolidated cash flow statement contract restructuring provision recognized cash cash equivalent include cash cash group detailed formal plan either equivalent defined commenced implementation announced investment financial instrument investment nonconsolidated subsidiary financial instrument contract give rise security measured cost active financial asset one entity financial market exists share security liability equity instrument another entity fair value asset cannot reliably measured financial asset group mainly include cash cash equivalent availableforsale financial asset trade loan receivables derivative financial trade receivables instrument positive fair value trade receivables reported financial liability group mainly comprise discernible risk covered book value trade loan borrowed bank trade payable finance receivables receivables representative lease payable derivative financial instrument fair value considering maturity date negative fair value credit risk determining recoverability trade receivables group considers change credit quality date credit originally granted loan receivables financial asset classified loan receivables measured amortized cost using effective interest method less impairment loss impairment loss trade receivables recognized using separate allowance account consolidated financial statement note note financial statement 123 financial liability 5 use judgment estimate financial liability measured except derivative preparation consolidated financial financial instrument amortized cost using statement management us estimate effective interest method assumption based best knowledge current future situation however actual result may differ estimate estimate derivative financial instrument assumption revised regular basis impact change estimate recognized derivative financial instrument foreign prospectively currency exchange contract interest rate swap contract measured fair value derivative addition group management exercise judgment financial instrument classified held trading defining accounting treatment specific trans unless designated hedging instrument action existing standard inter hedge accounting applied change pretations specifically treat accounting fair value derivative financial instrument problem concerned recognized either net income case cash flow hedge comprehensive income assumption estimate primarily concern effective portion change fair value following topic cash flow hedge business combination effective portion change fair value accounting business combination requires derivative instrument designated cash flow hedge asset acquired liability assumed recognized comprehensive income recorded respective fair value date ineffective portion recognized immediately net group obtains control application income financial result amount accumulated acquisition method requires certain estimate equity reclassified net income assumption made especially concerning fair period hedged item affect net income value acquired intangible asset property plant equipment liability assumed acquisition date useful life acquired statement cash flow intangible asset property plant equipment statement cash flow cash flow present measurement based large extent ed according allocation operating activity anticipated cash flow actual cash flow vary investing activity financing activity used calculating fair value may materially affect group future result cash flow operating activity determined operation using indirect method ie expense without effect payment added profit tax income without effect payment impairment asset subtracted cash flow financing activity composed primarily change equity impairment test conducted certain event lead instrument addition repayment loan assumption asset might impaired case carrying amount asset compared recoverable amount higher net realizable value value use calculation value use generally based discounted cash flow method using cash flow projection five year projection take account past experience represent management best estimate future sale revenue cost development cash flow planning period extrapolated using individual growth rate key assumption management based determination value use include 124 consolidated financial statement note note financial statement estimated growth rate weighted average cost provision contingent liability capital tax rate estimate contingent asset material impact respective value ultimately amount impairment provision recognized legal constructive obligation exist balance sheet date determine amount obligation certain intangible asset estimate assumption applied including determination probability capitalization selfconstructed intangible asset amount future outflow resource typically also includes significant level judgment eg significant estimate involved determination evaluation feasibility development project provision related onerous contract warranty expected market prospect determination cost asset retirement obligation legal proceeding useful life income tax trade receivables group operates various tax jurisdiction therefore determine tax position allowance doubtful account involves respective local tax law tax authority view significant management judgment review complex subject different individual receivables based individual customer interpretation taxpayer local tax authority creditworthiness current economic trend well deferred tax asset recognized analysis historical bad debt portfolio deductible temporary difference unused tax basis loss extent probable future taxable profit available deductible temporary difference unused tax employee benefit pension provision loss utilized future development uncertain partly beyond management control obligation pension postemployment assumption necessary estimate future taxable benefit determined accordance actuarial profit well period deferred tax valuation valuation rely key assumption asset recovered including discount rate expected salary increase mortality rate discount rate assumption estimate revised period determined reference yield highquality sufficient evidence revise assumption corporate bond appropriate duration currency management considers probable portion end reporting period deferred tax asset cannot realized corresponding valuation allowance recorded due changing market economic condition underlying key assumption may differ actual development may lead significant change 6 operating segment pension postemployment benefit obligation according ifrs 8 operating segment difference recognized identification reportable operating segment comprehensive income period based management approach ie occur sensitivity analysis see note 25 pension segment defined analogously internal employee benefit provision financial reporting entity therefore area activity considered operating segment business activity may result revenue expense operating result regularly reviewed entity chief operating decision maker executive member board director discrete financial information available internal reporting internal control reporting within sartorius stedim biotech based approach operating total solution provider customer accordingly identification sartorius stedim biotech reportable operating segment biopharm consolidated financial statement note note financial statement 125 key performance indicator operating item restructuring expense large group segment sartorius stedim biotech group project well proceeds loss disposal socalled underlying ebitda ebitda corresponds sale transfer financial asset property earnings interest tax depreciation plant equipment provided amortization underlying ebitda mean ebitda recurrent nature adjusted extraordinary item connection extraordinary item expense income segment asset segment liability exceptional onetime nature analyzed regular basis chief operating accordingly distort sustainable profitability decision maker therefore part segment material impact net worth segment report financial position earnings group example biopharm group k 2015 2014 change 2015 2014 change sale revenue 884331 683524 29 884331 683524 29 underlying ebitda 231347 160474 44 231347 160474 44 sale revenue 262 235 262 235 ebit 184532 120312 53 184532 120312 53 sale revenue 209 176 209 176 acquisition intangible tangible asset 54521 44242 23 54521 44242 23 reconciliation segment profit loss supplementary information region k 2015 2014 provide additional information required ifrs 8 underlying ebitda table present supplementary segment 231347 160474 information geographical region fiscal 2015 depreciation presentation region slightly changed amortization 39422 35289 result country formerly allocated extraordinary effect 7393 4873 market assigned region defined ebit 184532 120312 emea europe middleeast africa financial result 14854 15261 america asiapacific profit tax 169678 105051 key figure geographical area refer company location except sale revenue reported according customer location noncurrent asset correspond property plant equipment well intangible asset group affiliate allocated various region goodwill resulting reverse acquisition stedim 2007 associated intangible asset presented noncurrent asset europe 126 consolidated financial statement note note financial statement amount sale revenue single customer exceed 10 consolidated sale revenue 2015 2014 sale revenue noncurrent asset k 2015 2014 2015 2014 emea 397162 322135 653946 574847 thereof germany 105974 87963 248384 208258 thereof france 50486 45515 301876 306735 america 323461 219597 31681 27464 thereof usa 298552 204576 31681 27464 asia pacific 163707 141793 17556 16830 thereof china 38682 37290 1305 1439 thereof south korea 43320 31537 7563 7365 group 884331 683524 703183 619141 7 scope consolidation 2015 financial statement following subsidiary sartorius stedim russia tap biosystems phc ltd uk tap biosystems ltd uk sartorius stedim financiére sa france included scope consolidation figure minor importance assessing financial position group sale revenue total asset non consolidated company 1 group figure consolidated financial statement note note financial statement 127 financial statement following company included group financial statement ownership emea parent sartorius stedim biotech sa aubagne france company sartorius stedim belgium nv brussels belgium 100 sartorius stedim nordic taastrup denmark 100 sartorius stedim biotech gmbh goettingen germany 100 sartorius stedim plastic gmbh goettingen germany 100 sartorius north america holding gmbh hanover germany 100 sartorius stedim system gmbh guxhagen germany 100 sartorius stedim cellca gmbh laupheim germany 100 sartorius stedim uk ltd epsom uk 100 sartorius stedim biooutsource ltd glasgow uk 100 sartorius stedim lab ltd louth uk 100 tap biosystems group ltd royston uk 100 tap esop management ltd royston uk 100 automation partnership cambridge ltd royston uk 100 sartorius stedim fmt sa aubagne france 100 sartorius stedim france sa aubagne france 100 sartorius stedim aseptics sa lourdes france 100 sartorius stedim ireland ltd dublin ireland 100 sartorius stedim italy spa florence italy 100 sartorius stedim netherlands bv rotterdam netherlands 100 sartorius stedim austria gmbh vienna austria 100 sartorius stedim poland sp zoo kostrzyn poland 100 sartorius stedim switzerland ag tagelswangen switzerland 100 sartorius stedim spain sa madrid spain 100 sartorius stedim hungaria kft budapest hungary 100 sartorius stedim bioprocess sarl mhamdia tunisia 100 america sartorius stedim filter inc yauco puerto rico 100 sartorius stedim north america inc bohemia new york usa 100 allpure technology llc new oxford usa 60 asia pacific sartorius stedim australia pty ltd dandenong south victoria australia 100 sartorius stedim biotech beijing co ltd beijing china 100 sartorius stedim shanghai trading co ltd shanghai china 100 sartorius stedim india pvt ltd bangalore india 100 sartorius stedim japan kk tokyo japan 100 sartorius korea biotech co ltd seoul south korea 69 sartorius stedim malaysia sdn bhd kuala lumpur malaysia 100 sartorius stedim singapore pte ltd singapore 100 associate joint venture included scope consolidation company consolidated full ownership rate equal share voting right company sartorius stedim hungary included scope consolidation first time far company included due minor importance company initial consolidation lead material effect consolidated financial statement 128 consolidated financial statement note note financial statement 8 statement cash flow preliminary fair value fair value date statement cash flow show impact cash acquisition inflow outflow cash cash equivalent date acquisition group cash flow classified k k operating investing financing activity according intangible tangible asset 2068 3245 ia 7 statement cash flow inventory 468 476 trade receivables asset 307 312 context cash equivalent asset cash cash equivalent 41 42 converted cash within short maturity generally provision liability 484 406 less three month amount considered net asset acquired 2400 3669 statement cash flow equal amount 5001 1200 1835 statement financial position purchase price 4332 4332 goodwill 3132 2497 2014 group received grant related asset noncontrolling interest 1200 1834 connection purchase construction production facility puerto rico amount 41 million cash inflow reported cash flow investing activity payment recognized goodwill relates asset separately identified recorded also generate economic benefit group main 9 business combination benefit include expansion group portfolio strengthened position relevant biopharmaceutical market together synergy acquisition pure technology llc resulting combination full amount goodwill deductible local tax purpose april 25 2014 sartorius stedim biotech acquired 5001 u startup pure technology llc sartorius stedim biotech group chosen amount 6 million u dollar cash payment recognize amount noncontrolling interest pure specializes singleuse component solution level prorated share net identifiable biopharmaceutical application provides product asset without goodwill partial goodwill method complementary group portfolio may 31 2015 sartorius stedim biotech acquired share allpure remaining former additional stake 10 price 17 million u er also transferred sartorius stedim biotech transaction owner recognized 2022 latest purchase commitment forward equity reducing noncontrolling interest noncontrolling interest exact time retained earnings acquisition well purchase price depend future business performance acquired entity acquisition date corresponding liability acquisition biooutsource ltd disclosed noncurrent financial liability present value expected future payment april 17 2015 sartorius stedim biotech acquired 71 million liability initially recognized 100 voting right company retained earnings according ia 3223 biooutsource headquartered glasgow scotland subsequent measurement recognized profit biooutsource test safety quality biologic loss financial result drug vaccine pharmaceutical client become specialized offering comprehensive range purchase price allocation finalized 2015 service growing biosimilar industry follows service provided biooutsource part sartorius stedim biotech customer core process extend significantly beyond group current service offering consolidated financial statement note note financial statement 129 company achieved sale revenue approx purchase price allocation follows 9 million past twelve month employed 85 people fair value date acquisition purchase price allocation following k intangible asset 27175 fair value date property plant equipment 1558 acquisition trade receivables asset 914 k cash cash equivalent 1804 intangible asset 11409 deferred tax net 7533 property plant equipment 1517 provision liability 1329 inventory 842 net asset acquired 22589 trade receivables asset 2576 cash cash equivalent 1410 purchase price 26500 deferred tax net 2282 goodwill 3911 provision liability 2125 loan borrowing 699 net asset acquired 12648 purchase price 265 million paid cash expense directly attributable acquisition purchase price 30602 amounting 01 million recognized goodwill 17954 expense profit loss since initial consolidation group financial purchase price approx 306 million paid statement acquisition biooutsource cash expense directly attributable cellca contributed around 13 million sale acquisition amounting 02 million recognized revenue around 1 million group earnings expense profit loss acquisition taken place january 1 2015 group sale revenue would amounted approx 891 million group earnings approx acquisition cellca gmbh 120 million july 1 2015 sartorius acquired 100 share acquisition biooutsource cellca cella gmbh based laupheim germany founded focused extension product portfolio 2005 company around 30 employee especially area process development generated sale revenue approximately 6 million validation recognized goodwill represent euro 2014 cellcas major customer aspect well asset separately biopharmaceutical company well biosimilar identifiable goodwill deductible tax firm partly conduct process purpose development inhouse facility 130 consolidated financial statement note note statement profit loss note statement profit loss 10 sale revenue raw material supply sale revenue broken geographical caption consists following area consists following 2015 2014 2015 2014 12 month 12 month 12 month 12 month k k k k purchase consumed 197707 165023 france 50486 45515 cost purchased service 36770 26651 germany 105974 87963 total 234477 191674 country 727870 550045 total 884331 683524 personnel cost amount 36450 k realized caption broken follows subsidiary sartorius group 2015 13441 k 2014 2015 2014 12 month 12 month k k turnover broken product sale amounting 8441 million service amounting wage salary 196837 168470 402 million respectively 6511 million social security 40418 33192 324 million 2014 expense retirement benefit pension 5624 4901 total 242878 206564 detail country please refer geographical information given section 6 12 operating income expense 11 functional cost 2015 2014 statement profit loss presented 12 month 12 month k k according cost sale format ie expense allocated relevant function currency translation gain 12204 10327 production sale marketing research income decrease allowance bad debt 723 793 development general administration income release provision liability 909 1627 operating expense nature presented income grant 2944 2185 profit loss statement nature note 15 income 4459 3655 operating income 21239 18588 2015 rental payment amounting 79 million 2014 55 million made asset leased currency translation loss 17919 7650 operating lease extraordinary expense 7393 4873 allowance bad debt 1600 933 material expense personnel cost follows expense 3947 4899 operating expense 30860 18355 total operating income expense 9621 233 consolidated financial statement note note statement profit loss 131 item reported income grant discloses 14 income tax grant expense essentially related research development project recognized 2015 2014 income soon sufficiently reliable 12 month 12 month k k indication necessary prerequisite met current income tax 55098 34675 income includes income acquired deferred tax 4914 3297 cell culture medium business total 50184 31378 extraordinary item amounted 74 million previous year 49 million essentially cover income tax france calculated 3443 onetime expense strategic group project estimated taxable profit year germany integration acquisition related item rate 30 applied taxable income income generated outside france germany taxed rate applicable corresponding country 13 financial result considering french german average tax rate 2015 2014 impact tax legislation expected 12 month 12 month tax rate sartorius stedim biotech group k k roughly 29 following table describes interest similar income 150 423 difference expected tax expense affiliated income tax expense reported particular company 0 0 financial year income derivative financial instrument 1275 105 financial income 1429 1883 2015 2014 12 month 12 month financial income 2854 2411 k k interest similar expense 3543 5283 expected tax expense 29 49207 30465 affiliated company 903 122 difference group average income tax rate 4401 2375 expense derivative financial instrument 681 4655 permanent difference 2916 1251 interest expense pension 652 837 taxfree income tax exemption 1246 1444 financial expense 12832 6896 withholding similar financial expense 17708 17672 tax 2742 2030 total 14854 15261 966 1451 total 50184 31378 financial income financial effective tax rate 296 299 expense include mainly fair value change including foreign exchange loss liability connection purchase noncontrolling interest pure lonza liability see also chapter 26 expense derivative 2014 contain effect cancellation hedging relationship interest rate swap upon refinancing group 132 consolidated financial statement note note statement profit loss 15 profit loss statement nature 2015 2014 12 month 12 month k k sale revenue 884331 683524 purchase consumed 197707 165023 cost purchased service 36770 26651 personnel cost 242878 206564 amortization depreciation 39856 35620 operating cost 182588 129355 subtotal 699799 563212 operating profit ebit 184532 120312 financial income expense 14854 15261 income tax 50184 31378 noncontrolling interest 1495 1231 group net profit 117999 72442 16 earnings per share according ia 33 earnings per share earnings per share class share must determined separately basic earnings per share basic eps calculated basis weighted average number ordinary share period diluted earnings per share measured taking account share subscription option outstanding end period effect share option therefore considered weighted average number share 2015 2014 net profit tax k 119494 73673 group net profit tax k 117999 72442 earnings per share 768 472 diluted earnings per share 768 472 number share statutory level 15367238 15359238 dilution stock option exercised 1247 7871 weighted average number share used earnings per share calculation 15365991 15351367 future option 0 8000 potential option 0 0 weighted average number share used diluted earnings per share calculation 15365991 15359367 consolidated financial statement note note individual balance sheet item 133 note individual balance sheet item 17 goodwill intangible asset combination former sartorius biotechnology division former stedim group newly founded sartorius stedim biotech group follows goodwill strategy total solution provider customer various interdependency within goodwill business lowest level goodwill k monitored biopharm segment therefore gross book value jan 1 2014 308955 acquired goodwill allocated cgu currency translation 2259 business combination 2572 2014 impairment test conducted 2015 gross book value dec 31 2014 313786 measure recoverable amount basis impairment loss jan 1 2014 0 value use particular cashgenerating unit currency translation 0 biopharm segment cash flow forecast consider impairment loss 0 previous experience generally based impairment loss dec 31 2014 0 group management forecast period four net book value dec 31 2014 313786 year calculation based terminal year growth rate 25 year 2019 rate derived market expectation goodwill k forecast significant growth rate targeted biopharmaceutical market major growth driver gross book value jan 1 2015 313786 sartorius stedim biotech group aging currency translation 1711 increase population improved access business combination 21462 drug emerging market well ongoing gross book value dec 31 2015 336959 paradigm shift reusable product singleuse impairment loss jan 1 2015 0 product utilized bio manufacturing currency translation 0 biopharmaceutical industry impairment loss 0 impairment loss dec 31 2015 0 discount rate applied correspond weighted net book value dec 31 2015 336959 capital cost rate recognized follows 2015 2014 caption reported goodwill amount 336959 k capitalized difference asset tax tax tax tax resulting business combination according biopharm ia 36 goodwill acquired business combination segment 76 61 83 65 may amortized rather must tested annually impairment soon indication asset impairment 2015 impairment test result recognition impairment loss context increase recorded 2014 concern acquisition various sensitivity analysis based realistic variation allpure 2015 acquisition refers biooutsource assumption disclosed result cellca see note 9 impairment either following variation would theoretically represent breakeven point purpose impairment testing goodwill must allocated acquirer cashgenerating 2015 2014 unit cgus expected benefit discount rate 212 157 synergy combination cashgenerating unit terminal growth rate 471 179 cgu represents lowest level within entity cash flow 832 717 goodwill monitored internal management purpose may larger segment 134 consolidated financial statement note note individual balance sheet item intangible asset patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2014 33738 10779 108314 40410 54 193295 currency translation 1183 0 809 223 0 2214 business combination 2580 0 678 0 0 3258 acquisition 491 0 0 8447 251 9189 disposal 119 0 0 68 0 187 transfer 88 0 0 0 54 34 gross book value dec 31 2014 37962 10779 109800 49012 251 207804 amortization impairment loss jan 1 2014 11794 0 43432 21610 0 76836 currency translation 348 0 149 48 0 545 amortization impairment loss 3212 0 7787 6384 0 17382 disposal 119 0 0 0 0 119 transfer 0 0 0 0 0 0 amortization impairment loss dec 31 2014 15234 0 51368 28042 0 94644 net book value dec 31 2014 22727 10779 58433 20970 251 113160 patent capitalized license customer development payment similar right brand name relationship cost account total k k k k k k gross book value jan 1 2015 37962 10779 109800 49012 251 207804 currency translation 2067 4 565 456 0 3084 business combination 30617 207 7875 0 0 38699 acquisition 644 0 0 8154 67 8865 disposal 384 0 275 117 0 776 transfer 28 0 0 0 0 28 gross book value dec 31 2015 70933 10982 117965 57506 318 257704 amortization impairment loss jan 1 2015 15234 0 51368 28042 0 94644 currency translation 888 1 124 270 0 1281 amortization impairment loss 5487 28 8374 5167 0 19056 disposal 355 0 275 0 0 630 transfer 5 0 0 0 0 5 amortization impairment loss dec 31 2015 21259 27 59590 33479 0 114355 net book value dec 31 2015 49675 10955 58375 24027 318 143349 consolidated financial statement note note individual balance sheet item 135 stedim brand name acquired 2007 considered 2015 development cost 8154 k indefinite useful life therefore recognized asset 8447 k 2014 capitalized amortized foreseeable limit period development cost essentially covered cost brand name expected generate allocated staff involved rd raw net cash inflow group brand name material supply outside service directly tested annually impairment soon attributable overhead internally generated intangible indication asset impairment asset amortized according straightline method useful life usually integration stedim brand exceed five year sartorius stedim biotech brand separate measurement relevant cash flow longer amortization intangible asset allocated possible therefore separate impairment test corresponding function statement profit carried 2015 recoverable amount loss capitalized development cost amortization brand name considered level disclosed line cost sale biopharm segment cashgenerating unit cgu customer relationship obtained part reverse acquisition stedim constitute material intangible asset book value customer relationship amounted 348 million 2014 405 million year ended december 31 2015 remaining useful life seven year 18 property plant equipment factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2014 138763 92150 63628 14406 308948 currency translation 2747 1739 1499 811 6066 business combination 5 1 107 61 120 grant related asset 4060 0 0 00 4060 acquisition 3642 6181 6470 187596 35053 disposal 626 1997 5925 4043 8952 transfer 3189 3066 842 69219 175 gross book value dec 31 2014 143661 101141 66622 25926 337349 depreciation jan 1 2014 37711 53472 41901 6 133090 currency translation 393 1025 834 0 2252 depreciation 4898 6538 6802 0 18238 disposal 601 2360 5465 0 8426 transfer 0 6 0 6 0 depreciation dec 31 2014 42400 58682 44072 0 145154 net book value dec 31 2014 101260 42458 22550 25926 192195 136 consolidated financial statement note note individual balance sheet item factory office payment land building technical equipment account machinery construction improvement equipment equipment progress total k k k k k gross book value jan 1 2015 143661 101141 66622 25926 337349 currency translation 2489 1768 1340 34 5563 business combination 4220 1271 1510 1 7000 grant related asset 4060 0 0 0 4060 acquisition 6485 9195 7877 22099 45656 disposal 432 2145 5091 86 7755 transfer 3193 7620 2515 8105 192 gross book value dec 31 2015 155555 118850 69742 39799 383946 depreciation jan 1 2015 42400 58682 44072 0 145154 currency translation 427 1141 796 7 2357 depreciation 5571 8558 6237 434 20800 disposal 432 2249 4565 0 7247 transfer 0 1931 1926 0 5 depreciation dec 31 2015 47966 68064 44614 426 161070 net book value dec 31 2015 107589 50786 25128 39373 222875 depreciation included statement profit capitalized property plant equipment include loss according use asset cost asset held finance lease amounting sale selling distribution cost research 17137 k 2014 17384 k cost acquisition development cost general administrative expense asset total 19480 2014 18702 k operating expense 2015 fiscal 2014 significant impairment loss recognize intangible asset property plant equipment 19 deferred tax deferred tax asset deferred tax liability dec 31 2015 dec 31 2014 dec 31 2015 dec 31 2014 k k k k intangible asset 0 179 34693 22066 tangible asset 0 13 6826 5748 inventory 6195 3124 0 1011 receivables current asset 633 1097 1148 347 provision 9040 6604 0 0 liability 7450 1578 45 0 gross amount 23318 12595 42712 29172 carry forward taxable loss 574 259 0 0 tax undistributed earnings subsidiary 0 0 1325 1325 offset 13850 2685 13850 2685 net amount 10042 10169 30187 27813 change 127 2374 thereof recognized profit loss 74 4840 consolidated financial statement note note individual balance sheet item 137 deferred tax asset k 2015 2014 cash flow hedge 418 1084 balance sheet date group unused tax remeasurements net loss amount carried forward 60 million defined benefit obligation 7 1885 deducted future taxable profit 35 million net investment foreign 2014 deferred tax amount reported approx operation 1992 2069 26 million loss 13 million 2014 total 2403 5038 concerning remaining loss carried forward deferred tax amount recognized lack visibility future taxable profit 20 inventory deferred tax asset amount 01 million dec 31 2015 dec 31 2014 relate company reported loss year k k review earlier reporting year raw material supply 37765 29017 work progress 45632 33434 finished good deferred tax liability merchandise 60280 45941 payment account 3293 1583 deferred tax liability connection total 146970 109975 intangible asset refer asset acquired business combination consequently mainly linked customer relationship technology dec 31 2015 dec 31 2014 k k addition group recorded deferred tax liability gross amount inventory 160048 119626 tax amount 13 million 13 million 2014 writedowns 13078 9651 approx 307 million 200 million cumulative net amount inventory 146970 109975 undistributed earnings subsidiary effect group considers cumulative undistributed earnings intended systematically 21 current trade receivables reinvested subsidiary rather might used receivables pay dividend france germany dec 31 2015 dec 31 2014 group recognize deferred tax liability k k remaining retained earnings subsidiary trade receivables third earnings intended reinvested party 132964 116703 operation dividend paid amount due amount 5 dividend taxed customer contract work 3678 2070 french german taxation rule receivables subsidiary applicable withholding tax furthermore sartorius ag group 5702 6014 additional income tax consequence could arise trade receivables 142344 124787 case intermediate holding company fiscal 2015 previous year tax effect receivables subsidiary sartorius ag hedging instrument deferred tax asset group item refers company sartorius recognition remeasurements group defined benefit liability asset amount income tax incurred net investment group business area group foreign operation recognized carry longterm construction contract comprehensive income income tax recognized customerspecific contract recognized comprehensive income disclosed follows application ia 11 construction contract based table percentage completion method 138 consolidated financial statement note note individual balance sheet item item amount due customer contract trade receivables 46656 k 2014 30665 k work represents net amount cost incurred plus past due reporting date valuation recognized profit less recognized loss progress allowance made material billing connection construction contract change creditworthiness debtor aggregate amount cost incurred recognized could expected would pay amount profit loss project progress reporting outstanding trade receivables yet due date 17892 k 2014 17426 k project financial asset written advance payment 14214 k 2014 15356 k indication impairment recorded year contract revenue project progress 11747 k 2014 12423 k 22 financial asset trade receivables reported discernible risk covered book value trade dec 31 2015 dec 31 2014 receivables receivables representative k k fair value considering maturity date derivative financial credit risk determining recoverability trade instrument 9 57 receivables group considers change financial asset 8353 6790 credit quality date credit originally current financial asset 8362 6847 granted significant concentration credit risk due large base unrelated customer accordingly necessary make 23 issued capital provision cover risk beyond allowance already considered beginning 2014 fiscal year share capital company ten million three hundred development trade allowance ninety five thousand eight hundred six euro sixty six cent 1039580666 dec 31 2015 dec 31 2014 k k 2014 share capital company rose valuation allowance ten million three hundred ninety five beginning year 2615 2897 thousand eight hundred six euro sixty six increase year 1599 933 cent 1039580666 fifteen million three derecognition hundred fiftynine thousand two hundred thirty consumption 296 504 eight euro 15359238 following recovery amount previously impaired 721 793 condition foreign currency translation difference 71 82 meeting 17 july 2014 board business combination 91 0 director light authorization granted valuation allowance extraordinary shareholder meeting hold 8 end year 3359 2615 april 2014 reduced share capital nominal amount one million thirtysix thousand two hundred thirteen euro ten cent aging trade receivables past due impaired 103621310 cancelling entirety share acquired share buyback program dec 31 2015 dec 31 2014 authorized extraordinary shareholder k k meeting held 19 april 2010 ie one million six 130 day 24094 19790 hundred ninetyeight seven hundred ten 3190 day 13142 8775 1698710 share 91180 day 6857 1496 181360 day 1894 485 difference purchase price 360 day 668 118 cancelled share 6132719007 nominal total 46656 30665 value 103621310 difference equal sixty million two hundred ninety thousand nine hundred seventysix euro ninetyseven cent 6029097697 charged available premium included line capital reserve thirtyseven million eight hundred eightyeight thousand nine hundred twentynine consolidated financial statement note note individual balance sheet item 139 euro eighteen cent 3788892918 dec 31 dec 31 2014 balance twentytwo million four hundred two 2015 k thousand fortyseven euro seventynine cent 2240204779 item retained earnings number share beginning period 15359238 17042306 stock option exercised 8000 15642 share capital reduction transaction cancellation treasury share 0 1698710 share capital amounted nine million three number share hundred sixtynine thousand one hundred thirtyfive end period 15367238 15359238 euro eighteen cent 936913518 divided nominal value per share 100 100 fifteen million three hundred fiftynine issued capital amount k 15367 15359 thousand two hundred thirtyeight 15359238 share nominal unit value sixtyone cent 061 dividend 17 july 2014 board director using delegation power granted board director submit proposal extraordinary shareholder meeting 8 april 2014 annual general shareholder meeting payment decides carry share capital increase dividend year ended december 31 2015 capitalization five million nine follows payment net dividend 200 per hundred ninety thousand one hundred two share 2014 130 ie total disbursement euro eightytwo cent 599010282 3073447600 2014 1996700940 drawn issue premium included line capital reserve set forth annual account company financial period 24 noncontrolling interest closed 31 december 2013 approved extraordinary shareholder meeting held 8 april noncontrolling interest recognized 2014 statement financial position amounting 5778 k relate subsidiary sartorius korea biotech share capital increase carried pure technology llc interest sartorius increase thirtynine cent 039 nominal korea biotech 69 remaining 31 subject amount fifteen million three hundred fifty exercisable call option interest pure nine thousand two hundred thirtyeight 15359238 technology 6001 remaining share share comprising share capital company purchased sartorius stedim biotech end nominal unit value went sixtyone cent 2022 latest 061 one euro 100 purchase price noncontrolling interest december 31 2014 december 31 2015 entity variable depend future dilutive instrument share performance activity subscription option plan share registered name owner least four year benefit noncontrolling interest allocated follows double voting right respective entity dec 31 dec 31 2015 2014 k k sartorius korea biotech co ltd 4080 4639 allpure technology llc 1699 2013 total 5778 6653 140 consolidated financial statement note note individual balance sheet item key figure amount 22888 k relates particular pension provision retirement pension plan dec 31 2015 dec 31 2014 germany provision totaled 24054 k 2014 k k primarily relate direct commitment sartorius korea biotech co ltd defined benefit pension plan sale revenue 43395 28576 commitment employee earn benefit net result 5129 2426 year service rendered company benefit total asset 25204 19338 earned depend salary level age attributed profit loss 1590 1238 respective employee pension benefit allpure technology llc generally funded asset sale revenue 5023 1885 net result 239 12 assumed discount rate reflect interest rate total asset 5474 4564 payable reporting date prime corporate attributed profit loss 96 6 industrial bond matching maturity denominated relevant currency corporate bond available matching significant restriction group longterm maturity insufficiently available ability access use asset settle matching interest rate determined liability mentioned entity extrapolation measurement postemployment benefit 25 pension employee benefit provision obligation based following actuarial assumption defined contribution plan germany sartorius stedim biotech group company make payment defined contribution plan dec 31 2015 dec 31 2014 primarily relating governmentrun pension plan discount rate 227 190 2015 total expense recognized defined future salary increase 300 300 contribution plan amounted 14779 k 2014 future pension increase 200 200 13786 k defined benefit plan regard assumption mortality invalidity table richttafeln rt 2005 g klaus pension provision similar obligation heubeck applied recognized consolidated financial statement sartorius stedim biotech group accordance actuarial principle remeasurements defined france benefit liability asset shown comprehensive income according standard ia 19 dec 31 2015 dec 31 2014 actuarial loss transferred discount rate 200 180 pension reserve essentially resulted change future salary increase 250 300 discount rate totaled 308 k actuarial loss future pension increase 200 200 6957 k 2014 amount reported statement profit loss comprehensive income consist following consolidated financial statement note note individual balance sheet item 141 2015 2014 remeasurements defined benefit liability asset k k allocated follows current service cost 1625 1175 past service cost 688 336 2015 2014 net interest expense 554 732 k k component defined experience adjustment 542 508 benefit cost recognized change demographic profit loss 1492 1571 assumption 393 154 return plan asset excl change financial interest 31 3 assumption 741 6255 remeasurements 194 6907 total 195 6918 component defined benefit cost recognized comprehensive income 225 6910 plan asset total 1717 8481 2015 2014 k k statement profit loss current service plan asset jan 1 4974 4416 cost disclosed according assignment interest income 98 105 employee respective function return plan asset excl interest 31 3 amount included consolidated statement remeasurements 2 12 financial position arising group obligation group contribution payment 904 798 respect defined benefit plan follows foreign currency translation difference 447 174 dec 31 2015 dec 31 2014 employee contribution 188 160 k k employer contribution 621 475 present value contribution plan obligation 37651 35557 participant 522 459 fair value change 0 0 plan asset 5914 4974 plan asset dec 31 5914 4974 net liability 31737 30583 composition plan asset present value defined benefit obligation developed follows plan asset primarily refer insurance contract germany switzerland 2015 2014 major equity debt investment included k k subsidiary south korea deposited amount present value 12 million 09 million 2014 local bank obligation jan 1 35557 27017 cash cash equivalent current service cost 1625 1175 past service cost 688 336 interest cost 652 837 remeasurements 193 6895 foreign currency translation difference 632 253 retirement benefit paid reporting year 998 877 employee contribution 188 160 contribution plan participant 474 411 change 16 23 present value obligation dec 31 37651 35557 142 consolidated financial statement note note individual balance sheet item sensitivity analysis sensitivity analysis presented may representative actual change defined increase decrease actuarial assumption benefit obligation unlikely change would following impact defined assumption would occur isolation one another benefit obligation positive sign mean furthermore present value defined benefit increase obligation obligation calculated using method applied calculating defined benefit 2014 obligation liability recognized statement financial position projected unit credit method k demographic assumption life expectancy 1 year 1 year maturity analysis effect 761 749 undiscounted cash flow defined benefit financial assumption obligation allocated maturity follows discount rate 100 bps 100 bps effect 5244 6729 dec 31 2015 dec 31 2014 future salary increase 50 bps 50 bps k k effect 711 667 1 year 1267 1204 future pension increase 25 bps 25 bps 15 year 5898 4924 effect 898 854 610 year 11847 8794 10 year 47919 49263 total 66931 64185 2015 k weighted average duration defined benefit demographic assumption obligation 180 year 2014 181 year life expectancy 1 year 1 year effect 754 741 financial assumption discount rate 100 bps 100 bps effect 5385 6957 future salary increase 50 bps 50 bps effect 755 707 future pension increase 25 bps 25 bps effect 879 838 26 loan borrowing balance current balance current dec 31 2015 dec 31 2015 dec 31 2014 dec 31 2014 k k k k liability bank 26438 13835 48132 32253 loan sartorius ag 73379 73379 39511 39511 total loan borrowing 99817 87214 87643 71764 december 2014 sartorius group refinanced financing sartorius stedim biotech group syndicated loan facility led bnp paribas long term credit volume agreement commerzbank ag lbbw single 400 million 300 million euro interest rate variable loan facility according loan agreement future credit margin based armslength principle financing group channeled parent company sartorius ag time sartorius ag signed loan agreement sartorius stedim biotech gmbh secures consolidated financial statement note note individual balance sheet item 143 noncurrent loan borrowing include noncurrent liability include liability liability connection acquisition remaining purchase price cell culture presented caption noncurrent medium business company lonza amount liability please refer chapter 27 42023 k currently expected liability paid two tranche 2017 2022 27 noncurrent liability furthermore item includes forward liability purchase commitment noncontrolling dec 31 2015 dec 31 2014 interest company pure see chapter 9 k k amount 5428 k owner remaining derivative financial share sell share company instrument 4037 1881 sartorius stedim biotech group 2022 latest liability 47451 42843 purchase price depends performance total 51488 44724 activity derivative financial instrument represent fair value interest rate swap agreement foreign currency forward contract context refinancing described designation interest rate swap agreement cancelled amount recognized comprehensive income posted profit loss period 28 provision noncurrent provision payment employee early retirement plan total k k k balance jan 1 2014 2380 623 3003 currency translation 0 0 0 consumption 1062 0 1062 reversal 0 0 0 addition 891 53 944 reclassification 0 6 6 balance dec 31 2014 2209 682 2891 payment employee early retirement plan total k k k balance jan 1 2015 2209 682 2891 currency translation 0 8 8 consumption 780 33 813 reversal 0 6 6 addition 1117 53 1170 reclassification 0 29 29 balance dec 31 2015 2546 732 3278 144 consolidated financial statement note note individual balance sheet item noncurrent provision comprise mainly provision partial retirement employee anniversary bonus included item obligation arise mainly german group company partial retirement plan allow employee work parttime 3 5 year actual retirement according ia 19 treatment severance payment earned future period must recognized profit loss respective period service actuarial gain loss well past service cost obligation recognized income expense noncurrent provision reported present value reporting date discount rate em ployees early retirement plan 03 2014 03 current provision financial 2014 2015 current provision developed follows warranty total k k k balance jan 1 2014 2009 2989 4998 currency translation 55 110 165 consumption 817 438 1255 release 799 487 1286 addition 2787 815 3602 change scope consolidation 0 0 0 change 0 0 0 balance dec 31 2014 3235 2989 6224 warranty total k k k balance jan 1 2015 3235 2989 6224 currency translation 92 62 154 change scope consolidation 151 79 230 consumption 1343 245 1588 release 440 141 581 addition 1873 1989 3862 change 0 288 288 balance dec 31 2015 3569 4445 8014 consolidated financial statement note note individual balance sheet item 145 measuring provision recognizable 30 financial obligation contingent obligation based past business asset liability transaction past event probably resulting cash payment resource representative case previous year economic benefit whose amount significant contingent liability contingent asset reliably estimated reported provision reported group financial obligation refer rental obligation future minimum lease payment provision recognized legal constructive lease noncancellable lease obligation third party warranty provision break follows contain expense returned product replacement delivery repair specific risk recognized occurrence likely general warranty risk considered basis dec 31 2015 dec 31 2014 experience past provision contain k k mainly onerous contract uncertain liability operate lease employee due within one year 5771 4439 due within 2 5 year 11506 7212 due thereafter 3301 2070 29 current liability 31 financial instrument financial risk trade payable dec 31 2015 dec 31 2014 general information k k payment received section give overview impact account order 39242 31964 financial instrument financial statement trade payable third sartorius stedim biotech group provides party 54532 36964 additional information balance sheet item payable subsidiary sartorius ag group 6824 12210 contain financial instrument total 100598 81139 derivative measured fair value determined according marktomarket method recognized mathematical method used fair value based market data available financial liability time value derivative calculated reflect estimate market condition dec 31 2015 dec 31 2014 k k end year derivative financial instrument 3460 4867 personnelrelated liability 26374 22437 liability 11493 20774 total 41327 48078 derivative financial instrument refer fair value interest rate swap agreement foreign currency hedging transaction forward contract mainly related u 146 consolidated financial statement note note individual balance sheet item b class financial instrument following table compare carrying amount fair value category financial instrument reconcile balance sheet item carrying carrying amount fair value amount fair value category acc dec 31 2015 dec 31 2015 dec 31 2014 dec 31 2014 ia 39 k k k k financial asset available sale 1330 1330 1214 1214 trade receivables loan receivables 142344 142344 124787 124787 financial asset loan receivables 8353 8353 6790 6790 derivative financial instrument held trading 0 0 12 12 derivative financial instrument hedging relationship hedging instrument 9 9 45 45 financial asset 8362 8362 6847 6847 cash cash equivalent loan receivables 31831 31831 18544 18544 loan borrowing financial liability cost 99817 100919 87643 88976 finance lease liability ia 17 18443 25175 18338 21465 trade payable financial liability cost 61356 61356 49175 49175 trade payable na 39242 39242 31964 31964 trade payable 100598 100598 81139 81139 derivative financial instrument held trading 2801 2801 3408 3408 derivative financial instrument hedging relationship hedging instrument 4696 4696 3340 3340 financial liability financial liability cost 53906 61494 57784 60805 financial liability fair value profit loss 5428 5428 6183 6183 financial liability na 25985 25985 22088 22088 financial liability 92815 100403 92802 95823 carrying amount financial instrument category shown following table dec 31 2015 dec 31 2014 k k available sale asset 1330 1214 loan receivables 182528 150121 held trading asset 0 12 asset held hedging instrument 9 45 financial liability cost 215078 194602 held trading liability 2801 3408 fair value profit loss 5428 6183 liability held hedging instrument 4696 3340 equity investment measured acquisition fair value financial instrument cost financial asset possible determine determined basis market information fair value reliably due absence active available reporting date allocated market applies mainly share non one three level fair value hierarchy consolidated subsidiary mainly linked accordance ifrs 13 sale affiliate group calculation fair value activity would therefore relevant economic decision user currently planned sell asset consolidated financial statement note note individual balance sheet item 147 level 1 financial instrument calculated carrying amount liability reconciled basis price quoted active market identical follows asset liability level 2 financial instrument calculated basis input factor k 2015 2014 derivable observable market data basis balance jan 1 6183 0 market price similar instrument level 3 initial recognition 0 7113 financial instrument calculated basis fair value change 0 1678 input factor cannot derived observable interest expense included market data profit loss 93 72 payment 1532 0 financial instrument recognized fair effect foreign value reporting date exclusively derivative exchange translation 684 676 form forward contract interest rate balance dec 31 5428 6183 swap measured basis quoted exchange rate market yield curve level 2 increase decrease sale revenue 10 fair value disclosed financial liability following year would lead increase recognized amortized cost especially liability decrease liability 06 million 06 million bank finance lease measured basis market interest rate taking current indicative credit spread account level 2 net gain loss financial instrument liability connection forward acquire net gain loss various category noncontrolling interest allpure financial instrument presented following recognized present value expected future table payment payment derived expected revenue allpure business time 2015 2014 purchase taking consideration 12 month 12 month k k mentioned riskadjusted discount rate level 3 available sale asset 0 97 fair value remaining financial asset loan receivables 3103 2276 liability disclosed approximate carrying financial asset liability held trading 595 3396 amount account predominantly short term maturity fair value profit loss 93 1606 financial liability cost 13503 1668 measurement fair value group recognizes transfer level net result financial asset available sale fair value hierarchy end reporting mainly comprises gain loss equity investment period change occurred dividend gain disposal share current reporting period transfer level net result loan receivables mainly includes effect currency translation valuation level 3 liability based change allowance discounted cash flow technique taking con sideration expected future payment discounted net result financial asset liability held using riskadjusted discount rate expected trading predominantly comprises change payment determined considering possible fair value derivative financial instrument well development future revenue amount interest income interest expense paid scenario significant financial instrument unobservable input calculation future revenue considered growth rate approximately 5 million per year average 148 consolidated financial statement note note individual balance sheet item net result liability measured amortized e management exchange rate risk cost mainly comprises effect foreign currency translation fair value change group exposed currency risk one third sale revenue generated u dollar total interest income expense financial asset currency linked u dollar lesser liability measured fair value without extent foreign currency therefore recognition profit loss follows derivative financial instrument used hedge net currency exposure resulting currency 2015 2014 translation sale revenue currency hedging 12 month 12 month forward contract used limited extent k k structured hedge transaction interest income 362 628 interest expense 3767 5624 forward contract secure right simultaneously create obligation sell established foreign currency amount exercise date specific c capital risk management exchange rate euro independently exchange rate actually valid date profit sartorius stedim biotech group capital loss resulting difference current managed order maximize earnings previously established exchange rate participating company optimizing ratio generally measured income expense equity liability furthermore ensure statement profit loss group company operate premise goingconcern principle addition target profit forward concluded optimize hedging transaction financial liability detailed regarded transaction secure right create obligation managed capital furthermore cash swap agreed amount foreign currency cash equivalent well equity capital corresponding euro amount fixed exchange rate several target date long profit resulting exchange transaction goal financial risk management exceed contractually defined limit treasury department sartorius stedim group strategy provides hedging biotech group centrally focused sartorius one half year also hedging measure corporate administration gmbh subsidiary reviewed regular interval order adapt sartorius ag centralized treasury department currency fluctuation performs service company sartorius group including sartorius stedim biotech group balance sheet date forward contract coordinate access national international carried amount 107 million 2014 financial market addition treasury 625 million hedge risk fluctuation department monitor control financial risk eur usd exchange rate amount cover internal risk reporting analyzes risk according roughly one third expected net exposure degree scope essentially risk entail u dollar within period two year furthermore currency interest rate liquidity risk japanese yen british pound swiss franc hedged smaller volume sartorius stedim biotech group strives minimize impact currency interest rate risk following table show forward transaction using derivative financial instrument hedging well target profit forward contract transaction controlling carried balance sheet date different staff member moreover group internal auditing department regularly monitor use financial instrument trading derivative financial instrument done hedging purpose consolidated financial statement note note individual balance sheet item 149 fair value dec 31 2014 currency volume maturity k forward contract usd 23000000 q1 2015 1442 usd 14500000 q2 2015 844 usd 12000000 q3 2015 750 usd 8000000 q4 2015 422 usd 5000000 q1 2016 75 usd 62500000 3533 forward contract jpy 50000000 q2 2015 21 jpy 60000000 q3 2015 25 jpy 110000000 47 target profit forward jpy 150000000 q4 2015 15 jpy 150000000 15 fair value dec 31 2015 currency volume maturity k forward contract usd 15000000 q1 2016 1098 usd 14500000 q2 2016 734 usd 15500000 q3 2016 680 usd 15000000 q4 2016 844 usd 11500000 q1 2017 463 usd 10500000 q2 2017 520 usd 12000000 q3 2017 577 usd 13000000 q4 2017 492 usd 107000000 5407 target profit forward usd 14000000 q3 2017 43 forward contract gbp 500000 q1 2016 4 forward contract chf 2000000 q1 2016 49 chf 1000000 q2 2016 51 chf 3000000 100 target profit forward jpy 525000000 q3 2017 23 derivative financial instrument measured vice versa u dollar would appreciated time acquisition cost fair value 10 euro resulting impact subsequent balance sheet date change value result would 45 million 2014 derivative financial instrument recognized 33 million comprehensive income statement profit loss balance sheet 179 million 2013 122 million date derivative financial instrument serve hedge cash flow risk qualified hedging variation swiss franc chf euro relationship exists based criterion ia 39 would primarily impact valuation treasury hedging valuation adjustment liability connection acquisition recognized comprehensive income cumulative cell culture medium business lonza 2012 amount 2015 47 million 2014 33 million denominated chf increase chf amount recognized equity included profit euro 5 would lead increase loss period hedged transaction liability amounting 22 million 2014 19 million affect result decrease chf euro 5 would lead decrease liability amounting u dollar would depreciated 10 20 million 17 million euro equity would increased 146 million 2014 100 million result would increased 36 million 2014 27 million 150 consolidated financial statement note note individual balance sheet item f interest risk management loan outstanding variable interest rate result group receives particular variable sartorius stedim biotech mainly financed interest rate valid market pay fixed parent company sartorius ag major loan interest rate taken variable interest rate therefore group continues exposed interest rate risk following table provides overview control interest risk appropriate ratio interest hedging contract available reporting fixed variable loan maintained date furthermore group concluded interest rate hedge form interest swap cover majority hedging hedging fair value volume volume fair value dec 31 2015 dec 31 2014 hedged dec 31 2015 dec 31 2014 instrument k k end term interest rate k k aug swap 40000 60000 2018 168 179 1920 1385 march forward swap 0 40000 2019 168178 0 1822 total 1920 3207 group hedging strategy secure roughly 50 risk exposure period five year dec 31 2015 raised loan variable interest rate amount approx 80 million hedged volume 40 million next five year g liquidity risk management maturity financial liability excluding derivative financial instrument show following pattern carrying amount dec 31 2014 cash flow dec 1 year 1 5 year 5 year k 31 2014 k k k k loan borrowing 87643 98509 80200 14299 4010 finance lease 18338 35976 1611 8397 25968 trade payable 49175 49175 49175 0 0 liability excluding derivative 63967 73300 21123 23069 29108 financial liability 219122 256959 152109 45764 59086 carrying amount cash flow dec 31 2015 dec 31 2015 1 year 1 5 year 5 year k k k k k loan borrowing 99817 115053 101556 13497 0 finance lease 18443 36600 1954 8616 26029 trade payable 61356 61356 61356 0 0 liability excluding derivative 59334 68073 11882 23887 32303 financial liability 238949 281081 176748 46001 58332 consolidated financial statement note note individual balance sheet item 151 cash flow shown table include include liability purchase commitment undiscounted expected payment connection cell culture medium business company lonza respective financial liability including forward liability acquisition associated interest payment based interest remaining share pure rate balance sheet date following table illustrate liquidity analysis loan borrowing include loan raised derivative financial instrument based parent company sartorius ag liability undiscounted cash flow carrying amount dec 31 2014 cash flow dec 1 year 1 5 year 5 year k 31 2014 k k k k gross fulfilment forward contract 3541 3599 3501 98 0 payment obligation 52236 48118 4118 0 payment claim 48637 44617 4020 0 net fulfilment interest rate swap 3207 4418 1231 3187 0 derivative 6748 11616 8233 3383 0 carrying amount cash flow dec 31 2015 dec 31 2015 1 year 1 5 year 5 year k k k k k gross fulfilment forward contract 5577 5569 3517 2052 0 payment obligation 93668 51311 42357 0 payment claim 88165 47860 40305 0 net fulfilment interest rate swap 1920 1947 761 1186 0 derivative 7497 13019 7729 5290 0 group control liquidity risk maintaining credit line additional facility bank continuously tracking forecasted actual cash flow managing maturity profile financial asset liability table provides overview credit line available reporting date credit line credit line credit line 1 year 1 5 year 5 year interest rate used unused dec 31 2014 k k k dec 31 2014 dec 31 2014 loan sartorius ag 300000 300000 0 0 variable 39511 260489 bilateral credit variable line 67846 52221 12500 3125 fixed 48132 19714 total 367846 352221 12500 3125 87643 280203 152 consolidated financial statement note note individual balance sheet item credit line credit line credit line 1 year 1 5 year 5 year interest rate used unused dec 31 2015 k k k dec 31 2015 dec 31 2015 loan sartorius ag 300000 0 300000 0 variable 73379 226621 bilateral credit variable line 32525 20025 12500 0 fixed 26438 6087 total 332525 20025 312500 0 99817 232708 market interest rate 10 percentage 32 sharebased payment point higher interest expense statement profit loss would 08 million 2014 sharebased payment relate stock option plan 05 million higher effect would allocated group personnel overcompensated increase fair value interest rate swap 10 million 16 million various stock option plan outstanding december 31 2014 december 31 2015 regard decrease interest rate base summarized follows interest rate 0 considered resulting impact financial result would dec 31 2015 dec 31 2014 01 million 03 million 2014 caused number number option option valuation interest rate swap outstanding beginning period 8000 23642 allocated period 0 0 h risk associated cancelled period 0 0 financial instrument exercised period 8000 15642 lapsed period 0 0 reporting date sartorius stedim biotech outstanding end group exposed risk volatility period 0 8000 share price exercisable end period 0 8000 number share number number number option date initial subscribed number share option subject total general date number director number subscribed granted target number meeting board share director initial subscrip exercisable performan beneficiary authorizing granted executive bene tion fiscal year dec 31 ce dec valid plan approval subscribed executive concerned ficiaries price 2014 2014 31 2014 option june 23 2000 july 23 2004 140000 0 0 19 923 15642 0 0 0 june 10 2005 sept 15 2005 127500 0 0 15 1887 0 5000 0 1 june 10 2005 nov 10 2006 35000 0 0 2 2951 0 3000 0 1 total 302500 0 36 15642 8000 0 2 8000 consolidated financial statement note note individual balance sheet item 153 number share number number number option option date initial subscribed number share granted subject total general date number director number subscribed target number meeting board share director initial subscrip exercisable performanc beneficiary authorizing granted executive bene tion fiscal year dec 31 e dec 31 valid plan approval subscribed executive concerned ficiaries price 2015 2015 2015 option june 10 2005 sept 15 2005 127500 0 0 15 1887 5000 0 0 0 june 10 2005 nov 10 2006 35000 0 0 2 2951 3000 0 0 0 total 162500 0 17 8000 0 0 0 0 cost fiscal 2015 0 k new additional level sartorius stedim biotech majority stock option granted 2015 option shareholder sartorius ag sharebased payment exist exercised program therefore closed form socalled phantom stock unit plan respective board member granted sartorius stedim biotech share purchase option certain number phantom stock year allocated group senior represent agreed amount money exercise managerial employee director fair value stock possible four year service performed consideration allocation depending certain requirement regarding option measured reference fair performance sartorius ag share value option date allocation stock paid amount based share order perform estimate group us price exercise date payment capped binomialtype mathematic model amount 25 time share price time virtual option granted detail please total fair value plan thus measured refer remuneration report recognized expense spread full vesting period plan expense recognized fair value phantom stock unit disclosed personnel cost offset increase reserve follows cash received group upon exercise option recognized cash cash equivalent corresponding item issued capital reserve fair value granted fair value number jan 1 yearend phantom subscription particular dec 31 stock unit price year 2015 paid exercisable k k k 8358 2662 223 0 556 paid tranche phantom stock unit 2011 2015 tranche phantom stock unit 2012 7115 3312 235 572 0 tranche phantom stock unit 2013 3686 6936 256 343 0 tranche phantom stock unit 2014 3228 8403 271 291 0 tranche phantom stock unit 2015 2954 9878 292 729 0 total 25341 1277 1935 556 154 consolidated financial statement note disclosure disclosure consolidated financial statement prepared described structure lead various relation going concern basis transaction related party transaction sartorius stedim biotech sa subsidiary presented note 7 related party material event reporting date company eliminated consolidation disclosed note detail material event occurred reporting date transaction group related party belonging sartorius group disclosed number employee sale purchase commission average workforce employed year 2015 3995 3642 2014 certain business area member sartorius group act contract manufacturer sartorius stedim biotech group vice versa respective 33 related party transaction carried arm length principle disclosed table sale revenue purchase general sale revenue purchase majority shareholder sartorius stedim 2015 2015 k k biotech sa sartorius ag hold either directly indirectly 100 subsidiary vl related party sartorius group 36450 4762 finance sa controlling stake company 743 equity capital 845 voting sale revenue purchase 2014 2014 right k k related party sartorius sartorius group organized two division group 13441 5850 bioprocess solution mainly run sartorius stedim biotech group lab product service mainly run company sartorius certain product group sartorius stedim group structure lead fact group biotech portfolio sold sale force hold two subsidiary country sartorius entity arranging company partially share space staff sale sartorius stedim biotech group resource furthermore german group company paid commission amount 89 million carry various central function accordingly 70 million 2014 commission typically deliver service worldwide entity eg calculated percentage generated sale support company sartorius corporate revenue administration gmbh 100 subsidiary sartorius ag incorporated numerous group function like group finance hr investor relation legal central marketing service charged within group significant extent also sartorius stedim biotech consolidated financial statement note disclosure 155 management fee shareholder cost administration charge shared cost two sartorius stedim biotech sa board member described company also member sartorius ag executive board country share certain function cost paid german parent company underlying contract include mainly sublease service sartorius stedim biotech portion office space central administrative function remuneration charged sartorius accounting controlling human resource stedim biotech sa 14 million 2015 07 million management respect relevant 2014 charged sartorius stedim company charge rent salary social security cost biotech gmbh 16 million 2015 08 million expense service well pro 2014 rated profit margin service provide shareholder function like group financial significant contract context one reporting compliance investor relation sartorius stedim biotech gmbh germany performed mentioned sartorius sartorius corporate administration gmbh corporate administration gmbh germany company provides central service service charged sartorius stedim administrative function sartorius stedim biotech sa amount 06 million 2014 biotech gmbh group company 06 million calculation service fee typically includes surcharge 3 total cost 3 surcharge compliant arm length principle routine shareholder loan task following oecd eu guideline 2015 service approx 308 million provided described note 26 sartorius stedim biotech sartorius stedim biotech gmbh 239 million 2014 group raised loan parent company amount cover following function sartorius ag credit 300 million current utilization approx 73 million 2014 marketing communication ebusiness business 40 million interest charged based development variable interest rate plus armslength credit margin environment health security factory maintenance finance human resource information technology central service general organization compensation key management personnel 2014 2015 executive board management received following remuneration total shortterm postemployment longterm termination sharebased k benefit benefit benefit benefit payment k k k k k 2015 1 6715 3173 305 506 0 2731 1 2014 4116 2823 450 404 0 458 1 information please refer chapter corporate governance see page 75 109 156 consolidated financial statement note statutory auditor report consolidated financial statement statutory auditor report consolidated financial statement free translation english statutory ended accordance international financial auditor report consolidated financial statement issued reporting standard adopted european union french language provided solely convenience english speaking user statutory auditor report includes information specifically ii justification assessment required french law report whether modified information presented opinion consolidated accordance requirement article l 8239 financial statement includes explanatory paragraph discussing auditor assessment certain significant accounting french commercial code code de commerce auditing matter assessment made purpose relating justification assessment bring issuing audit opinion consolidated financial statement attention following matter taken whole provide separate assurance individual account caption information taken outside note 5 judgement estimate consolidated consolidated financial statement report also includes information relating specific financial statement refers significant judgment verification information given group management report estimate made management particularly report read conjunction construed concerning capitalization research accordance french law professional auditing standard development expenditure impairment test applicable france goodwill asset indefinite useful life year ended december 31 2015 periodend company systematically performs impairment test goodwill asset indefinite shareholder useful life also assesses whether indication loss value longterm asset according compliance assignment entrusted u term condition defined note 17 goodwill shareholder meeting hereby report intangible asset consolidated financial statement year ended december 31 2015 audit accompanying consolidated financial work consisted assessing data assumption statement sartorius stedim biotech judgment estimate based justification assessment reviewing test basis calculation performed specific verification required law company comparing accounting estimate previous period corresponding achievement consolidated financial statement examining procedure implemented management approved board director role express approve estimate verifying note opinion consolidated financial statement consolidated financial statement provide based audit appropriate disclosure assumption option adopted company opinion consolidated financial statement assessment made part audit conducted audit accordance professional consolidated financial statement taken whole standard applicable france standard require therefore contributed opinion formed plan perform audit obtain reasonable expressed first part report assurance whether consolidated financial statement free material misstatement audit iii specific verification involves performing procedure using sampling technique method selection obtain audit required law also verified accordance evidence amount disclosure professional standard applicable france consolidated financial statement audit also includes information presented group management report evaluating appropriateness accounting policy used reasonableness accounting estimate matter report fair presentation made well overall presentation consistency consolidated financial statement consolidated financial statement believe audit evidence obtained sufficient marseille february 19 2016 appropriate provide basis audit opinion statutory auditor opinion consolidated financial statement give true fair view asset liability french original signed financial position group december 31 2015 kpmg audit deloitte associés result operation year division kpmg sa john evans christophe perrau annual financial statement sartorius stedim biotech sa note 158 consolidated financial statement note annual financial statement annual financial statement parent company balance sheet asset thousand depreciation amortization gross provision net net dec 31 2015 dec 31 2015 dec 31 2015 dec 31 2014 intangible asset 552 32 520 548 property plant equipment 17430 9698 7732 7491 financial investment 128079 128079 128113 total noncurrent asset 146061 9730 136331 136152 inventory work progress 0 0 0 0 receivables trade receivables third party 0 0 0 0 receivables 15376 0 15376 4663 marketable security 0 0 0 0 deposit cash equivalent 13 13 6 total current asset 15389 0 15389 4669 prepaid expense 50 50 62 currency translation adjustment 0 0 0 total asset 161500 9730 151770 140883 parent company balance sheet equity liability thousand dec 31 2015 dec 31 2014 share capital 15367 15359 share premium 16315 16140 reserve 2126 1630 retained earnings carried forward 13416 9032 profit period 29312 24845 regulated provision 4088 4088 total equity 80623 71094 provision liability charge 0 0 total provision liability charge 0 0 loan borrowing 0 0 trade payable 1070 784 tax social charge payable 57 46 liability noncurrent asset 75 193 liability 69945 68767 total liability 71147 69789 currency translation adjustment 0 0 total equity liability 151770 140883 consolidated financial statement note annual financial statement 159 parent company income statement thousand dec 31 2015 dec 31 2014 sale revenue 1593 1465 inventory movement 0 0 capitalized production cost 0 0 depreciation amortization reversal 0 0 operating income expense reallocation 5 0 purchase consumed 0 0 external charge service 3058 2597 tax duty 814 800 personnel cost 0 0 addition amortization depreciation provision 684 654 operating expense 349 231 operating profit ebit 3307 2817 net financing income expense 33286 27194 profit loss ordinary activity 29979 24377 exceptional income expense 14 0 income tax 653 468 net profit loss 29312 24845 160 consolidated financial statement note annual financial statement 1 materiel event exercise 3 accounting principle method sartorius stedim biotech sa subject parent company financial statement year french tax audit bduring exercise 2015 audit ended december 31 2015 prepared covered year 2012 2013 presented accordance french accounting rule compliance principle prudence amount adjustment significant reporting distinct financial year pre sumption going concern 2 materiel event reporting date annual financial statement prepared accordance clause crc regulation envisaged sartorius stedim biotech sa 2014 03 september 8 2014 french chart absorbs pursuant merger absorption account company vl finance simplified joint stock company share capital 4614710 euro whose sartorius stedim biotech sa listed compartment registered office zone industrielle le paluds euronext paris stock exchange isin fr code avenue de jouques 13400 aubagne company 0000053266 also prepares consolidated financial registry marseille number 377 509 112 statement accordance ifrs standard adopted european union december 31 2015 proposed merger part internal reorganization project sartorius group simplify legal structure including detention 31 noncurrent asset french subsidiary achieve saving operating cost appeared existence vl noncurrent intangible tangible asset valued finance legal structure legal interest acquisition cost excluding cost incurred company holding company acquisition one financial investment entity sartorius stedim biotech sa intangible asset property plant equip ment company applied french regulation crc please note vl finance employee 2002 10 recodified article 2 4 regulation brand patent commercial crc 2004 06 relative amortization activity depreciation impairment asset according component approach consolidated financial statement note annual financial statement 161 311 intangible asset 313 financial investment following thus valuated heading investment relate mainly shareholding incorporation cost patent software subsidiary treasury share held within scope share buyback program asset amortized straightline basis recorded acquisition cost including fee linked using following indicative useful life acquisition incorporation cost one five year writedown provision may established take software one three year account particular either stock exchange patent twenty year price underlying asset subsidiary leasehold eighteen year based financial position prospect period use shareholding subsidiary subject impairment part implementation integrated software test direct labor cost concerned included amount capitalized cost function time elapsed 32 receivables payable intangible asset valued acquisition cost less receivables payable recorded nominal amortization impairment reported ongoing value basis receivables whose collection doubtful subject provision doubtful debt 312 property plant equipment property plant equipment ppe recognized acquisition value including installation cost asset depreciation calculated standard economic life asset using straightline method noncurrent asset depreciated straightline basis using following indicative period use building twenty forty year improvement fixture fitting ten fifteen year plant equipment four ten year office equipment three five year motor vehicle four five year property plant equipment valued acquisition cost less depreciation impairment reported ongoing basis 162 consolidated financial statement note annual financial statement 4 noncurrent asset thousand 41 intangible asset gross value dec 31 2014 increase 2015 decrease 2015 dec 31 2015 incorporation cost 4 0 0 4 patent 0 0 0 0 software license 0 0 0 0 business goodwill 548 0 548 intangible asset progress 0 0 0 0 total 552 0 0 552 amortization depreciation 4 28 0 32 net amount 548 28 0 520 42 property plant equipment gross value dec 31 2014 increase 2015 decrease 2015 dec 31 2015 land 496 0 0 496 building 14402 372 0 14774 plant equipment 0 0 0 0 1143 331 0 1474 property plant equipment progress 492 193 0 685 total 16533 897 0 17430 amortization depreciation dec 31 2014 addition release dec 31 2015 building 8953 449 0 9402 plant equipment 0 0 0 0 89 207 0 296 total 9042 656 0 9698 property plant equipment net 7491 241 0 7732 increase tangible asset includes fixture fitting amount 703 k asset construction amount 193 k consolidated financial statement note annual financial statement 163 43 financial investment investment dec 31 2014 increase 2015 decrease 2015 dec 31 2015 shareholding 127877 0 8 127869 writedown shareholding 0 0 0 0 deposit guarantee 235 0 25 210 treasury share 0 0 0 0 writedown treasury share 0 0 0 0 total 128112 0 33 128079 following included financial 100 share capital sartorius stedim fmt investment sa french company created connection contribution asset transfer 2013 9999 share capital sartorius stedim bioprocess sarl tunisian company investment 01 k 100 share capital sartorius stedim among investment two biotech gmbh company governed german law tunisian entity liquidated year following merger sartorius stedim 2015 amount corresponds share group june 2007 sartorius stedim biotech russian company sartorius stedim ru 100 share capital sartorius stedim aseptics sa french company acquired 2004 5 trade receivables thousand maturity receivables yearend thousand type receivable net amount less 1 year 1 year deposit guarantee 210 0 210 noncurrent asset 210 0 210 advance payment account 0 0 0 trade receivables 0 0 0 personnel 0 0 0 social security 0 0 0 tax duty 249 249 0 group 15125 15125 0 receivables 2 2 0 current asset 15376 15376 0 prepaid expense 50 50 0 total receivables 15636 15426 210 group item receivables group tax duty 249 k item primarily entail subsidiary 15125 k relates current account cash net tax receivable including french tax relief advance provided sartorius stedim biotech gmbh system 222 k vat receivables sartorius stedim fmt sa sartorius stedim bioprocess tunisia 164 consolidated financial statement note annual financial statement 6 maturity liability yearend thousand less 1 type liability net amount 1 year 5 year 5 year loan borrowing credit institution originally less 2 year 0 0 0 0 originally 2 year 0 0 0 0 current bank overdraft accrued interest 0 0 0 0 trade payable 1070 1070 0 0 including bill exchange 0 0 0 0 advance payment account order 0 0 0 0 tax social security payable 57 57 0 0 liability noncurrent asset 75 75 0 0 group associate 69945 69945 0 0 1 1 0 0 total liability 71147 71147 0 0 group item liability group subsidiary 69945 k relates cashpooling liability current account cash advance provided sartorius ag sartorius stedim france sa sartorius stedim fmt sa sartorius stedim aseptics sa accrued expense included account represented 380 k concerned following item type expense dec 31 2015 accrued banking charge 0 supplier invoice received 324 paid vacation including social charge 0 bonus including social charge profit sharing 0 social security payable 57 tax payable 0 employee profit sharing 0 total charge payable 380 7 parent company statement change equity thousand 71 equity december 31 2015 share capital 15367 k annual general shareholder meeting april 7 comprising 15367238 share 1 par value 2015 approved appropriation net profit year 24845 k follows change equity 2015 result following event allocation retained earnings carried forward 4383 k exercise stock option resulting issue 8000 share par value 1 paid legal reserve 496 k total 8 k dividend total 19966 k net dividend per 175 k share premium associated share share 130 paid capital increase consolidated financial statement note annual financial statement 165 equity appropriation appropriation appropriation appropriation profit profit profit profit 2014 2014 2014 2015 change increase decrease total number share 15359238 15359238 8000 15367238 share capital 15359 15359 8 15367 share premium 0 0 175 175 merger premium 16140 16140 16140 legal reserve 1040 496 1536 1536 reserve 590 591 591 balance carried forward 9032 4383 13415 13415 dividend paid 0 19966 19966 19966 0 net profit appropriated 24845 24845 0 0 profit reporting year 0 29312 29312 regulated provision 4088 4088 4088 total 71095 0 71096 29495 19966 80624 72 stock option share subscription option vested exercised end 2014 8000 exercized part policy motivating group senior first semester 2015 executive sartorius stedim biotech sa granted stock option number employee 31 december 2015 stock option program closed 8 risk provision thousand 81 provision provision addition release provision type provision dec 31 2014 2015 2015 dec 31 2015 regulated provision accelerated amortization depreciation 4088 0 0 4088 subtotal 1 4088 0 0 4088 provision liability charge exchange risk 0 0 0 0 cost 0 0 0 0 taxation 0 0 0 0 subtotal 2 0 0 0 0 grand total 4088 0 0 4088 82 market risk exposure current future tax position thousand operating cash flow risk january 1 2008 company chose adopt french tax integration regime within december 31 2015 net amount framework tax group lead company foreign currency current asset liability group sartorius stedim biotech sa member company tax integration group tax relief sartorius stedim aseptics sa sartorius stedim france sa sartorius stedim fmt sa sartorius stedim financière sa 166 consolidated financial statement note annual financial statement member company report income tax 2015 net impact according integration tax regime parent consolidation rule french tax integration corporation benefit tax relief related regime tax relief income 823 k consolidating gain loss amount income tax fiscal 2015 settled member company sartorius stedim biotech sa 2016 tax integration regime 3661 k 9 operating income thousand 91 sale revenue operating segment dec 31 dec 31 operating segment 2015 2014 service 1593 100 1465 100 total 1593 100 1465 100 92 sale revenue geographical region dec 31 dec 31 geographical region 2015 2014 france 1593 100 1465 100 export 0 0 0 eu country 0 0 north american continent 0 0 total 1593 100 1465 100 sale revenue corresponds rent paid entity sartorius stedim fmt sa use premise located aubagne within operational activity 10 breakdown income tax thousand dec 31 2015 dec 31 2014 profit income tax profit profit income tax tax charge tax tax charge profit tax gross taxable income 29979 1476 28503 24377 552 23825 exceptional income expense 14 0 14 0 0 0 french tax integration relief 0 823 823 0 1020 1020 net taxable income 29965 653 29312 24377 468 24845 11 information director remuneration meeting attendance fee paid sartorius stedim biotech sa general management remuneration paid member board company fiscal 2015 director director meeting attendance fee amounted 207 k fee related 2014 part executive board remuneration fiscal year paid 2015 recharged sartorius ag sartorius stedim biotech sa amount 1372 k consolidated financial statement note annual financial statement 167 12 offbalance sheet commitment thousand dec 31 dec 31 type commitment comment 2015 2014 commitment given guarantee bilateral credit line 0 34500 guarantee currency hedging contract 0 20000 commitment renting leasing 0 0 commitment received contractual loan capacity credit institution 0 0 commitment connection lease summarized following table 1 year 1 5 year 5 year leasing k k k total buyback value tangible asset building improvments 291 1164 509 1964 0 total 291 1164 509 1964 payment cumulatives depreciation cumulative leasing historical value year payment year depreciation tangible asset building improvments 2391 271 681 133 133 total 2391 271 681 133 133 building operational 1st january 2015 13 information related party company sartorius stedim biotech sa consoli thousand dated financial statement sartorius ag weender landstrasse 94 108 37075 goettingen affiliate parent company sartorius ag germany company owned sartorius stedim biotech sa sartorius stedim fmt sa sartorius stedim bioprocess sarl sartorius stedim aseptics sa sartorius stedim biotech gmbh following find table main amount related party item dec 31 2015 dec 31 2014 investment 127869 127869 trade receivables 0 440 receivables 15125 994 trade payable 0 381 liability 69661 68510 income investment 34405 28893 financial income 781 0 finance expense 1899 1698 168 consolidated financial statement note annual financial statement following find table subsidiary shareholding reserve share premium loan change sale retained outstand exvat earnings ing deposit share ownership book value advance financial net dividend dec 31 2015 capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 84232 79949 79949 3495 0 392079 45028 31000 sartorius stedim fmt sa 10000 euro 42940 0 42940 42940 30722 0 129737 4667 600 sartorius stedim bioprocess sarl 9999 dinar 5950 2743 38244 234 3603 euro 3132 3132 4139 0 17571 108 1655 sartorius stedim ru 10000 ruble 10 0 72818 1171 0 euro 0 0 0 0 0 1067 17 0 sartorius stedim aseptics sa 448 3277 10000 euro 1848 1848 5906 0 8057 2196 1150 reserve share premium loan change sale retained outstand exvat earnings ing deposit share ownership book value advance financial net dividend dec 31 2014 capital appropriation share held granted pledge year profit received gross net sartorius stedim biotech gmbh 10000 euro 6000 84232 79949 79949 40070 0 312387 36954 24000 sartorius stedim fmt sa 10000 euro 42940 0 42940 42940 1909 0 91527 1219 1362 sartorius stedim bioprocess sarl 9999 dinar 5950 2743 35389 3666 3379 euro 3132 3132 73 0 15709 1627 1500 sartorius stedim ru 10000 ruble 10 0 70710 2514 0 euro 0 0 0 0 0 1391 49 0 sartorius stedim aseptics sa 10000 euro 448 3277 1848 1848 5002 0 7678 2295 2031 consolidated financial statement note statutory auditor report financial statement 169 statutory auditor report financial statement year ended december 31 2015 note 313 43 financial statement set rule accounting method relative free translation english report issued valuation investment treasury share within french provided solely convenience scope assessment rule englishspeaking user report read accounting principle company conjunction construed accordance verified appropriateness accounting french law professional auditing standard method specified information applicable france provided note financial statement made sure correct application shareholder assessment made part audit compliance assignment entrusted u financial statement taken whole shareholder meeting hereby report therefore contributed opinion formed year ended december 31 2015 expressed first part report audit accompanying financial statement sartorius stedim biotech sa iii specific verification information justification assessment specific verification information required also performed accordance law professional standard applicable france specific verification required french law annual financial statement approved board director role express matter report fair presentation opinion financial statement based audit consistency financial statement information given management report opinion financial statement board director document addressed shareholder respect financial position conducted audit accordance financial statement professional standard applicable france standard require plan perform audit concerning information given accordance obtain reasonable assurance whether requirement article l 2251021 french financial statement free material misstatement commercial code code de commerce relating audit involves performing procedure using remuneration benefit received director sampling technique method selection commitment made favor obtain audit evidence amount verified consistency financial disclosure financial statement audit also statement underlying information used includes evaluating appropriateness accounting prepare financial statement policy used reasonableness accounting applicable information obtained estimate made well overall presentation company company controlling company financial statement believe audit controlled based work attest evidence obtained sufficient accuracy fair presentation information appropriate provide basis audit opinion accordance french law verified opinion financial statement give true required information concerning identity fair view asset liability financial shareholder holder voting right position company december 31 2015 properly disclosed management report result operation year ended accordance french accounting principle marseille february 19 2016 ii justification assessment statutory auditor accordance requirement article l 823 french original signed 9 french commercial code code de commerce kpmg audit deloitte associés relating justification assessment division kpmg sa bring attention following matter john evans christophe perrau 170 consolidated financial statement note statutory auditor report financial statement supplementary information 172 supplementary information information legal nature information legal nature general information issuer corporate purpose france abroad company purpose corporate name purchase develop administrate manage corporate name company portfolio equity security security voting right sartorius stedim biotech social right company regardless activity mean including way legal deed document issued com setting new company contribution kind pany always preceded followed word type social right subscription right société anonyme abbreviation sa merger purchase social right statement share capital heading 1 article 1 incorporation company company bylaw manage conduct coordinate activity subsidiary affiliate applicable registered office provide said company service administrative financial accounting legal registered office aubagne 13400 france nature opinion advise order zi le paluds avenue de jouques study research necessary phone number 33 04 42 84 56 00 development growth office may transferred another location generally financial commercial département french county state industrial personal real property operation adjacent county state simple decision linked directly indirectly abovementioned board director subject ratification next corporate purpose complementary annual general shareholder meeting anywhere related similar purpose may promote else france decision taken extraordinary development accomplishment thereof general shareholder meeting trade commercial register ape code board director decides transfer registered office authorized revise bylaw company registered registre du result heading 1 article 2 company commerce et de sociétés de marseille bylaw number rcs b 314 093 352 economic activity code ape 6420z holding company activity legal form applicable law inspection legal document public limited liability company joint stock company registered office company société anonyme subject french legislation particularly french commercial code reference document may viewed registered office company website website amf validity date incorporation duration present reference document bylaw statutory auditor report financial company incorporated september 28 1978 statement last three fiscal year although société anonyme company duration report mail document historical 99 year effective upon registration french financial information company trade commercial register registre du commerce subsidiary last three fiscal year evaluation et de sociétés unless subject dissolution declaration made expert extension provided present company bylaw document statutory statutory heading 1 article 3 document found registered office supplementary information information legal nature 173 financial year shareholder meeting financial year also referred fiscal year convocation cover period twelve month beginning january 1 ending december 31 year annual ordinary general shareholder meeting convened take decision result revision bylaw extraordinary specific clause company bylaw general shareholder meeting called decide authorize direct indirect revision bylaw special meeting bring together holder form share specific class share consider revision right class share decision made share may nominative bearer form according general meeting binding shareholder shareholder choice share entitled even absent dissenting legally recorded account accordance incapable incapacitated heading 3 article 13 french law bylaw general meeting convened board director default independent auditor person thus empowered general appropriation profit meeting held registered office place stated notice convocation heading 3 income statement summarizes income excerpt article 14 bylaw form expense reporting year discloses timescale notice convocation governed difference deduction amortization depre french law ciation provision profit said reporting year least 5 must deducted annual agenda profit reduced appropriate prior loss heading 3 point 2 excerpt article 14 bylaw set legal reserve deduction cease obligatory legal reserve amount one notice letter call shall indicate tenth share capital obligatory deduction indication required law particularly resume whatever reason legal reserve agenda company electronic address written fall one tenth distributable profit question shareholder may sent eventually comprises profit reporting year less prior mention obligation collect opinion loss amount transferred reserve pursuant prior approval mass security share french law company bylaw increased holder giving access share capital profit brought forward profit distributed among shareholder proportion number meeting may deliberate matter share one hold annual general placed agenda may however remove one shareholder meeting may decide distribute director time amount taken reserve available expressly indicating reserve one shareholder representing percentage transfer made however dividend disbursed share capital required law may way priority annual profit condition time limit set forth law require reporting year except reduction capital inclusion agenda draft resolution distribution may made shareholder equity fall would consequently fall accordance article r 225 71 r 225 74 amount capital together reserve commercial code request made french law company bylaw permit shareholder register draft resolution distribute revaluation surplus distributable agenda written question sent may corporated full part headquarters registered letter recorded company capital however transferring delivery beginning publication meeting amount reserve pursuant french law announcement 25 day general annual general shareholder meeting may transfer meeting delay 20 day beginning amount considers necessary available publication meeting announcement reserve ordinary extraordinary reserve carry one published 45 day general forward meeting date reception request company taken account 174 supplementary information information legal nature request new item agenda must legal representative shareholder motivated request register draft resolution legally incapable incapacitated individual provided text draft resolution may representing corporate shareholder take part short explanation reason request meeting whether shareholder subject justification possession representation required share capital accordance regulatory rule shareholder may also postal voting using registration form sent company according moreover accordance article l 2323 67 law regulation acceptable paragraph 2 labor code request draft registration must received company three resolution made work council added day date meeting agenda sent next 10 day following publication meeting announcement case remote voting using electronic vote heading 3 point 1 excerpt article 14 bylaw proxy vote given electronic signature vote made according condition current meeting unable make valid regulation decision due lack required quorum second meeting appropriate second legal document relative legal information meeting adjourned called least ten day shareholder made available advance form first meeting registered office company admission meeting power provision applicable administration heading 3 point 3 excerpt article 14 bylaw management company every shareholder right attend general board director meeting participate discussion heading 3 point 3 excerpt article 6 9 bylaw person proxy regardless number share held simple proof identity ownership 1 subject legal exemption company directed share right participate general meeting board director composed minimum subject condition share must three member maximum eighteen recorded name shareholder shareholder appointed broker either composition board director made nominative share account held company balance number men woman bearer share account held authorized broker zero hour paris time second 2 duration company existence working day prior meeting recording director shall appointed renewed office registration share bearer share account ordinary general meeting however case held authorized broker must confirmed merger director may appointed extra share certificate provided broker share ordinary general meeting deciding transaction certificate must attached postal voting form proxy form application admission 3 director must entire term office pas issued name shareholder least one share behalf shareholder represented appointed broker certificate must also supplied 4 director term office three year shareholder wish attend general meeting person received director duty shall cease end ordinary admission pas zero hour paris time general meeting deciding account second working day prior meeting financial year elapsed held year term office director concerned expires shareholder may represented another shareholder spouse partner signed civil partnership furthermore may represented moral physical person choice accordance article l 225 106 106 3 commercial code aim representative must present valid proof proxy supplementary information information legal nature 175 director may renewed office may 8 director individual cannot concomitantly removed office time ordinary hold three seat board director general meeting supervisory board sociétés anonymes registered office metropolitan france subject 5 person may appointed director exception provided law reached age 75 appointment would result one third member board 9 company employee may appointed director exceeding age proportion director unless employment agreement corresponds exceeded oldest director shall automatically effective employment shall lose benefit deemed resigned end ordinary employment agreement number director general meeting approving account bound company employment agreement financial year exceeded may exceed one third director office 6 director may individual legal entity organization management board director legal entity required upon director appointment appoint permanent representative subject condition 1 board director elect chairman obligation incurs liability among member individual though personally director without prejudice determines remuneration set duration several liability legal entity represented chairman term office may exceed office director legal entity director terminates mandate given permanent representative shall 2 person may appointed chairman board promptly notify company registered letter director age 75 chairman decision well identity new office exceeds age shall deemed permanent representative applies automatically resigned event death resignation permanent representative 3 chairman represents board director organizes directs work report 7 one director seat become vacant general meeting ensures proper operation two general meeting due death company decisionmaking body ensures resignation board director may proceed particular director make appointment interim basis fill position fulfill duty seat board appointment must made within three month vacancy number 4 case absence impediment affecting director fallen minimum chairman board director appoints acting article association without falling chairman meeting statutory minimum 5 board director appoints secretary interim appointment made manner may chosen either among director board subject ratification next ordinary outside secretary shall replaced simple general meeting failing ratification decision decision board taken act accomplished shall nonetheless remain valid meeting decision board number director fall 1 board director meet upon call statutory minimum director remaining office chairman often required interest required immediately call ordinary meeting company however director representing least one fill vacant seat board third member board director may precisely indicating meeting agenda call director appointed replacement another shall board met within last two month remain office remaining term office predecessor ceo chairing board director may request chairman call board meeting specified agenda 176 supplementary information information legal nature 2 meeting shall take place registered office dealing third party company location indicated notice call bound even act board director call meeting indicating agenda outside corporate purpose unless prove sent least 7 day beforehand letter telegram telex third party knew act ultra vires fax call may verbal meeting may could reasonably unaware thereof held immediately director agreement view circumstance specified mere publication article association 3 board director validly deliberate suffice establish proof thereof least one half director required present represented 2 board director shall carry control verification deems appropriate board decision taken majority member present represented director shall receive information necessary performance duty may obtain acting chairman casting vote document considers useful general management 4 attendance sheet shall held signed director participating board meeting 3 board director may give delegation authority representative choice within 5 internal regulation established board limit authority law director may provide director participating article association board meeting videoconference accordance applicable regulation deemed present board may decide creation review purpose calculating quorum majority committee charge studying issue board chairman submits provision shall apply adoption following decision general management heading 3 article 10 bylaw appointment remuneration removal chairman ceo executive vice president mode operation closing annual account consolidated account accordance article l 225 51 1 preparation management report report commercial code company general management group management ensured responsibility either chairman board director 6 board director deliberation recorded individual appointed board minute held accordance applicable law director title ceo minute signed acting chairman one two director choice two mode operation general management made board copy excerpt minute board director board decision concerning choice director deliberation shall validly certified mode operation general management taken chairman ceo majority vote director present represented shareholder third party power board director informed choice made board director condition set forth applicable 1 board director determines company regulation business guideline ensures implemented subject power expressly granted board director may modify option chosen law shareholder meeting within limit time corporate object deal matter relating proper running company change mode operation general deliberation governs affair company management shall entail modification article association supplementary information information legal nature 177 depending mode exercise chosen regard third party executive vice president board director chairman ceo shall ensure executive vice president power responsibility general management ceo company upon cessation duty case ceo appointed board director impediment affecting ceo executive vice set duration term office determines president shall retain unless otherwise decided remuneration applicable restriction board director office authority power appointment new ceo performance duty ceo must ceo may removed office time age 75 age limit exceeded board director removal ceo course term office ceo shall also chairman may give rise damage decided deemed automatically resigned new without valid cause ceo shall appointed condition exercise voting right ceo may removed office time majority quorum board director removal ceo heading 3 article 15 bylaw also chairman may give rise damage decided without valid cause annual extraordinary general meeting quorum calculated basis share power ceo comprising share capital special meeting basis share class concerned ceo vested broadest power act net share entitled voting right virtue circumstance name company law ceo shall exercise power within limit corporate object subject power expressly double voting right conferred holder granted law shareholder meeting registered share fully paid board director registered name holder least four year ceo represents company dealing third party company bound even act event postal voting form received ceo outside corporate object company prior meeting unless prove third party knew considered calculating quorum act ultra vires could reasonably condition timeframe set decree unaware thereof view circumstance specified mere publication article right vote conferred share proportional association suffice establish proof thereof capital represent equal par value every share capital income right carry right executive vice president one vote upon motion ceo whether position event share pledged voting filled chairman board director right exercised holder security another person board director may name one issuing company may validly vote share individual responsibility assisting subscribed acquired taken pledge ceo title executive vice president share taken account calculate quorum maximum number executive vice president may exceed five voting take place vote cast show hand sitting standing roll agreement ceo board director call decided officer meeting shall determine scope extent power granted executive vice president information voting right set remuneration limit bylaw voting right event conversion bearer form converted share immediately forfeit double voting right 178 supplementary information information legal nature event capital increase incorporation term payment dividend cash reserve profit share premium double voting set general meeting default board right applies new share issued allocated free director cash dividend must paid within charge shareholder basis existing share maximum nine month end already carry right heading 2 article 3 reporting year unless timeframe extended company bylaw revision bylaw legal authorization however profit may unanimously passed general shareholder distributed interim dividend prior meeting extraordinary session august 24 approval annual financial statement 1994 may cancelled general shareholder balance sheet prepared end meeting convened extraordinary session financial year certified independent ratification special meeting auditor discloses company realized beneficiary shareholder profit since close previous financial year recognition necessary amortization december 31 2015 11627386 depreciation provision well deduction share double voting right total relevant prior loss amount 15367238 share thus total voting right transferred reserve required french law 26994624 company bylaw interim dividend may exceed profit thus defined reimbursement annual general shareholder meeting held dividend may required shareholder unless least year within six month year end distribution made violation legal consider financial statement year subject provision company determines extension timeframe legal decision beneficiary aware illegality annual general shareholder meeting may distribution time occurred could ignore validly deliberate upon first convocation nature dividend occurs shareholder present represented voting post share reimbursement timebarred three hold least one quarter share right year payment dividend dividend vote quorum required upon second collected within five year payment convocation meeting decides basis timebarred majority vote held shareholder present represented including shareholder voting post excerpt bylaw heading 3 article 16 liquidity contract liquidity contract concluded crossing legal threshold sartorius stedim biotech sa stockbroker gilbert dupont following asset appeared shareholder whose shareholding cross legal liquidity account december 31 2015 threshold defined french law either upwards downwards must declare said crossing notification number share 658 autorité de marchés financier pursuant law force bylaw company liquidity account cash balance 23253720 provide additional threshold declaration information following asset appeared liquidity account date notification identification shareholder contract implementation issued within legal regulatory framework number share 0 company authorized seek identity bearer shareholder liquidity account cash balance 421860 payment dividend annual general shareholder meeting power give every shareholder part dividend payable option receiving dividend share provided french law cash supplementary information information asset financial position result group 179 information asset financial position result group major contract several service agreement entered apart abovementioned service agreement entity division sartorius group contract material obligation sartorius stedim biotech group order enable commitment concluded outside entity division benefit certain ordinary course company business general administrative service term member sartorius stedim biotech group party among service agreement service agree strategy sale marketing organization ment highest volume importance within sartorius stedim biotech group towards place sartorius stedim biotech gmbh customer create valuable longterm relationship sartorius corporate administration gmbh 100 therefore example key account management subsidiary sartorius ag sartorius corporate endeavor conclude longterm framework contract administration gmbh provides general administrative customer total solution provider sartorius service sartorius stedim biotech stedim biotech strives use contract cover entity sartorius group service include entire product portfolio sartorius stedim among others accounting treasury management biotech fit validated process payroll accounting human resource system customer legal service sartorius corporate administration gmbh invoice service basis internal external cost incurred plus margin 3 service invoiced sartorius corporate administration gmbh sartorius stedim biotech gmbh 2015 totaled million 308 million 239 2014 180 supplementary information information asset financial position result group registered trademark trademark application international registration name eu germany france country designated usa australia brazil mexico uk canada 16112007 962279 sartorius 13082007 16112017 17082007 14012008 09112007 stedim 006228019 au ch kr ru sg 3709002 13 trademark 1371410 biotech 13082017 tr vn 10112019 application reg progress 26061985 494574 23102014 04101968 26062025 22071988 16122014 16071988 013398722 873661 bx ch de e 1572999 4 trademark 1246230 biostat 23102024 31102018 fr pt 26122019 application 16072016 12112001 07041983 10122001 28112001 002458461 1065357 2677224 609610 hydrosart 12112021 07042023 21012023 06052019 04101999 15111999 001330885 2450203 maxicaps 04102019 08052021 15022005 16022005 004289724 3195052 midicaps 15022025 02012017 18011979 1107904 09082019 __________ 09081978 26101988 07021979 18011979 980370 1495753 1144895 1107903 minisart 09082018 26102018 30122020 18012020 13061979 17101989 05121979 18112014 20121986 987883 1555685 1200237 908615248 1125952 sartocheck 13062019 17102019 06072022 reg progress 20122020 06061979 17101989 15061982 20121986 988000 1555684 1197792 1125951 sartocon 06062019 17102019 15062022 20122020 02112004 28072004 10112004 004103701 30443764 3178067 virosart 02112024 31072024 28112016 06031985 494396 06032025 bx ch de dz 03061983 eg e fr hu kp 08082007 25101984 1057870 li mc pt ro r 3689721 1228900 sartoflow 30062023 ru sd vn 09292019 25102025 10012000 15022000 18112014 001454461 2429825 2 trademark sartopore 10012020 20022021 application 24011995 630378 24012025 de bx ch ___________________ 31082005 19041993 27022006 879252 31081993 31011995 03092003 31011995 004614038 93465632 27022016 2041550 651778 810249 2009384 flexboy 31082025 19042023 jp 04032017 31012025 03092023 31012025 20021998 02091997 27021998 03092003 000753202 97693975 2414947 810250 flexel 20022018 02092017 26122020 03092023 01071998 000865865 palletank 01072018 31082005 004614046 raft 31082025 15101999 001344266 evam 15102019 05061989 1535354 nutrikit 05062019 05061989 1535352 nutripoche 05062019 22022001 01021995 758706 95556118 22022021 biosafe 01022025 de dk gb ch 16102009 07052009 1028463 06112009 26102009 008285173 16102019 4 trademark 793270 flexact 07052019 au cn jp kr u application 18112026 22102014 22042014 1226740 21102014 012807996 22102024 9084706060 flexsafe 22042024 cn jp kr mx sg tr u reg progress apart trademark mentioned sartorius stedim biotech group owner applicant 338 different trademark various country date indicated daymonthyear supplementary information information asset financial position result group 181 registered trademark trademark application name japan denmark finland ireland malaysia norway sweden china argentina india taiwan 14012008 18012008 sartorius 08112007 11 trademark 11 trademark stedim 5170560 28112007 2 trademark 19112007 2 trademark biotech 03102018 12 trademark application 13 trademark application 22021988 2021770 22022018 __________ 27081986 28061985 05011988 01071985 11071985 27051987 31031988 26042012 17122014 04052012 1880889 233586 100350 116688 8502982 128877 209760 10830519 4 trademark 2326343 biostat 27082016 29082016 05012018 30062016 11072022 27052017 31032018 14032025 application 04052022 21112001 4663672 hydrosart 18042023 15101999 4535058 maxicaps 11012022 25022005 4906540 midicaps 04112025 09021979 1583197 minisart 26042023 29091983 14112014 1618759 3367508 sartocheck 29092023 reg progress sartocon 28012005 24112004 5040228 4379959 virosart 13042017 21062018 sartoflow 02022000 12112014 4495393 2 trademark sartopore 03082021 application 19011995 323347 flexboy 16052017 02031998 4470133 flexel 27042021 28022006 5005301 palletank 24112016 raft evam nutrikit nutripoche biosafe 12112014 4 trademark 30102009 flexact application 4 trademark 21102014 3361996 flexsafe reg progress apart trademark mentioned sartorius stedim biotech group owner applicant 338 different trademark various country date indicated daymonthyear 182 supplementary information special report statutory auditor related party agreement commitment special report statutory auditor related party agreement commitment free translation english report issued agreement commitment submitted french provided solely convenience approval general meeting shareholder englishspeaking reader report read conjunction construed accordance hereby inform advised french law professional auditing standard agreement commitment authorized applicable france course year submitted general meeting shareholder approval accordance general meeting shareholder approve financial article l 22538 french commercial code statement year ended december 31 2015 code de commerce shareholder agreement commitment already approved capacity statutory auditor company general meeting shareholder hereby report certain related party agreement commitment hereby inform advised agreement commitment already approved required inform basis general meeting shareholder whose information provided u term implementation continued year condition agreement commitment indicated u may identified performance engagement required comment whether beneficial marseille february 19 2016 appropriate ascertain existence agreement commitment responsibility statutory auditor accordance article r 22531 french commercial code code de commerce evaluate french original signed benefit resulting agreement commitment prior approval kpmg audit deloitte associés kpmg sa departement addition required applicable inform accordance article r 22531 john evans christophe perrau french commercial code code de commerce partner partner concerning implementation year agreement commitment already approved general meeting shareholder performed procedure considered necessary comply professional guidance issued french national auditing body compagnie nationale de commissaires aux comptes relating type engagement supplementary information resolution submitted annual combined shareholder meeting april 5 2016 183 resolution submitted annual combined shareholder meeting april 5 2016 resolution submitted annual total value liability assumed eight hundred ordinary shareholder meeting nine thousand seven hundred four euro 809704 first resolution net asset contributed four million four hundred approval company absorption merger fortynine thousand eight hundred fifty vl finance sa increase share capital euro 4449850 company remuneration said merger b remuneration contribution made shareholder meeting fulfilled respect merger according exchange quorum majority requirement pertaining ratio three point fifty five 355 share extraordinary shareholder meeting company one 1 share vl finance sa considered ie obtain whole number company share without fractional share seventyone 71 draft agreement merger including share company twenty 20shares vl schedule executed 18 february 2016 finance sa company vl finance sa whereby vl finance sa contribute asset c completion mergerabsorption liability company respect merger transaction end shareholder meeting retroactively 1 january 2016 accounting subject satisfaction condition tax purpose subject satisfaction precedent set article 4 draft merger condition precedent provided article 4 agreement draft merger agreement setting retroactive effective date board director report shareholder accounting tax purpose 1 january 2016 meeting result transaction carried vl finance sa 1 january 2016 document e established connection completion date merger deemed merger registered french financial completed appropriate benefit cost market authority autorité de marchés financier company considered completed company since 1 january 2016 report merger auditor term 2 result foregoing shareholder merger value contribution meeting 1 approves provision contained draft resolve upon final completion merger merger agreement schedule consequently capital company increased subject satisfaction condition precedent amount one million six hundred thirty provided article 4 draft merger eight thousand two hundred twenty two agreement merger absorption vl finance euro 1638222 fifteen million three sa company notably hundred sixtyseven thousand two hundred thirtyeight euro 15367238 seventeen million appraisal contribution five thousand four hundred sixty euro specified contribution value used shall 17005460 creation one million accounting value amount basis six hundred thirty eight thousand two vl finance sas financial statement 31 hundred twentytwo 1638222 new share december 2015 par value 1 euro per share fully paid providing beneficial ownership date value asset contributed five million two final completion merger hundred fiftynine thousand five hundred fifty specified vl finance sa share whose four euro 5259554 ownership stripped right stripped shall transferred share company issued 184 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 consideration merger via principle responsible selling buying equitable subrogation consequently new necessary number share failing share entitle holder distribution renounce right attached fractional share dividend approved subsequent issuance subject statutory regulatory provision fully fungible existing second resolution share company request euronext paris admit new share issued trading reduction share capital unrelated loss cancelling treasury share held following b note company article completion merger association provide granting double voting right benefit shareholder holding shareholder meeting fulfilled share registered form least four 4 year quorum majority requirement pertaining company share allocated extraordinary shareholder meeting sole shareholder vl finance sa framework considered board director report merger granted double voting right statutory auditor special report reduction accordance provision article l 225 share capital unrelated loss 124 french commercial code provided hold vl finance sas share least four 4 1 note asset contributed company year connection merger referred first resolution include one million six hundred forty c approves condition precedent two thousand ninetyfive 1642095 share final completion mergerabsorption company stock par value one 1 euro subject resolution amount cannot keep merger premium comprising difference value net asset contributed ie four 2 resolve subject final completion million four hundred forty nine thousand merger referred first resolution eight hundred fifty euro 4 449 850 absence objection creditor connection value capital increase carried capital reduction subject consideration contribution ie one million six resolution definitive resolution hundred thirty eight thousand two hundred objection reduce share capital company twentytwo euro 1 638 222 nominal amount one million six hundred credited merger premium account fortytwo thousand ninetyfive euro 1642095 amount two million eight hundred eleven decreasing seventeen million five thousand thousand six hundred twenty eight euro four hundred sixty euro 17005460 2811628 existing new fifteen million three hundred sixty three thousand shareholder entitled three hundred sixty five euro 15363365 resolve necessary take merger 3 resolve basis share capital premium account amount needed added company date shareholder meeting reserve including legal reserve share capital decrease shall carried regulatorytype provision resulting notably cancelling one million six hundred forty application favorable tax regime two thousand ninetyfive 1642095 share merger subject company contributed vl finance sa company connection aforementioned merger e authorizes board director charge merger premium account part expense 4 resolve difference right tax fee resulting merger contribution value cancelled share well resulting increase aggregate nominal value ie two million eight company capital final completion hundred forty three thousand three hundred merger proceed premium euro 2843300 setoff merger deduction order comply requirement premium account two million eight hundred tax regulation eleven thousand six hundred twenty eight euro 2811628 balance amounting f resolve event fractional right thirty one thousand six hundred seventytwo vl finance sa sole shareholder owning euro 31672 shall set carry sufficient number share exercise right forward account company supplementary information resolution submitted annual combined shareholder meeting april 5 2016 185 reduction share capital subject sa approved decision day merger resolution carried subject final referred first resolution hereto completion merger vl finance sa company referred first resolution recalled condition precedent set absence objection creditor company article 4 merger agreement following twenty 20 day period referred article l 225 205 french commercial code registration french financial market event objection expressed authority autorité de marchés financier following definitive resolution objection document referred article 212 34 general regulation amf following final completion share capital decrease share capital company shall approval company sartorius ag sole equal fifteen million three hundred sixty three shareholder vl finance sa merger thousand three hundred sixty five euro early dissolution without liquidation vl 15363365 divided fifteen million three hundred finance sa sixty three thousand three hundred sixty five 15363365 share one euro 1 par value approval company combined shareholder meeting merger well accordingly shareholder meeting give capital increase resulting merger power board director purpose ii subsequent company share capital decrease 1 acknowledging absence objection note result preceding resolution creditor definitive resolution reviewed aforementioned document objection event objection justifying fulfillment condition precedent expressed taking measure necessary resolve set article 4 merger agreement claim accordingly noting final company vl finance sa completion capital reduction resolved condition precedent fulfilled term present resolution corresponding amendment article association consequently acknowledges final completion merger absorption vl finance sa 2 signing document necessary carry company term draft merger capital reduction agreement resulting increase company share capital nominal amount one 3 ensuring completion legal formality million six hundred thirty eight thousand two including registration transaction hundred twentytwo euro 1638222 tax authority increasing latter fifteen million three hundred sixtyseven thousand two hundred thirtyeight euro 15367238 seventeen million third resolution five thousand four hundred sixty euro 17005460 creation one million six acknowledgement completion merger hundred thirty eight thousand two hundred twentytwo 1638222 new share par shareholder meeting fulfilled value one euro 1 per share fully paidup quorum majority requirement pertaining decided first resolution understood extraordinary shareholder meeting intended following cancellation considered board director report draft treasury share held company share agreement mergerabsorption vl finance capital shall decreased aggregate par value sa company dated 18 february 2016 one million six hundred forty two thousand statutory auditor special report reduction ninety five euro 1642095 accordance share capital unrelated loss subsequent second resolution subject approval merger minute decision chairman shareholder meeting vl finance sa dated 18 february 2016 document e established connection merger registered french financial market authority autorité de marchés financier noted sole shareholder vl finance 186 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 fourth resolution nominative registration new share name relevant shareholder split 6 par value company share subject final completion merger referred shareholder meeting resolve expense first resolution relating split par value share shall borne company operation thus shareholder meeting fulfilled quorum completed without charge formality majority requirement pertaining shareholder extraordinary shareholder meeting considered board director report resolve shareholder meeting grant power subject final completion merger board director may grant share capital reduction referred first authorized person extent allowed law third resolution split six 6 par value company share order reduce par carry exchange new share former value company share one euro share 1 amount equal one sixth euro 16 rounded sixteen cent decimal mark six thousand make adjustment required share split six hundred sixty seven euro cent 0166667 including adjustment number share multiply six 6 number share forming may obtained beneficiary stock option share capital following completion granted prior split six 6 par value mentioned merger share capital reduction together exercise price option shall therefore increase fifteen million three hundred sixty three thousand three hundred amend article association company sixtyfive 15363365 share ninetytwo million accordingly one hundred eight thousand one hundred ninety 92180190 share amount share capital carryout act formality declaration result company thus remaining unchanged decision consequently shareholder meeting resolve split share capital company six 6 fifth resolution result exchange six 6 new share par value rounded sixteen cent decimal mark six increase share capital company way thousand six hundred sixty seven euro cent incorporation reserve order increase 0166667 one 1 former share par individual par value share company value one euro 1 020 shareholder meeting resolve split shareholder meeting fulfilled par value share enter effect quorum majority requirement applying immediately following final completion ordinary shareholder meeting read share capital reduction referred second report board director report resolution proposed shareholder meeting statutory auditor establishing existence available reserve amount twenty eight shareholder meeting acknowledges split million nine hundred four thousand eight par value corresponding allocation hundred eighty six point thirty eight euro 28 new share shareholder shall affect 904 88638 subject approval first right granted share provided company fourth resolution presented shareholder ÿ article association new share benefiting meeting compliance provision right granted former share article l 225 109 l 225 129 6 l 225 130 substitute particular split french commercial code share par value shall affect double voting right provided article 3 title 2 double acknowledged split six 6 voting right company article association par value company share result shall applied new share issued fourth resolution presented shareholder division former share specified meeting result par value share period four 4 year referred article number indefinite number digit determined relation date decimal mark rounded sixteen cent decimal supplementary information resolution submitted annual combined shareholder meeting april 5 2016 187 mark six thousand six hundred sixty seven euro share capital set eighteen million four cent 0166667 hundred forty six thousand thirty eight euro 18436038 decides order set par value share number two digit decimal mark divided ninetytwo million one hundred subject implementation transaction eighty thousand one hundred ninety listed herein first fourth 92180190 fully subscribed paidup share resolution presented shareholder meeting par value twenty euro cent 020 meaning merger correlative share capital increase share capital reduction split par value share increase share seventh resolution capital company amount three million seventytwo thousand six hundred seventy delegation authority granted board three euro 3072673 way incorporation director issue share andor security giving access reserve available company account share capital company andor security giving right allotment debt instrument decides share capital increase contemplated preferential subscription right resolution completed way increase shareholder individual par value share company set twenty euro cent 020per shareholder meeting fulfilled share quorum majority requirement pertaining extraordinary shareholder meeting decides share capital increase contemplated considered board director report resolution shall completed immediately statutory auditor special report implementation split six 6 par acknowledged share capital fully value share company referred paidup accordance provision fourth resolution proposed shareholder article l 225 129 l 225 129 6 l 225 132 l meeting 225 134 l 228 91 l 228 93 french commercial code result share capital increase share capital set amount eighteen million 1 delegate authority board director four hundred forty six thousand thirty eight right subdelegate accordance euro 18436038 divided ninetytwo million applicable law regulation proceed one one hundred eighty thousand one hundred several time france abroad proportion ninety 92180190 share twenty euro time considers appropriate euro cent 020 individual par value currency monetary unit established reference basket currency preferential subscription right shareholder maintained sixth resolution issuance share preference share andor security kind whatsoever amendment article 5 title 1 share capital security giving right issuance company article association accordingly preference share giving access share capital company new existing share andor ii shareholder meeting fulfilled issuance security giving right allotment quorum majority requirement pertaining debt instrument valuable consideration free extraordinary shareholder meeting resolve subject consideration governed article l 228 91 et seq acknowledgement board director french commercial code specified completion reduction capital referred share security referred ii second resolution hereinabove split may subscribed either cash way par value share share capital compensation receivables certain due increase respectively referred fourth fifth payable held upon company resolution hereinabove amend article 5 title 1 share capital company article 2 delegate authority board director association follows right subdelegate accordance applicable law regulation proceed one article 5 share capital several time france abroad proportion time considers appropriate euro 188 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 currency monetary unit established authority irreducible basis proportion reference basket currency preferential number share owned subscription right shareholder maintained issuance security giving access share note board director may grant capital company company hold shareholder additional preferential right directly indirectly half share introducing reducible subscription right exercisable capital andor ii issuance security giving proportion shareholder existing preferential access share capital company right within limit request directly indirectly hold half company share capital subject authorization note delegation authority automatically competent body company referred entail benefit holder security ii may issued pursuant delegation authority express waiver shareholder 3 set following limit amount company preferential subscription right issuance may carried pursuant respect share security may give present delegation authority access immediately future nominal amount share capital increase note pursuant article l 225 134 share capital increase may carried french commercial code irreducible immediately future pursuant applicable reducible subscription absorb delegation authority shall exceed maximum entirety issuance share amount two million four hundred thousand euro security giving access share capital 2400 00000 equivalent value company board director may use amount date issuance decision condition provided law order including nominal value share shall determine option listed issued applicable pursuant adjustment made order protect right holder security giving access company share limit capital increase amount capital accordance applicable law subscription provided said amount equal regulation well contractual provision least three quarter amount issuance specified limit nominal amount decided upon capital increase without preferential subscription right shareholder set freely allocate unsubscribed eighth ninth tenth eleventh twelfth thirteenth share security giving access share fourteenth resolution submitted capital company shareholder meeting shall deducted overall limit offer part unsubscribed share security giving access share capital b nominal value debt instrument company public french market abroad may issued pursuant delegation authority shall exceed maximum amount resolve issuance warrant giving two million euro 2000 00000 equivalent entitlement subscribe company share value amount date issuance may also made way free allocation decision specified amount owner existing share specified include abovepar reimbursement premium board director may decide fractional provided ii limit allotment right neither negotiable issuance debt instrument set eighth ninth transferable corresponding security tenth eleventh twelfth thirteenth fourteenth sold resolution submitted shareholder meeting shall deducted overall limit acknowledges board director shall report use made delegation 4 shareholder meeting authority next ordinary shareholder meeting accordance applicable law resolve company shareholder regulation preferential right subscribe issuance issuance share andor security board director may decide pursuant delegation supplementary information resolution submitted annual combined shareholder meeting april 5 2016 189 5 shareholder meeting grant board share well term condition director right subdelegate accordance completion share capital increase applicable law regulation power implement delegation authority set term company particular necessary time fixed period right purchase exchange stock exchange decide share capital increase determine offmarket security giving access share nature share andor security issued capital company issued issued immediately future purpose decide amount share capital increase canceling security taking account issue price share andor security applicable legal provision issued applicable amount issue premium determine condition accordance applicable law allotment right holder determine date term condition security giving access share may share capital increase characteristic temporarily suspended share andor security issued addition case bond debt instrument discretion charge cost capital determine whether subordinated increase premium arising thereon level subordination accordance deduct premium sum necessary provision article l 228 97 french increase legal reserve commercial code set interest rate interest rate may fixed variable zerocoupon determine make adjustment take account indexed specify circumstance compulsory impact transaction involving share optional suspension cancellation interest capital company particular change payment stipulate term fixed perpetual nominal value share increase share capital possibility reduction increase incorporation reserve free allocation nominal value set term issuance share stock split reverse stock split distribution including granting guarantee security dividend reserve premium interest amortization including asset redemption capital possibility redemption delivery company transaction affecting shareholder equity asset necessary security may share capital set term enabling accompanied warrant entitling holder necessary right holder security giving allotment acquisition subscription bond access share capital company debt instrument defined market preserved authority example due redemption remuneration term right duly record completion capital increase indexation option right amend carried pursuant delegation authority term relevant share andor security make necessary amendment article term compliance applicable association company formality generally enter agreement particular determine mean payment share ensure completion proposed issue take andor security giving access may measure accomplish formality required give access share capital company issuance listing financial administration issued immediately future share andor security issued delegation authority exercise right attached set necessary term exercise thereto right right conversion exchange redemption case may including delivery delegation authority granted period company asset share andor security twentysix 26 month date already issued company attached shareholder meeting render ineffective share andor security giving access may date within limit case may give access share capital company unused portion previous delegation issued immediately future authority purpose particular period may retrospective dividend payable new 190 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 eighth resolution france abroad proportion time considers appropriate euro currency delegation authority granted board monetary unit established reference basket director issue share andor security giving currency issuance share andor capable giving access share capital security giving capable giving access company andor security giving right share capital company following issuance allotment debt instrument without preferential company company hold directly subscription right shareholder indirectly half share capital public offering company directly indirectly hold half company share capital security shareholder meeting fulfilled giving capable giving access share capital quorum majority requirement pertaining company delegation authority extraordinary shareholder meeting automatically entail express waiver considered board director report shareholder preferential subscription right statutory auditor special report respect share andor security giving acknowledged share capital fully capable giving access share capital paidup accordance provision company security may give access article l 225 129 trough l 225 129 6 l 225 134 l 225 136 l 228 91 l 228 93 3 delegate authority board director french commercial code right subdelegate accordance applicable law regulation proceed 1 delegate authority board director public offering one several time right subdelegate accordance france abroad proportion time applicable law regulation proceed considers appropriate euro currency public offering one several time monetary unit established reference basket france abroad proportion time currency issuance security giving considers appropriate euro currency access share capital company monetary unit established reference basket company hold directly indirectly half currency issuance share share capital andor ii issuance security preference share andor security kind giving access share capital company whatsoever security giving right directly indirectly hold half issuance preference share giving access company share capital subject share capital company new existing authorization competent body share andor ii issuance security company referred ii equity security giving access equity security giving right allotment debt 4 set following limit amount instrument valuable consideration free issuance may carried pursuant consideration governed article l 228 91 et seq delegation authority french commercial code specified share security referred ii nominal value share capital increase may subscribed either cash way share capital increase may carried compensation receivables certain due immediately future pursuant payable held upon company share andor delegation authority shall exceed maximum security could issued pay share andor amount two million four hundred thousand euro security andor financial security would 2400 00000 equivalent value contributed company within public exchange amount date issuance decision offer process realized either france abroad including nominal value share according local regulation instance within issued applicable pursuant adjustment frame triangular merger anglosaxon made order protect right holder scheme arrangement fulfilling security giving access company share condition fixed article l 225 148 french capital accordance applicable law commercial code regulation well contractual provision specified nominal value share capital 2 delegate authority board director increase carried pursuant delegation right subdelegate accordance authority shall deducted overall limit set applicable law regulation proceed paragraph 3a seventh resolution public offering one several time submitted shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april 5 2016 191 b nominal value debt instrument shareholder company absorb may issued immediately pursuant entirety issuance board director may delegation authority shall exceed maximum use condition provided law amount two million euro 2000 00000 order shall determine option equivalent value amount date listed issuance decision specified amount include abovepar limit share capital increase amount reimbursement premium provided subscription received provided said ii nominal value debt instrument amount equal least three quarter amount shall deducted overall limit set issuance decided upon paragraph 3b seventh resolution submitted shareholder meeting freely allocate unsubscribed share security 5 resolve waive shareholder preferential subscription right share andor security note pursuant article l 225 136 may issued pursuant delegation french commercial code authority specified board director may grant shareholder priority issue price share issued shall subscription period respect part least equal minimum set forth applicable issuance share andor security giving access law regulation date issuance share capital company period decision term shall determine accordance provision article l 225 135 paragraph 5 issue price security giving capable french commercial code priority subscription giving access share capital company period shall give rise creation negotiable issued share shall amount right shall exercised proportion number collected company immediately increased share owned shareholder may applicable amount could collected exercised board director considers later company shall share appropriate reducible irreducible basis issued consequently issue security specified share andor security least equal amount set forth subscribed said manner subject paragraph public offering france abroad state board director shall report public offering share andor security decided use made delegation authority pursuant delegation authority may next ordinary shareholder meeting accordance carried one offering issued applicable law regulation simultaneously private placement set forth article l 411 2 ii french monetary shareholder meeting grant board financial code decided pursuant delegation director right subdelegate accordance authority ninth resolution submitted applicable law regulation power shareholder meeting implement delegation authority particular shareholder meeting decide increase share capital determine note delegation authority automatically nature share andor security entail benefit holder security issued giving capable giving access share capital company may issued decide amount capital increase issue pursuant delegation authority express price share andor security issued waiver shareholder preferential applicable amount issue premium subscription right respect share security may give access immediately determine date term condition future capital increase increase characteristic share andor security issued addition note pursuant article l 225 134 case bond debt instrument french commercial code subscription determine whether subordinated including applicable subscription made level subordination accordance 192 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 provision article l 228 97 french discretion charge cost capital commercial code set interest rate interest increase premium arising thereon rate may fixed variable zerocoupon deduct premium sum necessary indexed specify circumstance compulsory increase legal reserve optional suspension cancellation interest payment stipulate term fixed perpetual determine make adjustment take account possibility reduction increase impact transaction involving share nominal value set term issuance capital company particular change including granting guarantee security nominal value share increase share capital interest amortization including incorporation reserve free allocation possibility redemption delivery company share stock split reverse stock split distribution asset necessary security may dividend reserve premium accompanied warrant entitling holder asset redemption capital allotment acquisition subscription bond transaction affecting shareholder equity debt instrument defined market share capital set term enabling authority example due redemption necessary right holder security giving remuneration term right access share capital company indexation option right amend term share andor security question duly record completion capital increase term compliance applicable carried pursuant delegation authority formality make necessary amendment article association company determine mean payment share andor security giving capable giving generally enter agreement particular access share capital company ensure completion proposed issue take issued immediately future measure accomplish formality required issuance listing financial administration set necessary term exercise share andor security issued delegation right right conversion exchange authority exercise right attached redemption case may including delivery thereto company asset share security already issued company attached delegation authority granted period share andor security giving access share twentysix 26 month date capital company issued immediately shareholder meeting render ineffective future particular period date within limit case may may retrospective dividend unused portion previous delegation payable new share well term authority purpose condition completion share capital increase ninth resolution set term company necessary time fixed period delegation authority granted board right purchase exchange stock exchange director issue share andor security giving offmarket security giving access share capable giving access share capital capital company issued issued company andor issuance security giving immediately future purpose right allotment debt instrument without canceling security taking account preferential subscription right shareholder applicable legal provision private placement referred article l 411 2 ii french monetary financial code determine condition accordance applicable law allotment right holder security giving access share may temporarily suspended supplementary information resolution submitted annual combined shareholder meeting april 5 2016 193 shareholder meeting fulfilled security giving capable giving access quorum majority requirement pertaining share capital company decision shall extraordinary shareholder meeting automatically entail benefit holder considered board director report security may issued statutory auditor special report noted company express waiver shareholder share capital fully paidup preferential subscription right respect share accordance one hand provision security giving capable giving access article l 225 129 l 225 129 2 l 225 134 capital company security l 225 136 l 228 91 l 228 93 entitle french commercial code hand article l 411 2 ii french monetary 3 delegate authority board director financial code right subdelegate accordance applicable law regulation proceed one 1 delegate authority board director several time france abroad proportion right subdelegate accordance time considers appropriate euro applicable law regulation proceed currency monetary unit established private placement referred article l reference basket currency preferential 411 2 ii french monetary financial code subscription right shareholder maintained one several time france abroad issuance security giving capable giving proportion time considers appropriate access share capital company condition maximum limit determined company hold directly indirectly half law regulation euro share capital andor ii issuance security currency monetary unit established reference giving capable giving access share capital basket currency issuance share company directly indirectly hold preference share andor security half company share capital subject kind whatsoever security giving right authorization competent body issuance preference share giving capable company referred ii giving access share capital company new existing share andor ii issuance 4sets following limit amount security equity security giving access issuance may carried pursuant equity security giving right delegation authority allotment debt instrument valuable consideration free consideration governed nominal value share capital increase article l 228 91 et seq french commercial share capital increase may carried code specified share security immediately future pursuant referred ii may subscribed delegation authority shall exceed maximum either cash way compensation amount two million four hundred thousand euro receivables certain due payable held upon 2400 00000 equivalent value company amount date issuance decision including nominal value share 2 delegate authority board director issued applicable pursuant adjustment right subdelegate accordance made order protect right holder applicable law regulation proceed security giving access company share private placement referred ii article l capital accordance applicable law 411 2 french monetary financial code regulation well contractual provision one several time france abroad specified firstly limit mutual proportion time considers appropriate limit set paragraph 4a eighth resolution condition maximum limit determined shall deducted secondly law regulation euro nominal amount either capital increase currency monetary unit established reference share capital increase made delegation basket currency issuance share andor shall deducted overall limit set security giving capable giving access paragraph 3a seventh resolution submitted share capital company issue shareholder meeting issuance company company hold directly indirectly half share b nominal value debt instrument capital company hold directly may issued pursuant delegation indirectly half share capital authority shall exceed maximum amount 194 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 two million euro 200000000 equivalent note pursuant article l 225 136 value amount date issuance french commercial code decision specified firstly limit mutual limit set paragraph 4b issue price share issued directly shall eighth resolution shall deducted least equal minimum stipulated law secondly amount include regulation applicable date abovepar reimbursement premium issuance decision provided ii nominal amount debt instrument shall deducted overall limit issue price security giving capable set paragraph 3b seventh resolution giving access share capital company submitted shareholder meeting sum received immediately company increased applicable likely 5 decides waive preferential subscription right subsequently received share shareholder company share andor issued result issuance security security may issued pursuant shall least equal minimum subscription delegation authority price referred preceding paragraph private placement referred ii article l 411 2 acknowledges board director shall french monetary financial code report use made delegation decided delegation authority may authority next ordinary shareholder meeting associated context one issue multiple accordance applicable law regulation issue share andor security public offering share andor security decided delegation shareholder meeting grant board authority subject eighth resolution director right subdelegate accordance submitted shareholder meeting applicable law regulation power implement delegation authority shareholder meeting particular note delegation authority automatically decide share capital increase determine entail benefit holder security nature share andor security giving capable giving access capital issued company may issued pursuant delegation authority express waiver decide amount share capital increase shareholder company preferential issue price share andor security subscription right respect share issued applicable amount issue security may give access immediately premium future determine date term condition note pursuant article l 225 134 capital increase increase characteristic french commercial code subscription including share andor security issued addition appropriate subscription case bond debt instrument shareholder company absorb determine whether subordinated entirety issuance board director may level subordination accordance use condition provided law provision article l 228 97 french order shall determine option commercial code set interest rate interest listed rate may fixed variable zerocoupon indexed specify circumstance compulsory limit share capital increase amount optional suspension cancellation interest subscription provided said amount equal payment stipulate term fixed perpetual least three quarter amount possibility reduction increase issuance decided upon nominal value set term issuance including granting guarantee security freely allocate unsubscribed interest amortization including share security giving access share possibility redemption delivery company capital company asset necessary security may accompanied warrant entitling holder allotment acquisition subscription bond supplementary information resolution submitted annual combined shareholder meeting april 5 2016 195 debt instrument defined market duly record completion capital increase authority example due redemption carried pursuant delegation authority remuneration term right indexation make necessary amendment article option right amend term association company share andor security question term compliance applicable formality generally enter agreement particular ensure completion proposed issue take determine mean payment share measure accomplish formality required andor security giving capable giving issuance listing financial administration access share capital company share andor security issued delegation issued immediately future authority exercise right attached thereto set necessary term exercise right right conversion exchange delegation authority granted period redemption case may including delivery twentysix 26 month date company asset share security shareholder meeting render ineffective already issued company attached date within limit case may share andor security giving access share unused portion previous delegation capital company issued immediately authority purpose future particular period may retrospective dividend payable new share well term tenth resolution condition completion share capital increase delegation authority board director increase number share andor security giving set term company capable giving access share capital necessary time fixed period company issued case share capital increase right purchase exchange stock exchange without preferential subscription right offmarket security giving access share shareholder capital company issued issued immediately future purpose shareholder meeting fulfilled cancelling security taking account quorum majority requirement pertaining applicable legal provision extraordinary shareholder meeting considered board director report determine condition accordance statutory auditor special report accordance applicable law allotment right holder provision article l 225 135 1 r 225 security giving capable giving access 118 french commercial code share may temporarily suspended 1 delegate authority board director discretion charge cost capital right subdelegate accordance increase premium arising thereon applicable law regulation decide deduct premium sum necessary issuance made pursuant seventh ninth increase legal reserve resolution increase number share andor security giving capable giving access determine make adjustment take account capital company issued case share impact transaction involving share capital increase company without capital company particular change preferential right shareholder price nominal value share increase share capital price initial issuance within time incorporation reserve free allocation limit provided law regulation market share stock split reverse stock split distribution practice day issuance decision dividend reserve premium day period thirty 30 calendar day asset redemption capital closing subscription within limit transaction affecting shareholder equity fifteen percent 15 initial issue particularly share capital set term enabling order grant overallotment option provided necessary right holder security giving release share andor security access share capital company issued delegation authority may made preserved either cash way compensation 196 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 receivables certain due payable held upon capital provision article l 225 148 company french commercial code applicable 2 decides nominal value share capital 2 decides nominal amount share increase decided pursuant delegation capital increase may realized immediately authority shall deducted amount future delegation authority may fixed overall limit paragraph 3a seventh exceed ten percent 10 share capital resolution submitted shareholder meeting company specified firstly maximum mutual limit set paragraph 4a board director may without prior eighth resolution shall deducted authorization granted shareholder meeting secondly nominal amount capital use delegation filing third party increase made delegation authority shall public tender offer company security deducted overall limit set paragraph 3a end offer period seventh resolution submitted shareholder meeting delegation authority granted period twentysix 26 month date 3 decides security giving capable shareholder meeting render ineffective giving access capital company issued date within limit case may may consist debt security associated unused portion previous delegation issuance security enable issuance authority purpose intermediate security specified firstly nominal amount debt security may issued pursuant delegation authority may eleventh resolution exceed sum two million euro 2000 00000 equivalent value amount delegation authority granted board date issuance decision secondly director decide issue share andor security maximum mutual limit set giving capable giving access share capital paragraph 4b eighth resolution shall company consideration contribution deducted ii nominal amount debt kind share andor security giving capable security shall deducted overall limit set giving access capital without preferential paragraph 3b seventh resolution submitted subscription right shareholder shareholder meeting shareholder meeting fulfilled 4 decides waive preferential subscription right quorum majority requirement pertaining shareholder company share andor extraordinary shareholder meeting security giving capable giving access considered board director report share capital company may issued statutory auditor special report accordance pursuant delegation holder share provision article l 225 129 et seq l 225 andor security subject contribution 147 l 228 91 l 228 93 french kind commercial code 5 note delegation authority 1 delegate authority board director automatically entail benefit holder right subdelegate accordance security giving capable giving access applicable law regulation decide one share capital company may issued several time proportion time pursuant delegation authority express considers appropriate report waiver shareholder company contribution statutory auditor referred article l preferential subscription right respect share 225 147 french commercial code issuance security may give access immediately share excluding preference share future security kind whatsoever excluding security giving capable giving entitlement preference shareholder meeting grant board share giving capable giving access share director right subdelegate accordance capital company whether new existing applicable law regulation power share consideration contribution kind implement delegation authority granted company consisting share particular andor security giving capable giving access supplementary information resolution submitted annual combined shareholder meeting april 5 2016 197 decide increase share capital company twelfth resolution consideration contribution kind determine nature share andor delegation authority granted board security issued director increase share capital company capitalization reserve earnings set list share andor security contributed premium sum upon capitalization approve valuation contribution kind would permitted establish term issuance share andor security remunerating contribution shareholder meeting fulfilled necessary amount cash payment quorum majority requirement pertaining made approve granting particular advantage ordinary shareholder meeting considered reduce contributor consent board director report accordance valuation contribution kind provision article l 225 129 l 225 129 6 compensation particular advantage l 225 130 french commercial code determine issuance procedure 1 delegate authority board director characteristic security remunerating right subdelegate accordance contribution kind make adjustment applicable law regulation proceed one take account impact transaction several time proportion time share capital company particular change considers appropriate increase share capital nominal value share increase share company incorporation share capital incorporation reserve free allocation premium reserve earnings amount share stock split reverse stock split may converted capital successively distribution dividend reserve premium simultaneously accordance applicable law asset redemption capital article association freely allocating new transaction affecting shareholder equity share andor increasing nominal value share capital set term enabling existing share combination two necessary right holder security giving procedure according term set access share capital company preserved 2 resolve nominal amount share capital increase share capital increase may discretion charge cost capital carried immediately future pursuant increase premium arising thereon delegation authority shall exceed deduct premium sum necessary maximum amount two million four hundred increase legal reserve thousand euro 2400 00000 specified nominal amount limit separate duly record completion capital increase overall limit set paragraph 3a seventh carried pursuant delegation authority resolution submitted shareholder meeting make necessary amendment article association company shareholder meeting grant board director right subdelegate accordance generally enter agreement particular applicable law regulation power ensure completion proposed issue take implement delegation authority measure accomplish formality required particular issuance listing financial administration share andor security issued delegation determine amount nature sum authority exercise right attached incorporated capital set number new thereto share issued andor amount nominal value existing share delegation authority granted period increased decide date may twentysix 26 month date retrospective new share shareholder meeting render ineffective entitled dividend increase nominal date within limit case may value existing share take effect unused portion previous delegation authority purpose 198 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 decide event share issued thirteenth resolution fractional right negotiable delegation authority granted board corresponding share sold director issue share andor security giving proceeds sale allocated capable giving access share capital holder right term specified law company reserved member company saving regulation plan without preferential subscription right shareholder make adjustment take account impact transaction involving share capital shareholder meeting fulfilled company particular change quorum majority requirement pertaining nominal value share increase share extraordinary shareholder meeting capital incorporation reserve free allocation considered board director report share stock split reverse stock split statutory auditor special report accordance distribution dividend reserve premium provision article l 225 129 et seq asset redemption capital article l 225 138 l 225 138 1 french transaction affecting shareholder equity commercial code article l 3332 1 et seq share capital set term enabling french labor code necessary right holder security giving access share capital company 1 delegate authority board director preserved right subdelegate accordance applicable law regulation proceed one discretion charge cost several time proportion time capital increase available reserve arising considers appropriate issuance share thereon deduct amount sum preference share andor security necessary increase legal reserve kind whatsoever security giving right issuance preference share giving capable duly record completion capital increase giving access share capital company carried pursuant delegation authority new existing share reserved member make necessary amendment article company saving plan plan whose association company member capital increase may reserved equivalent term article l 3332 18 generally enter agreement particular french labor code implemented within french ensure completion proposed issue take foreign entity group entity falling within measure accomplish formality required scope company consolidated combined issuance listing financial administration financial statement pursuant article l 3344 1 share andor security issued delegation l 3344 2 french labor code authority exercise right attached specified payment share andor thereto security may subscribed either cash way compensation receivables certain due delegation authority granted period payable held upon company either twentysix 26 month date incorporation reserve benefit shareholder meeting render ineffective premium share capital event free date within limit case may share allocation result discount andor unused portion previous delegation abundance authority purpose 2 decides nominal amount share capital increase share capital increase may carried immediately future pursuant delegation authority shall exceed maximum amount two million four hundred thousand euro 2400 000 00 specified maximum separate overall limit set paragraph 3a seventh resolution submitted shareholder meeting supplementary information resolution submitted annual combined shareholder meeting april 5 2016 199 3resolves waive preferential subscription right establish accordance law list shareholder company respect company group company share andor security giving access share beneficiary indicated paragraph 1 may capital company may issued pursuant subscribe share andor security giving delegation authority favor capable giving access capital beneficiary defined paragraph 1 note company thereby issued may freely delegation authority automatically entail allotted share andor security giving capable benefit holder security may giving access capital company issued pursuant delegation authority express waiver shareholder company decide subscription share andor preferential subscription right respect security may made directly beneficiary share security may give access immediately belonging entity group saving plan via future dedicated mutual fund vehicle entity permitted applicable law regulation 4 resolve issue price share andor security giving capable giving access determine condition particular regard share capital company set accordance length service must met article l 3332 18 et seq french labor beneficiary new share security may code provided discount set shall issued capital increase made according lower twenty per cent 20 average resolution quoted price company share regulated market euronext paris twenty 20 trading set opening closing date subscription day preceding date decision setting share andor security opening date subscription period reserved member company saving plan exceed set amount issuance made twenty per cent 20 average however present delegation authority particular shareholder meeting expressly authorizes board determine issue price term condition director reduce cancel aforementioned subscription payment delivery date discount considers appropriate particular entitlement dividend share andor order take consideration international security may retrospective rule accounting standard inter alia locally applicable reduction event oversubscription legal accounting tax social provision term condition issue subject country certain beneficiary board applicable legal regulatory limit director may also substitute part discount granting share andor security giving provide possibility proceed according access share capital company pursuant condition shall determine case may provision adjustment required accordance legal regulatory provision 5 authorizes board director according delegation authority freely allot share case issue new share charge andor security giving access immediately amount required pay said share future share capital company reserve profit share premium member company saving plan replace part discount andor applicable discretion charge cost capital abundance specified total increase premium arising thereon advantage resulting allocation relation deduct premium sum necessary discount andor abundance may increase legal reserve exceed legal regulatory limit duly record completion capital increase shareholder meeting grant board carried pursuant delegation authority director right subdelegate make necessary amendment article accordance applicable law regulation association company power implement delegation authority particular generally enter agreement particular ensure completion proposed issue take measure accomplish formality required issuance listing financial administration 200 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 share andor security issued delegation charge difference purchase price authority exercise right attached cancelled share nominal value thereto available premium reserve delegation authority granted period amend article association company twentysix 26 month date accordingly shareholder meeting render ineffective date within limit case may complete necessary formality provide unused portion previous delegation declaration disclosure authority authority purpose particularly autorité de marchés financier fourteenth resolution generally take appropriate measure authorization granted board director authorization granted period twentysix reduce share capital company way 26 month date shareholder cancellation share acquired meeting render ineffective date implementation share buyback program within limit case may unused portion previous authorization shareholder meeting fulfilled purpose quorum majority requirement pertaining extraordinary meeting considered board resolution submitted annual director report statutory auditor special ordinary shareholder meeting report accordance provision article l 225 209 et seq article l 225 213 french commercial code fifteenth resolution 1 authorizes board director cancel one approval financial statement year ended several time sole initiative portion 31 december 2015 discharge director share acquired company implementation share buyback program annual shareholder meeting accordance limit ten per cent 10 company share quorum majority requirement ordinary capital twentyfour 24 month period meeting shareholder considered provided ten per cent 10 limit corporate account year ended 31 december applies amount company share capital 2015 well report board director necessary adjusted take report statutory auditor concerning account transaction affecting share capital financial statement approved financial company occur subsequently shareholder statement year ended 31 december 2015 meeting disclosed net profit 29311748 presented transaction reflected 2 authorizes board director reduce financial statement summarized report share capital company accordingly result annual shareholder meeting grant shareholder meeting grant board full unreserved discharge director director right subdelegate accordance execution management duty said applicable law regulation power reporting year implement authorization particular annual shareholder meeting asserts set definitive amount capital reduction overall expense referred article 39 4 determine term condition general tax code noted reduction duly record reduction supplementary information resolution submitted annual combined shareholder meeting april 5 2016 201 sixteenth resolution share company nominal value 100 including share issued result approval consolidated financial statement completion merger referred first year ended 31 december 2015 third resolution hereinabove entitle holder payment net dividend valued 200 annual shareholder meeting accordance quorum majority requirement ordinary dividend paid 15 april 2016 meeting shareholder considered corporate consolidated account year specified treasury share ended 31 december 2015 well report canceled upon date detachment board director report statutory auditor dividend shall entitled dividend concerning consolidated account approved distribution consolidated financial statement year ended 31 december 2015 disclosed net profit k distributed amount 200 per share 119494 presented transaction reflected eligible allowance 40 applied physical financial statement summarized people residing france referred article 1583 2 report general tax code reminded distributed amount seventeenth resolution three last financial year amounted assignment financial result year ended income eligible tax rebate 31 december 2015 setting dividend income fiscal year ended dividend distributed annual shareholder meeting fulfilled dec 31 2014 19967009 0 quorum majority requirement pertaining dec 31 2013 18412315 0 ordinary shareholder meeting decided assign dec 31 2012 16876856 0 follows income year ended 31 december 2015 totaling 2931174842 legal reserve 800 eighteenth resolution balance resulting deduction legal reserve approval related party agreement referred 2931094842 article l225 38 subsequent commercial code following added balance year earlier profit carried forward 1341553087 annual shareholder meeting accordance quorum majority requirement ordinary would yield distributable profit meeting shareholder considered 4272647929 special report statutory auditor concerning regulated agreement referred article l225 38 total amount dividend disbursed subsequent commercial code recognizes shareholder 30734476 report conclusion stating absence concluded regulated agreement agreement balance resulting disbursement 1199200329 continued past year remaining amount 1199200329 carried forward next year 202 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 nineteenth resolution ordinary shareholder meeting give favorable opinion element compensation due fixing overall annual amount granted 2013 financial year mr volker attendance fee board director member niebel executive vice president described k 716 annual shareholder meeting accordance quorum majority requirement ordinary meeting shareholder approved overall twentythird resolution annual amount attendance fee allocated preceding financial year amounting notice element compensation due granted 283200 2015 financial year mr oscarwerner reif executive vice president twentieth resolution annual shareholder meeting complying 243 recommendation afepmedef notice element compensation due code updated june 2013 deliberating accordance granted 2015 financial year mr joachim quorum majority requirement kreuzburg chairman chief executive officer ordinary meeting shareholder give favorable opinion element compensation due annual shareholder meeting complying granted 2013 financial year mr oscar 243 recommendation afepmedef werner reif executive vice president described code updated june 2013 deliberating accordance k 713 quorum majority requirement ordinary meeting shareholder give favorable opinion element compensation due twentyfourth resolution granted 2015 financial year mr joachim kreuzburg chairman chief executive officer proposal renewal term duty mr joachim described k 804 kreuzburg member board annual shareholder meeting indicates twentyfirst resolution term duty mr joachim kreuzburg director company due expire end next notice element compensation due annual shareholder meeting regard granted 2015 financial year mr reinhard resolve approve renewal term duty vogt executive vice president new threeyear term expire end annual shareholder meeting 2019 convoked annual shareholder meeting complying approve financial statement financial year 243 recommendation afepmedef ending 31 december 2018 code updated june 2013 deliberating accordance quorum majority requirement mr joachim kreuzburg whose term duty ordinary shareholder meeting give favorable renewed accepts renewal function opinion element compensation due declares incompatibility prohibition granted 2015 financial year mr reinhard prevents renewal vogt executive vice president described k 568 twentyfifth resolution twentysecond resolution proposal renewal term duty mr volker niebel member board notice element compensation due granted 2015 financial year mr volker niebel annual shareholder meeting indicates executive vice president term duty mr volker niebel director company due expire end next annual shareholder meeting complying annual shareholder meeting regard 243 recommendation afepmedef resolve approve renewal term duty code updated june 2013 deliberating accordance new threeyear term expire end quorum majority requirement annual shareholder meeting 2019 convoked supplementary information resolution submitted annual combined shareholder meeting april 5 2016 203 approve financial statement financial year annual shareholder meeting indicates ending 31 december 2018 term duty mr bernard lemaitre director company due expire end next mr volker niebel whose term duty renewed annual shareholder meeting regard accepts renewal function declares resolve approve renewal term duty incompatibility prohibition prevents new threeyear term expire end renewal annual shareholder meeting 2019 convoked approve financial statement financial year ending 31 december 2018 twentysixth resolution mr bernard lemaitre whose term duty renewed proposal renewal term duty mr reinhard accepts renewal function declares vogt member board incompatibility prohibition prevents renewal annual shareholder meeting indicates term duty mr reinhard vogt director company due expire end next twentyninth resolution annual shareholder meeting regard resolve approve renewal term duty proposal renewal term duty mr liliane new threeyear term expire end de lassus member board annual shareholder meeting 2019 convoked approve financial statement financial year annual shareholder meeting indicates ending 31 december 2018 term duty mr liliane de lassus director company due expire end next mr reinhard vogt whose term duty renewed annual shareholder meeting regard accepts renewal function declares resolve approve renewal term duty incompatibility prohibition prevents new threeyear term expire end renewal annual shareholder meeting 2019 convoked approve financial statement financial year ending 31 december 2018 twentyseventh resolution mr liliane de lassus whose term duty renewed proposal renewal term duty mr arnold accepts renewal function declares picot member board incompatibility prohibition prevents renewal annual shareholder meeting indicates term duty mr arnold picot director company due expire end next thirtieth resolution annual shareholder meeting regard resolve approve renewal term duty proposal renewal term duty mr henri new threeyear term expire end riey member board annual shareholder meeting 2019 convoked approve financial statement financial year annual shareholder meeting indicates ending 31 december 2018 term duty mr henri riey director company due expire end next mr arnold picot whose term duty renewed annual shareholder meeting regard accepts renewal function declares resolve approve renewal term duty incompatibility prohibition prevents new threeyear term expire end renewal annual shareholder meeting 2019 convoked approve financial statement financial year ending 31 december 2018 twentyeighth resolution mr henri riey whose term duty renewed accepts proposal renewal term duty mr renewal function declares bernard lemaitre member board incompatibility prohibition prevents renewal 204 supplementary information resolution submitted annual combined shareholder meeting april 5 2016 thirtyfirst resolution share company acquired may exchanged sold transferred mean authorization granted board director market outside market mutual agreement enable company trade share including sale share block compliance applicable regulation shareholder meeting fulfilled quorum majority requirement pertaining dividend attached treasury share ordinary shareholder meeting considered company shall affected retained earnings report board director compliance account provision article l 225 209 et seq french commercial code directly applicable shareholder meeting grant board provision european commission regulation director right subdelegate compliance 22732003 22nd december 2003 general applicable law regulation necessary regulation autorité de marchés financier amf power implement authorization financial market authority market practice particular establish term condition accepted amf share buyback program compliance applicable law present resolution notably 1 authorizes board director right proceed case may adjustment subdelegate compliance applicable law required transaction share capital place regulation make company purchase purchase order stock market enter share purpose animation agreement notably keeping register sale company share market framework purchase share make liquidity agreement complying ethic rule declaration amf organization recognized amf carry formality generally take appropriate measure 2 decides maximum amount dedicated share buyback program referred resolution authorization granted twentyfourth may exceed excluding acquisition cost five 24month term date present million euro 5 000 00000 countervalue shareholder meeting render ineffective amount currency date hereof unused portion case date board director may however adjust may prior authorization given identical abovementioned maximum amount share buy subject matter back program case transaction share capital company including change par value ordinary share share capital increase thirtysecond resolution way incorporation receivable followed creation allocation free share division authority formality regrouping security order take account impact said transaction share value annual shareholder meeting give full authority bearer original copy extract 3 acknowledges maximum number share minute present annual shareholder acquired company may way meeting accomplish necessary procedure exceed 01 overall number share composing share capital company purchase share company may carried time exclusion period public offering relating share capital company mean whatsoever market outside market overthecounter including way purchase block way utilization optional operational mechanism utilization forward financial instrument negotiated regulated market overthecounter possibly third party acting behalf company compliance provision last paragraph article l 225 206 french commercial code supplementary information information reference document annual financial report 205 information reference document annual financial report declaration responsibility reference document 2015 annual financial report hereby certify taken reasonable received completion letter auditor measure effect information stating audited information contained present reference document contained reference document best knowledge accordance financial position financial statement fact make omission likely affect import read document entirety certify best knowledge historical financial information presented financial statement prepared accordance document discussed auditor report applicable accounting standard give fair found page 156 169 reference view asset liability financial position document profit loss company activity included consolidation february 24 2016 management report 17 73 present fair review development performance business financial position company activity included consolidation well description main risk uncertainty exposed joachim kreuzburg chairman board ceo 206 supplementary information information reference document annual financial report table reconciliation heading note 1 european regulation 8092004 april 29 2004 european order facilitate understanding present commission column right document concerning presentation sartorius corresponding page present document stedim biotech sa table left heading part 1 european regulation n8092004 april 29 2004 page 1 person responsible 11 person responsible information 205 12 certification person responsible registering document 205 2 independent auditor 21 name address independent auditor issuer 108109 3 selected financial information presentation selected historical financial information every year period 31 covered financial information 2 2433 4 risk factor 5260 5 information issuer 51 history development company 18 511 corporate name commercial name issuer 172 512 place registration number issuer 172 513 date establishment life issuer 172 registered office legal form issuer legislation governing operation 514 country origin address 172 52 investment 28 521 principal investment including amount carried 33 134136 6 overview operation 61 principal operation 20 2425 62 principal market 2223 63 dependence patent license contract 56 60 180181 64 competition 23 7 organigram organizational chart 71 description group 126127 72 list subsidiary 127 8 property plant equipment 81 significant existing planned property plant equipment 28 33 44 82 environmental issue 3447 9 analysis financial situation result 91 financial position 2829 113115 92 operating profit 2426 112 130131 10 cash position capital 2830 6367 115 101 issuer capital short longterm 138139 164165 102 cash flow 28 114 103 borrowing condition financial structure 2829 142143 150152 104 expected source financing 62 148152 11 research development patent license 3031 180181 12 information trend 9 6162 13 profit forecast estimate 9 6162 14 governing management supervisory executive body 141 composition governing management body nature family link amongst person 7684 1411 conviction fraud within last five year least 84 1412 bankruptcy sequestration liquidation member governing body 84 1413 indictment andor official public sanction member governing body 84 142 conflict interest level governing management body 84 15 remuneration benefit 151 remuneration paid benefit kind 7172 97106 supplementary information information reference document annual financial report 207 heading part 1 european regulation n8092004 april 29 2004 page 152 pension retirement benefit 140142 16 operation governing management body 161 expiration date current mandate term office 7684 162 service agreement member 84 163 audit remuneration committee issuer 84 164 corporate governance 8588 17 employee 171 workforce end period covered historical financial information 2 3638 154 172 shareholding capital 104105 152153 165 173 employee shareholding capital 67 18 principal shareholder 181 crossing threshold 67 148 182 double voting right 67 177178 183 control business 15 154 19 transaction related party 154155 20 financial information issuer asset financial situation profit 201 historical financial information result last five year 73 202 20132014 consolidated financial result 2427 112 203 2014 statement profit loss 112 20132014 consolidated financial statement statement financial position statement profit loss statement cash flow statement change equity note consolidated 204 financial statement 112155 205 verification annual historical information independent auditor report 156 169 206 last financial information 4 207 dividend distribution policy 15 139 164165 208 legal arbitration procedure 59 209 significant change financial commercial situation 1823 21 additional information 211 share capital 63 amount issued capital number share authorized number share issued fully paid number share issued fully paid par value per share reconciliation number 2111 share outstanding beginning end year 6367 138139 164165 2112 share representing capital applicable number book value face value share held behalf issuer 2113 subsidiary issuer 6367 2114 amount convertible security exchangeable security security warrant 139 152153 information term acquisition right obligation authorized unissued 2115 capital undertaking increase capital 6367 138139 information capital member group option agreed 2116 conditionally unconditionally put option applicable 2117 history share capital period covered historical financial information 6367 212 memorandum article association 172 2121 object purpose issuer 172 2122 member administrative management supervisory body 7684 174177 2123 right preference restriction attaching class existing share 177178 2124 action required change right shareholder 177178 condition governing manner annual general meeting extraordinary general 2125 meeting shareholder called including condition admission 173174 provision issuer article association statute charter bylaw would effect 2126 delaying deferring preventing change control issuer 173178 provision article association statute charter bylaw governing ownership 2127 threshold shareholder ownership must disclosed 173178 condition imposed memorandum article association statute charter bylaw 2128 governing change capital condition stringent required law 173178 22 major contract 178179 23 information provided third party declaration expert declaration interest applicable 24 document accessible public 4 25 information shareholding 127 208 supplementary information afep medef code afep medef code information implementation provision afep medef code relating corporate governance listed company accordance provision article 251 corporate governance code listed company effect date hereof code listed company referring code required precisely report reference document implementation provision case nonappliance one provision company required provide understandable relevant circumstantial information according rule apply explain recommended amf recommendation n 2014 08 22 september 2014 company indicate specific table provision applied related information general table afep medef code recommendation measure implemented article disposition code sartorius stedim biotech 1 board director collegial body 13 composition organization yes half organization board work likewise membership must board represented foreign suited shareholder makeup size nature director proof group firm business particular circumstance facing international dimension moreover member board professional background necessary degree technical expertise allows himher help evolution activity framework way board committee work subject special attention board totally able work mission appropriate balance power publication internal rule yes internal rule organization operation described internal rule synthetized document drawn published part full company reference year entire website reference document document published website updated board meeting 18 february 2015 2 board director market 212 communication market 213 corporation rigorous policy communication yes press release published analyst market certain practice selective disclosure company website intended assist analyst forecast result transmitted professional prohibited distributor order assure form communication must allow everyone access effective diffusion information time investor conference call listened board ensure investor receive relevant information website addition balanced enlightens strategy development model longterm strategy corporation presentation activity reflecting permanent pedagogic effort towards investor 22 offbalance sheet commitment risk listed company must equipped reliable procedure yes information identification monitoring assessment commitment risk already presented note provide shareholder investor relevant information financial statement area reference document purpose annual report specify internal procedure set yes rating company identify monitor offbalancesheet commitment evaluate published year supplementary information afep medef code 209 measure implemented article disposition code sartorius stedim biotech corporation material risk reference document company must develop clarify information provided sheet commitment shareholder investor regarding offbalancesheet commitment outlined reference material risk disclose company rating financial document consolidated rating agency well change occurred financial account year 3 separation office chairman board director chief executive officer 31 corporation opts separation office chairman applicable chief executive officer appropriate task entrusted chairman board director addition conferred upon law must described 32 option uniqueness dissociation function yes explaining essential shareholder third party fully informed choice chairman choice made separation office chairman chief company governance executive officer maintenance position single office internal control report motivation choice addition form disclosure required regulation reference document annual report may serve medium governance regard company situation disclosure shareholder entitled board report ground justification decision 4 board director strategy 4 internal rule board director consider decide upon transaction genuinely strategic importance review ad hoc committee appropriate internal rule board director specify case prior approval board director required yes board director setting related principle may differ according internal rule division group concerned including updating principle material transaction outside scope rule reference document firm stated strategy subject prior approval board year director opposite entire element integral part board rule according board director informed director internal rule corporation financial situation cash position commitment rule related external acquisition disposal also major investment organic growth internal restructuring action board director informed timely fashion corporation cash position appropriate take decision relating funding indebtedness 5 board director general meeting shareholder 52 communication shareholder yes annual shareholder meeting decisionmaking body area shareholder meeting stipulated law also privileged moment company relevant time dedicated engage dialogue shareholder session must presentation board occasion managing body report corporation business director activity operation board director specialized committee order committee audit compensation etc also opportunity open exchange prolific genuine open dialogue shareholder debate governance purpose presentation generally followed interesting debate shareholder board director must take care infringe upon specific power shareholder meeting transaction proposes modify fact law corporate purpose company basis contract founding corporation even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business even change corporate purpose company involved board director must refer matter meeting shareholder transaction relates material part group asset business 210 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech 6 membership board director guiding principle 63 composition board director yes board director board consider would desirable balance within committee composed membership within committee board member woman foreign director established particular regard representation men group point woman nationality diversity skill take appropriate willingness pursue action assure shareholder market duty international growth performed necessary independence objectivity diversity board publish reference document objective method result director suggests policy matter 2015 shareholder meeting nominate two independent woman director french american within board director moreover diversity skill board member career profile enable board benefit experience management scientific level 64 woman men representation yes board director regard representation men woman objective appointed april 7th 1015 board shall reach maintain percentage least 20 two woman mr susan dexter woman within period three year least 40 woman within anne marie graffin period six year shareholder meeting 2010 respectively french date listing company share regulated market american citizen whichever later director permanent representative legal independant board member entity director representing employee shareholder taken regard group account order determine percentage case effectively anticipated director representing employee provision law recommendation set code afepmedef board director parallell pursuing effort select high profile potential additional applicant seat latter board case board undertakes commitment use best effort reach rate 40 woman due time legally required board comprises fewer nine member difference applicable end six year number director gender may excess two 65 specific assignment entrusted referent director applicable board decided confer special task upon director relate governance shareholder relation particular appointing lead director vice president task resource prerogative access must described internal rule supplementary information afep medef code 211 measure implemented article disposition code sartorius stedim biotech 7 representation employee 73 representation employeesthe french code de commerce require applicable appointment shareholder assembly one director company fall among employee case reaching holding rate 3 within scope capital share employee shareholder obligation appoint director french code de commerce provides category type company board member actually reaching certain employee threshold one employee analyzing impact representatitves shall elected seat board director new regulation repercussion company applicable way director director representing employee shareholder director representing employee entitled vote applicable board director collegial body assigned duty december 31st 2015 acting time interest company board director director may selected board participate committee director representing 74 without prejudice legal provision specific director employee representing employee shareholder director representing employee right subject obligation particular applicable relation confidentiality take responsibility see 72 member board 8 minority shareholder 8 desirable within board representative various yes company main specific group interest board could become shareholder take battleground vested interest instead representing shareholder responsibility conformity whole regard shareholder corporation controlled majority shareholder group direct distinct board shareholder acting concert latter assumes specific responsibility director one monitor shareholder direct separate like conflict interest board director majority shareholder must take particular care moreover commitment avoid possible conflict interest secure transparency specifically stated board information provided market fairly take interest internal rule provision account article 5 9 independent director 92 independent director yes company duly although quality board director cannot defined simply appointed shareholder reference percentage independent director director meeting dated 7 april two required honest competent active regularly attending additional independent director involved important board director presence independent director significant proportion independent director order percentage would increase satisfy expectation market also order improve higher 40 quality proceeding independent director account half member board widely held corporation without controlling shareholder controlled company independent director account least third director representing employee shareholder director representing employee taken account order determine percentage 93 qualification independent director discussed appointment committee reviewed every year board director prior publication annual report board director must upon motion appointment yes intendant director committee review individually position member qualification reviewed basis criterion mentioned notify conclusion regularly board shareholder annual report shareholder meeting director moreover director appointed identification independent director 7 april 2015 shareholder carried corporation management board meeting approved appointment two board director may consider although particular director additional independent meet criterion cannot held independent director 4 10 owing specific circumstance person company thee director board ownership structure reason director could defined 212 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech conversely board may consider director meet criterion nevertheless independent director 94 criterion reviewed committee board order director qualify independent prevent risk conflict interest director management corporation group following employee executive director company yes independent director employee director parent company latter qualification reviewed yearly consolidates position previous board director five year 2015 shareholder meeting executive director company corporation approves nomination hold directorship directly indirectly employee additional 2 independent appointed executive director company currently director 4 10 office held office less five year director director board director could defined customer supplier investment banker commercial banker material company group moreover board make significant part whose business corporation evaluation quantitative group account qualitative criterias evaluation significant relationship company particularly analyzed group must debated board criterion lead board regard evaluation must explicitly stated reference document aspect economical dependence company group member board mandate function related close family tie executive director yes independent director auditor corporation within previous five qualification regularly year reviewed board director board make director corporation twelve meeting steadiness year examination accordance announced criterion although may executive director chairman board see may considered independent company justify based criterion set 10 evaluation board director work 101 assessment board work yes year member sound corporate governance board director evaluate board director formal ability meet expectation shareholder entrusted autoevaluation board authority direct corporation reviewing time time performance based specific membership organization operation implies criterias functioning corresponding review board committee modality effective contribution member every board consider balance organization committee shall constitutes time time 2015 board done formal autoevaluation perspective board monitor te fitness role task work member provided committee meeting 9 december therefore evaluation process take account following 2015 application goal indicated criterion make assessment operating process ii prepare important debate appropriate questionning list anticipated timeline iii measure effective contribution director framework board preparation work accordingly board think desirable balance membership committee created member consider time time adequacy organization operation performance task 11 meeting board committee 11 information board director meeting yes reference document number meeting board director indicates number committee held past financial year mentioned meeting level annual report must also provide shareholder attendance past relevant information relating director attendance year 2015 meeting 1 board director frequency duration meeting board director held 9 meeting allow indepth review discussion level attendance supplementary information afep medef code 213 measure implemented article disposition code sartorius stedim biotech matter subject board authority applies meeting 100 board committee audit compensation appointment 2 audit committee nomination etc held 5 meeting proceeding unambiguous minute meeting level attendance summarize discussion specify decision made 95 particular importance since provide necessary record 3 remuneration board done order carry duty without committee held unnecessarily detailed mention briefly question raised 1meetings level reservation stated attendance 100 4 rule rigourously applied meeting minute duly reflected internal rule 12 director access information 12 law recognizes principle chairman chief yes internal rule includes executive officer bound disclose director document modality right information required performance duty information confidentiality manner right disclosure exercised related director confidentiality duty set internal rule board director board responsible necessary determining relevance document requested corporation must also provide director appropriate information throughout life corporation meeting board importance urgency information requires ongoing disclosure also include relevant information including criticism relating corporation article press financial analyst report conversely director bound request appropriate information consider necessary perform duty accordingly director considers able take part proceeding appropriate information bound say board order obtain necessary information director opportunity meet corporation principal executive manager even outside presence executive director latter case given prior notice 13 director training 13 director training yes start director one major condition appointing director function different training ability cannot expected priori every director session offered order specific prior knowledge corporation organization help accomplish activity director accordingly provided mission best applies considers necessary supplementary training relating specialized member corporation specific feature business market committee audit committee member provided time yes member audit appointment information relating corporation specific committee necessary accounting financial operational feature expertise due professional background particular provided infomations remuneration committee accounting financial special figure company 14 theration director term office 14 time timescale term office yes conformed code without affecting duration current term duration director recommendation duration term office set bylaw status exceed office term 3 year 7 maximum four year shareholder called express director duty term election sufficient frequency renewed 2016 three renewed 2018 term staggered avoid replacement entire body favor smooth replacement director information director yes information annual report detail date beginning expiry iterated director director term office make existing staggering clear biographical presentation also mention director addition list office board director position held corporation nationality age composition principal position list name member board 214 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech committee meeting shareholder asked appoint director extend mentioned internal term booklet notice calling meeting rule board shareholder must contain biographical notice outlining bylaw company title iii curriculum vitae addition item required statute article 63 number share member board also mentioned reference document even though required law imperative bylaw yes status title iii art 63 internal rule set minimum number share corporation within reference document concerned director must personally hold must appear provides information annual report andor booklet notice calling meeting shareholder 15 committee board 15 existence composition committee yes board director number structure committee determined compensation committee board however addition task assigned audit committee duty select law recommended compensation appointment suggest nomination new director executive director subject preparatory work director specialized committee board director board appointed specialized committee address right obligation particular concern creation committee shall event specialized committee remove matter purview board sole specified internal rule statutory decisionmaking authority allowed cause division inherent committee within board collegial body remain accountable performance duty committee act place board rather extension board facilitating work reason particular quality report committee board inclusion annual report description committee activity stressed committee board may contact exercising duty internal rule complies principal manager corporation informing chairman majority board director subject reporting back board recommendation formulated contact afep medef code committee board may request external technical study relating matter within competence corporation expense informing chairman board director board director subject reporting back board thereon event committee recourse service offered external consultant eg compensation consultant order obtain information compensation system level applicable main market committee must ensure consultant concerned objective committee must provided internal rule setting duty mode operation committee internal rule approved board may integrated internal rule board set separate provision committee secretariat task shall undertaken person nominated chairman committee agreement chairman existence crossdirectorships committee avoided 16 audit committee 16 existence yes board director board appoint audit committee duty audit committee inseparable board director legally bound approve corporate account prepare consolidated account approving account main occasion board assumes two essential duty review management performance verification reliability clarity information provided shareholder market supplementary information afep medef code 215 measure implemented article disposition code sartorius stedim biotech 161 composition yes referred audit audit committee member competent finance committee chairman financial accounting accountancy competency within description director background proportion independent director audit committee excluding audit committee director representing employee shareholder director representing composed 50 employee taken account least equal two independent director third including chairman committee include executive director yes member audit committee executive manager executive director appointment extension term office audit yes chairman audit committee chairman proposed appointmentsnominations committee reached committee specially reviewed board relevant level expertise finance accounting since last year 162 mission examine statement et insure relevance yes internal rule already permanency accounting method used consolidated includes scope foreseen account annual account afep medef code 1621 follow process elaboration company financial indicated reference statement document statutory auditor refer inform follow efficiency internal control system closely audit committee management risk result mission report half year result also desirable time review account annual result audit committee consider major transaction connection mission conflict interest could arisen time available reviewing account sufficient less two day review board review account audit committee accompanied presentation statutory auditor stressing essential point result statutory audit particular adjustment resulting audit significant weakness internal control identified auditor work also accounting method chosen also accompanied presentation chief yes audit committee financial officer describing corporation risk exposure examines least trimestral material offbalancesheet commitment basis main financial operation analysis account statutory auditor submit conclusion twice year audit committee 1622 committee must interview statutory auditor regularly including yes audit committee meet interview without executive manager present statuary auditor least twice year statutory auditor must particular interviewed committee meeting dealing evaluation process preparing financial information review account order report execution task conclusion work 1623 committee steer procedure selection statutory yes audit committee pilot auditor submit recommendation board director selection statuary regarding statutory auditor proposed appointment auditor shareholder meeting committee shall suggest board procedure selection particular need make call tender must supervise call tender approve specification choice firm consulted making sure selection result appointment best bidder lowest bidder committee particular receive year following yes order deal information statutory auditor topic related green book statement independence european community company appointed amount fee paid network statutory auditor deloitte co statutory auditor company controlled company entity controlling sustainability report company respect service directly related statutory auditor assignment 216 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech information concerning service supplied respect task directly related statutory auditor engagement committee review statutory auditor risk weighing independence protection measure taken order reduce risk committee must particular ensure amount fee paid company group share fee turnover firm network likely impair statutory auditor independence 163 functioning yes audit committee audit committee operating report board director secretary take minute provide board full information thereby facilitating latter meeting summary proceeding deliberation included reference document annual report include statement audit committee activity past financial year yes audit committee working method audit committee interview statutory auditor also intervention person responsible finance accounting treasury matter financial director risk possible hold interview committee wish without director qualified presence corporation executive management people specified within committee review consolidation scope applicable chairman internal control reason excluding certain company report audit committee committee able call upon outside expert needed regularly informed making sure requisite skill independence internal program regard effectiveness internal control risk management system committee ensure system exist implemented corrective action taken event significant weakness flaw end must informed main finding statutory auditor internal audit must interview responsible internal audit risk control give opinion organization service informed program internal audit receive internal audit report regular summary report committee shall examine risk material offbalancesheet commitment assess importance failure weakness communicated necessary inform board 17 committee charge appointment nomination 17 composition yes remuneration appointment nomination committee play essential role committee also charge shaping future company charge preparing nomination order future membership leadership body accordingly board avoid multiplication appoint member committee appointment specific committee nomination director executive director may may separate compensation committee 171 appointment nomination committee separate applicable compensation committee recommendation relating latter membership mode operation also applicable see hereafter however unlike provision governing compensation committee chief executive officer shall associated appointment nomination committee proceeding event office chairman board director chief executive officer separate chairman may member committee 172 allocation yes compensation committee charge submitting proposal board committee competency reviewing detail factor take account research examine select proceeding desirable balance membership board new application regard makeup change ownership corporation nomination board stock balance men woman board identification director give point evaluation potential candidate desirability extension term view recommendation particular organize procedure nomination future applicant board independent director perform review potential candidate director latter approached way committee selection nomination ad hoc committee established hand plan new member administrator supplementary information afep medef code 217 measure implemented article disposition code sartorius stedim biotech 18 committee charge compensation 181 composition yes member committee include executive director compensation committee nonexecutives composed 50 independent member committee employee director since company obligation considering requirement article l 225 271 commerce code studying current obligation majority independent director chaired independent director advised employee director member committee 182 committee operating report board director yes audit committee provide board full information thereby facilitating secretary take minute proceeding meeting summary report proceeding compensation committee deliberation provided within presented board deliberate issue relating reference document compensation executive director without presence latter annual report include statement compensation committee activity past financial year 183 remuneration committee must ensure board director yes remuneration given best condition determine compensation committee working method benefit accruing executive director decision made specified internal control board director chairman report furthermore committee must informed compensation policy applicable principal executive manager executive director company purpose executive director attend meeting compensation committee 19 number directorship executive nonexecutive director 19 executive director hold two directorship yes chairman exercise listed corporation including foreign corporation affiliated actually term office within group20 must also seek opinion board surveillance control carl accepting new directorship listed corporation zeiss ag 3 office term within consultative committee moreover reference document indicates executive director mandate listed company including foreign one case separate chairman board may draw specific recommendation issue taking account particular situation mission conferred himher noexecutive director hold four directorship listed corporation including foreign corporation affiliated group recommendation apply time appointment next renewal term office director keep board informed directorship held company including participation committee board company france abroad 20 ethical rule director 21 director compensation 211 member board director compensation yes information 212 shall recalled method allocation director indicated section compensation total amount determined meeting director fee shareholder set board director take account reference document way shall determine director actual attendance method allocation meeting board committee therefore include significant defined board variable portion director mentioned reference document president report company governance 218 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech internal control natural director attendance meeting specialized committee give rise additional amount director fee similarly undertaking individual task vice president lead director may give rise additional fee payment extraordinary compensation subject application procedure related party agreement amount director fee reflect level responsibility assumed time need apply duty board must review adequacy level director fee regard duty responsibility placed director 213 rule allocation director fee individual amount yes attendance fee payment thereof made director set annual stated specified clearly report reference 22 termination employment contract case appointment executive director yes executive director recommended employee becomes executive director employed company stop employee contract company company company group either conventional termination resignation 23 compensation executive director 231 principle setting executive director compensation role yes compensation policy board director deliberated remuneration board director supervisory board responsible committee submission determining compensation executive director based proposal board oscar werner reif made compensation committee volker niebel joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level parent company sartorius stedim biotech us utmost attention code afep medef principle order determine said compensation relevant board committee must take account following principle comprehensiveness balance benchmark consistency understandability rule proportionality 232 compensation policy allocation stock option grant free yes compensation policy share deliberated remuneration compensation executive director must appropriate balanced committee submission fair compensation must strengthen sense solidarity board oscar werner reif motivation within company volker niebel market benchmark may sole one executive joachim kreuzburg reinhard director compensation depends work carried result vogt representing group obtained also responsibility taken executive director bear sartorius ag compensation ultimate responsibility management team warrant policy deliberated higher compensation general policy award stock option decided level mother performance share debated within compensation house sartorius stedim committee basis recommendation committee biotech approved board director board director must monitor evolution component compensation several year regard corporate performance supplementary information afep medef code 219 measure implemented article disposition code sartorius stedim biotech 2322 fixed compensation yes compensation policy fixed part may calculated differently depending whether deliberated remuneration executive director followed continuous career within company committee submission recruited outside company board oscar werner reif volker niebel unless principle fixed compensation may reviewed relatively exceptional element long interval eg every three year evolution stay moderated increase compensation must linked event affecting one year another one company must take account performance company applies component compensation including fringe benefit afep medef recommendation regard increase however company opts annual increase executive moderation director fixed compensation increase must moderated must respect principle consistency mentioned 231 board take care said fixed remuneration regard performance company joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech 2323 variable compensation yes variable compensation board may decide award executive director annual multi policy reviewed annual variable compensation remuneration committee oscar werner reif volker different form variable compensation may cumulative niebel annual variable cumulative amount must decided basis compensation multiannual aforementioned principle particular comprehensiveness set company proportionality variable compensation must determined unless exceptional element board director fixed period rule governing evolution stay moderated determination variable compensation must consistent one year another one annual multiannual assessment executive director performance company applied afep company strategy variable compensation reward medef recommendation director performance progress company regard increase period consideration share price must criterion moderation measuring performance stock market price constitute element compensation variation joachim kreuzburg reinhard vogt representing group sartorius ag compensation policy deliberated decided level mother house sartorius stedim biotech based quantitative criterion precisely measurable challenging term variable compensation must understandable shareholder clear complete information must provided year annual report variable compensation must subject achievement precise course predetermined objective quantitative criterion must simple relevant objective measurable suited corporate strategy criterion must regularly reviewed order avoid adhoc adjustment also necessary pay considerable attention possible threshold effect generated quantitative criterion highly specific circumstance may warrant award extraordinary variable component qualitative criterion must defined precisely variable part qualitative criterion used limit must determined qualitative part allowing applicable exceptional circumstance taken consideration variable compensation must set level balanced relation fixed part variable part maximum percentage fixed part adapted business conducted company 220 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech predefined board except justified case award variable compensation may restricted executive director event executive director leaf completion term envisaged assessment performance criterion payment variable part compensation must ruled unless exceptional circumstance justified board 2325 benefit taking position yes isnt benefit benefit taking position may granted new executive taking function executive director come company outside group case director amount must made public determined nocompetition benefit yes executive director context implementation procedure related party post contractual non transaction stipulated law conclusion nocompetition competition obligation agreement must subject substantial reflection compensation accordance german law committee due fact sartorius stedim biotech sa controlled german company obligation last two year director left group time noncompetition clause waived terminated director claim half latest remuneration received company board must authorize conclusion nocompetition agreement length requirement nocompetition amount benefit taking account actual effective scope nocompetition requirement decision board must made public board anticipate conclusion agreement mention allows board cancel agreement director leaf board must announce whether nocompetition agreement upheld time director leaf particular director leaf company claim claime²d pension right event nocompetition payment exceed ceiling two year compensation fixed variable termination benefit also paid aggregate two benefit must exceed ceiling see 2326 supplementary pension scheme mentioned article l13711 yes supplementary pension social security code senior executive executive director must scheme ae according comply condition prevent abuse responsibility executive director company supplementary pension scheme defined benefit must subject condition beneficiary must director employee company claiming pension right pursuant applicable rule order prevent abuse necessary impose certain additional rule without prejudice scheme closed new beneficiary may altered relevant benefit must taken account overall determination compensation basis general principle stated group potential beneficiary must materially broader sole executive director beneficiary must meet reasonable requirement seniority within company least two year determined board director benefit payment pension plan defined benefit year increase potential right shall progressive relation seniority scheme shall account percentage limited 5 beneficiary compensation progression must described benchmark period taken account calculation supplementary information afep medef code 221 measure implemented article disposition code sartorius stedim biotech benefit must cover several year necessary avoid period artificial increase compensation aimed increasing pension benefit necessary exclude scheme giving right immediately time high percentage total compensation end career addition information individual potential right particular reference income maximum percentage income supplementary pension scheme would confer must made public percentage may 45 reference income fixed variable compensation thee reference period 24 information executive director compensation awarding policy share option performance share 24 law imposes company obligation disclose yes chairman part management report aggregate compensation benefit type company governance paid financial year executive director well internal control report compiles amount compensation benefit type information non director received financial year company executive executive group director compensation comprehensive information must provided shareholder clear view individual compensation paid executive director also policy applied company order determine compensation paid 241 permanent information yes company applies executive director compensation component whether recommendation potential vested must publicly disclosed immediately meeting board approving relevant decision 242 annual report must include chapter drawn support compensation committee informing shareholder compensation received executive director variable remuneration yes indication detailed presentation policy determination determination criterion compensation paid executive director particular rule information application governing award annual variable part without jeopardizing criterion indicated confidentiality may linked certain element determining part dedicated variable part compensation presentation must indicate compensation within criterion basis variable part determined manner reference document criterion applied financial year compared initial expectation whether individual director personal target attained must also necessary specify payment variable part partly deferred indicate condition method deferred payment finally must necessary specify rule governing award multiannual variable compensation without jeopardizing confidentiality may justified certain element determining variable part compensation must indicate criterion basis compensation determined payment multiannual variable part made manner criterion applied pension yes company indicates information concerning pension system commitment provided information within part company taking account considerable variety pension dedicated compensation scheme necessary indicate whether executive director benefit within reference document pension scheme group senior executive benefit specific pension scheme describe main feature scheme particular calculation method individual compensation yes company indicates detailed presentation executive director individual personal compensation also compensation compared preceding financial year comparison previous broken fixed component variable component year made separating although french commercial code impose compensation due obligation appears information relevant shareholder remuneration paid financial consists connecting variable component financial year year breakdown respect calculated even though compensation fixed part variable one paid following financial year therefore recommended disclose priority basis compensation thee respect 222 supplementary information afep medef code measure implemented article disposition code sartorius stedim biotech financial year show summary table amount thee paid current preceding financial year director fee yes company indicates aggregate individual amount director fee paid director total amount individual rule allocating fee well rule governing attendance fee payment director fee awarded applicable general management team respect corporate office held affiliate group stock option description policy award stock option yes company indicates beneficiary explaining separately applicable specific information within part award policy applicable executive director particular dedicated compensation necessary indicate nature option purchase within reference document subscription option applicable criterion used define category beneficiary periodicity plan condition approved board regard exercise option dilutive impact option award summary table must show data relevant existing option plan used benchmark document performance share yes company indicates description share award policy applicable employee information within part certain category employee executive director dedicated compensation condition applicable criterion determined board within reference document director dilutive impact share award manner stock option summary table must show data particular number performance share awarded executive director total number share awarded main beneficiary employee group valorization stock option performance share fraction yes company indicates ot awarded executive manager executive director information within part valuation stock option performance share awarded dedicated compensation executive director time award accordance within reference document method used consolidated financial statement fraction capital awarded executive director standardized presentation recommended comply standardized presentation attached schedule hereto director compensation item 243 shareholder consultation individual remuneration fo executive yes company indicates manager executive director information within part board must present compensation executive director dedicated compensation annual general meeting presentation must cover element within reference document compensation due warded end closed financial year applies afep medef executive director recommendation fixed part annual variable part necessary multiannual variable part objective contribute determination variable part extraordinary compensation stock option performance share element longterm compensation benefit linked taking terminating office supplementary pension scheme benefit presentation followed advisory vote shareholder recommended shareholder vote one resolution presented chief executive officer chairman management board one resolution deputy chief executive officer member management board ordinary shareholder meeting issue negative opinion board acting advice compensation committee must discus matter another meeting immediately publish company website notice detailing intends deal opinion expressed shareholder general meeting supplementary information afep medef code 223 224 supplementary information glossary glossary industrial productspecific term biopharmaceuticals membrane chromatography biopharmaceuticals biologics pharmaceutical drug selective separation mixture substance adsorption manufactured extracted biological source specifically modified membrane membrane adsorbers flowing system bioreactor system used cultivating animal human cell culture membrane medium obtain cell part one thin film foil made polymer porous metabolite structure film used core component filtration application downstream processing collective term various step follow upstream monoclonal antibody processing production biopharmaceuticals example synthetic antibody increasingly used separation purification concentration treatment cancer autoimmune disease hiv downstream processing step cell mass upstream step processed meet purity quality requirement purification step downstream processing see downstream processing fda food drug administration technique used isolate one type molecule protein u regulatory agency responsible monitoring approving complex mixture usually cell tissue whole organism biotechnological pharmaceutical medical veterinary product food singleuse technology technology product single use example fermentation disposable filter bag anaerobic breakdown molecule technical process used produce transform intra extracellular substance help microorganism upstream processing upstream processing defined entire process early cell isolation cultivation cell banking culture fluid management technology expansion cell final harvesting refers part technology system use handling sensitive biological bioprocess cell cell line grown liquid example singleuse bag preparation storage bioreactors see bioreactor transportation biopharmaceutical solution intermediate final bulk product validation systematic checking essential step facility research development production including testing pharmaceutical ensure product manufactured made reliably reproducibly desired quality supplementary information glossary 225 business economic term amortization goodwill amortization relates potential reduction value difference price paid company business goodwill allocation purchase price intangible net asset goodwill form intangible asset asset acquired carried accordance ifrs 3 capex ratio investment rate cash flow ratio capital expenditure sale revenue cash balance inflow outflow fund representing operating activity organization normalized financial result financial result excluding fair value adjustment hedging derivative financial instrument instrument well currency effect foreign currency instrument hedging risk change loan market price foreign currency well interest rate normalized income tax ebit underlying income tax based underlying profit earnings interest tax tax noncash amortization ebit margin supply chain management ratio ebit see ebit sale revenue setup coordinated control integrated flow material information finance supply chain entire value added process ebitda earnings interest tax depreciation amortization underlying ebitda ebitda see ebitda adjusted extraordinary item see ebitda margin extraordinary item ratio ebitda see ebitda sale revenue underlying ebitda margin extraordinary item ratio operating ebitda see underlying ebitda sale essentially cover onetime expense corporate project revenue integration acquisitionrelated item underlying consolidated net profit fixed asset profit adjusted extraordinary item noncash amortization sum intangible asset property plant equipment based normalized financial result see normalized financial asset financial result well corresponding tax effect item free float share public company freely available investing public 226 supplementary information address address europe france germany hungary sartorius stedim biotech sa sartorius stedim biotech gmbh sartorius stedim hungária kft zone industrielle de paluds augustspindlerstrasse 11 kagyló u 5 avenue de jouques c 91051 37079 goettingen 2092 budakeszi 13781 aubagne cedex phone 495513080 phone 3623457227 phone 33442845600 fax 495513083289 fax 3623457147 fax 33442845619 infosartoriusstedimcom ssbsartoriushu infosartoriusstedimcom sartorius stedim plastic gmbh ireland sartorius stedim fmt sa karlarnoldstrasse 21 zone industrielle de paluds 37079 goettingen sartorius stedim ireland ltd avenue de jouques c 91051 phone 49551504500 unit 41 business centre 13781 aubagne cedex fax 495515045050 stadium business park phone 33442845600 infosartoriusstedimcom ballycoolin road fax 33442845618 dublin 11 infosartoriusstedimcom sartorius stedim system gmbh phone 441372737100 robertboschstrasse 5 7 fax 441372726171 sartorius stedim france sa 34302 guxhagen necustomersupportsartoriuscom zone industrielle de paluds phone 4956654070 avenue de jouques c 71058 fax 4956654072200 italy 13781 aubagne cedex infosartoriusstedimcom phone 33442845600 sartorius stedim italy spa fax 33442846545 sartorius stedim cellca gmbh via dellantella 76a infobiotechfrancesartoriusstedimcom erwinrentschlerstrasse 21 50012 antella bagno ripoli florence 88471 laupheim phone 39055634041 sartorius stedim aseptics sa phone 497392966480 fax 390556340526 zone industrielle de saux 6 rue ampère fax 4973929664829 infoitalysartoriuscom 65100 lourdes infosartoriusstedimcom phone 33562427373 poland fax 33 562420844 austria infosartoriusstedimcom sartorius stedim poland sp z oo sartorius stedim austria gmbh ul wrzesinska 70 modecenter strasse 22 62 025 kostrzyn top nr d20 d24 3rd floor phone 48616473840 1030 vienna fax 48618792504 phone 43179657630 biuroplsartoriuscom fax 431796576344 separationaustriasartoriuscom russia belgium llc sartorius stedim ru uralskaya str 4 letter b room 03h sartorius stedim belgium nv 199155 st petersburg rue colonel bourg 105 phone 78123275327 1030 brussels fax 78123275323 phone 3227560680 russiasartoriuscom fax 3227560681 infobelgiumsartoriuscom supplementary information 227 africa spain uk tunisia sartorius stedim spain sa sartorius stedim uk ltd sartorius stedim bioprocess sarl avda de la industria 32 longmead business centre km 24 route de zaghouan edificio payma blenheim road mohamdia bourbiâa 1145 28108 alcobendas madrid epsom surrey kt19 9qq bp87 ben arous phone 34902123367 phone 441372737100 phone 21679397014 fax 34913589623 fax 441372726171 fax 21679397019 pedidossartoriussartoriuscom necustomersupportsartoriuscom infosartoriusstedimcom sartorius stedim spain sa sartorius stedim lab ltd poligon le guixeres carrer marcus porcius 1 unit 6 edificio bcin stonedale road 08915 badalona barcelona stonehouse gloucestershire gl10 3rq phone 34934648012 phone 441453821972 fax 34934648020 fax 441453827928 biotech_spainsartoriusstedimcom necustomersupportsartoriuscom switzerland automation partnership cambridge ltd york way sartorius stedim switzerland ag royston ringstrasse 24a herfordshire sg8 5wy 8317 tagelswangen phone 441763227200 phone 41523543636 fax 441763227201 fax 41523543646 infotapbiosystemscom biotechswitzerlandsartoriusstedimcom sartorius stedim biooutsource ltd 1 technology terrace acre road todd campus west scotland science park glasgow g20 0xa phone 441419464222 fax 441419464552 informationsartoriusstedimcom 228 supplementary information north america latin america asia pacific usa argentina china sartorius stedim north america inc sartorius argentina sa sartorius stedim biotech beijing co ltd 5 orville drive int avalos 4251 33 yu road konggang industrial bohemia new york 11716 b1605ecs munro zone b shunyi district phone 16312544249 buenos aire 101300 beijing fax 16312544264 phone 541147210505 phone 861080426516 infosartoriusstedimcom fax 541147622333 fax 861080426580 leadsargsartoriuscom enquirycnsartoriusstedimcom allpure technology llc 80 progress avenue brazil sartorius stedim shanghai trading co ltd new oxford pa 17350 3 rd floor north wing tower 1 phone 17176243241 sartorius brasil ltda 4560 jinke road zhangjiang hitech park fax 17176243051 avenida senador vergueiro 2962 pudong district shanghai 201210 salesallpureinccom são bernardo campo sp phone 862168782300 cep 09600 004 fax 862168782332 puerto rico phone 551143628900 infocnsartoriuscom fax 551143628901 sartorius stedim filter inc leadsbrsartoriuscom india carretera 128 int 376 barriada arturo lluveras po box 6 mexico sartorius stedim india pvt ltd yauco puerto rico 00698 692 693 jakkasandra phone 17878565020 sartorius de méxico sa de cv kunnigal road fax 17878567945 circuito circunvalación poniente 149 nelamangala bangalore 562123 marcoslopezsartoriuscom ciudad satélite phone 918043505250 53100 naucalpan estado de méxico fax 918043505253 phone 525555621102 biotechindiasartoriuscom fax 525555622942 leadsmexsartoriuscom japan peru sartorius stedim japan kk 4th floor daiwa shinagawa north bldg sartorius peru sac 1 8 11 kitashinagawa shinagawaku avda emilio cavenecia 264 floor 7 tokyo 140 0001 san isidro phone 81337405407 15073 lima fax 81337405406 phone 5114410158 infosartoriuscojp fax 5114226100 leadspesartoriuscom supplementary information 229 malaysia australia sartorius stedim malaysia sdn bhd sartorius stedim australia pty ltd lot l3 e 3b enterprise 4 unit 5 7 11 rodeo drive technology park malaysia dandenong south melbourne bukit jalil victoria 3175 57000 kuala lumpur phone 61387621800 phone 60389960622 fax 61387621828 fax 60389960755 infoaustraliasartoriusstedimcom ehtansartoriuscommy singapore sartorius stedim singapore pte ltd 1 science park road capricorn 05 08a singapore science park 2 singapore 117528 phone 6568723966 fax 6567782494 marzjanaminsartoriusstedimcom south korea sartorius korea biotech co ltd 8th floor solid space 220 pangyoyeokro bundanggu seongnamsi gyeonggido 13493 phone 82316224900 fax 82316225790 infosartoriuscokr vietnam sartorius representative office unit c 17th floor tower big building 18 pham hung street dinh tu liem hanoi phone 84437955587 fax 84437955589 sartoriusvnhnvnnvn address visit website internet wwwsartoriuscom 230 supplementary information local presence worldwide local presence worldwide america bohemia ny usa wilmington de usa new oxford pa usa mexico city mexico yauco puerto rico são paulo brazil buenos aire argentina lima peru sale production production sale supplementary information local presence worldwide 231 emea africa dublin ireland goettingen germany royston uk guxhagen germany stonehouse uk laupheim germany epsom uk poznan poland glasgow uk budapest hungary brussels belgium vienna austria aubagne france tagelswangen switzerland lourdes france mohamdia tunisia florence italy madrid spain barcelona spain asia paciﬁc beijing china shanghai china seoul south korea tokyo japan hanoi vietnam bangalore india kuala lumpur malaysia singapore singapore melbourne australia 232 supplementary information financial schedule annual general shareholder meeting aubagne france april 5 2016 1 payment dividend april 15 2016 publication firstquarter figure 2016 april 21 2016 publication firsthalf figure 2016 july 25 2016 publication ninemonth figure 2016 october 24 2016 publication preliminary figure fiscal 2016 january 2017 annual general shareholder meeting aubagne france april 4 2017 publication firstquarter figure 2017 april 2017 1 subject approval annual general shareholder meeting contact petra kirchhoff andreas theisen vice president director corporate communication ir investor relation phone 495513081686 phone 495513081668 petrakirchhoffsartoriuscom andreastheisensartoriuscom publication published financial reporting system firesys sartorius stedim biotech sa firesys gmbh corporate communication frankfurt main germany c 91051 13781 aubagne cedex france photography peter ginter editorial deadline lohmar germany february 18 2016 frank stefan kimmel goettingen germany published february 26 2016 translation original frenchlanguage document de référence 2015 sartorius stedim biotech sa zone industrielle le paluds avenue de jouques c 91051 13781 aubagne cedex france phone 33442845600 fax 33442845619 infosartoriusstedimcom wwwsartoriusstedimcom sartorius stedim biotech sa printed germany publication og0046e151201 order 8600000196